

FORM PTO-1390
(REV. 10-2000)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

1007 Rec'd PCT/PTO 22 JAN 2002

ATTORNEY'S DOCKET NUMBER

20499P

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/031691

INTERNATIONAL APPLICATION NO.

PCT/US00/19585

INTERNATIONAL FILING DATE

18 July 2000

PRIORITY DATE CLAIMED

20 July 1999

TITLE OF INVENTION

NOVEL HUMAN CALCIUM SENSITIVE POTASSIUM CHANNEL SUBUNITS

APPLICANT(S) FOR DO/EO/US

VICTOR UEBELE, RICHARD SWANSON, YUAN LIU AND ARMANDO LAGRUTTA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures [35 U.S.C. 371(f)] at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).
4. ☒ A proper Demand for International Preliminary Examination was made and the US was elected by the expiration of the 19th month from the earliest claimed priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed [35 U.S.C. 371(c)(2)].
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)].
7. ☐ Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)].
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].
9. ☒ An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].

Items 11 to 16 below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT January 22, 2002
EXPRESS MAIL NO. EE18060716105
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C. 20231.
MAILED BY A-B-Crowley
DATE 1/22/02

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="font-size: 1.5em; font-weight: bold;">10/031691</div>		INTERNATIONAL APPLICATION NO. PCT/US00/19585		ATTORNEY'S DOCKET NUMBER 20499P	
--	--	---	--	------------------------------------	--

17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE [37 CFR 1.492(a)(1)-(5)]: Neither international preliminary examination fee (37 CFR 1.482) nor international search fee [37 CFR 1.445(a)(2)] paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1,040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee [37 CFR 1.445(a)(2)] paid to USPTO..... \$740.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS		PTO USE ONLY	
				\$100.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date [37 CFR 1.492(e)].				\$0.00			
Claims	Number Filed	Number Extra	Rate				
Total Claims	42 - 20 =	22	X \$18.00	\$396.00			
Independent Claims	16 - 3 =	13	X \$84.00	\$1,092.00			
Multiple dependent claim(s) (if applicable)		1	+ \$280.00	\$280.00			
TOTAL OF ABOVE CALCULATIONS =				\$1,868.00			
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.							
SUBTOTAL =				\$1,868.00			
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date [37 CFR 1.492(f)].				+	\$0.00		
TOTAL NATIONAL FEE =				\$1,868.00			
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				+			
TOTAL FEES ENCLOSED =				\$1,868.00			
				Amount to be refunded			
				charged			

a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 13-2755 in the amount of \$1,868.00 to cover the above fees.
 A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
 overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed.


**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive
 [37 CFR 1.137(a) or (b)] must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

MERCK & CO., INC.
 Patent Department, RY60-30
 P.O. Box 2000
 126 East Lincoln Avenue
 Rahway, New Jersey 07065-0970

DATE: January 22, 2002

PHONE #: (732) 594-6734


 SIGNATURE
Joseph A. Coppola
 NAME
38,413
 REGISTRATION NUMBER

10/031691

TITLE OF THE INVENTION

NOVEL HUMAN CALCIUM SENSITIVE POTASSIUM CHANNEL SUBUNITS

CROSS-REFERENCE TO RELATED APPLICATIONS

5 Not applicable.

STATEMENT REGARDING FEDERALLY-SPONSORED R&D

Not applicable.

10 REFERENCE TO MICROFICHE APPENDIX

Not applicable.

FIELD OF THE INVENTION

15 The present invention is directed to novel human DNA sequences encoding subunits of calcium sensitive potassium channels.

BACKGROUND OF THE INVENTION

20 Voltage-gated potassium channels form transmembrane pores that open or close in response to changes in cell membrane potential and selectively allow potassium ions to pass through the membrane. Voltage-gated potassium channels have been found in cells traditionally considered both excitable (*e.g.*, neurons, myocytes, secretory cells) and non-excitable (*e.g.*, T-cells, osteoclasts) and have been shown to maintain cell membrane potential and control the repolarization of action potentials in such cells. Following depolarization, voltage-gated potassium channels open, allowing potassium efflux and thus membrane repolarization. This behavior has made voltage-gated potassium channels important targets for drug discovery in connection with a variety of diseases. As a result, many voltage-gated potassium channels have been identified and many cloned. They are distinguishable by differences in primary structure and tissue-specific patterns of expression, as well as by electrophysiological and pharmacological properties. For reviews of voltage-gated potassium channels see Robertson, 1997, Trends Pharmacol. Sci. 18:474-483; Jan & Jan, 1997, J. Physiol. 505:267-282; Catterall, 1995, Ann. Rev. Biochem. 64:493-531.

30 Many functional voltage-gated potassium channels are believed to be tetramers of four α subunits, each of which contains six transmembrane spanning

segments. The α subunits making up a tetramer may be the same (in the case of homotetramers) or may be different (in the case of heterotetramers). The membrane-spanning α subunits making up the tetramers may sometimes be associated with additional, β subunits, which may alter the behavior of the α subunits.

5 A particular type of voltage-gated potassium channel is the voltage-gated and calcium sensitive potassium channel, also known as the calcium sensitive potassium channel. Calcium sensitive potassium channels are present in a wide variety of cells and are unique among voltage-gated potassium channels because their activity is regulated not only by changes in membrane potential but also by
10 intracellular calcium concentration. Plasma membrane depolarization and increases in cytoplasmic calcium concentration both raise the open probability of calcium sensitive potassium channels. Therefore, calcium sensitive potassium channels can serve as a link between cellular processes involving increases in intracellular calcium and membrane excitability. Calcium sensitive potassium channels are believed to
15 play a negative feedback role by terminating signaling events involving an increase in intracellular calcium, *e.g.*, glucose mediated insulin release, blood vessel muscle tone, bronchial airway smooth muscle tone, and regulation of intraocular pressure. (Tanaka et al., 1997, J. Physiol. 502:545-557; Kaczorowski et al., 1996, J. Bioenerg. Biomem. 28:255-267; Vergara et al., 1998, Curr. Opin. Neurobiol. 8:321-329).

20 Certain calcium sensitive potassium channels have been isolated and studied. Functional calcium sensitive potassium channels are composed of α subunits that may be associated with smaller β subunits. The α subunit is believed to form the channel pore while a previously described β subunit increases the calcium sensitivity of the channel and makes the channel susceptible to regulation by certain substances,
25 *e.g.*, dehydrosoyasaponin (McManus et al., 1995, Neuron 14:645-650). The calcium sensitive potassium channel from bovine tracheal smooth muscle was purified and shown to be composed of an ~130 kDa α subunit and a 31 kDa β subunit (Garcia-Calvo et al., 1994, J. Biol. Chem. 269:676-682). Tseng-Crank et al. (1994, Neuron 13:1315-1330) cloned nine related calcium sensitive potassium channel α subunits
30 from human brain. These α subunits are thought to be splice variants derived from a single gene, the *h-slo* gene (Tseng-Crank et al., 1994, Neuron 13:1315-1330). Knauss et al., 1994, J. Biol. Chem. 269:17274-17278 purified and cloned a β subunit of a calcium sensitive potassium channel from tracheal smooth muscle.

In most cells, the opening of calcium sensitive potassium channels results in the generation of non-inactivating, hyperpolarizing potassium currents. However, in certain cells (*e.g.*, chromaffin cells of the adrenal gland and hippocampal neurons), the currents are inactivating. Following the discovery of the invention described herein, Wallner et al., 1999, Proc. Natl. Acad. Sci. USA 96:4137-4132 disclosed the existence of the human $\beta 2$ calcium sensitive potassium channel subunit that, when combined with the α subunit, formed inactivating calcium sensitive potassium channels. The ability to confer inactivation was ascribed to the N-terminal 19 amino acids of the $\beta 2$ subunit.

U.S. Patent No. 5,776,734 is directed to nucleic acids encoding the bovine and human $\beta 1$ subunit of the calcium sensitive potassium channel. U.S. Patent No. 5,637,470 is directed to methods of identifying compounds that modulate the activity of calcium sensitive potassium channels.

SUMMARY OF THE INVENTION

The present invention is directed to novel human DNA sequences encoding β subunits of calcium sensitive potassium channels. The present invention includes DNAs that encode the β subunits $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$ of human calcium sensitive potassium channels. The DNAs comprise the nucleotide sequences shown in SEQ.ID.NO.:1 ($\beta 2$), SEQ.ID.NO.:3 ($\beta 3a$), SEQ.ID.NO.:5 ($\beta 3b$), SEQ.ID.NO.:7 ($\beta 3c$), and SEQ.ID.NO.:9 ($\beta 3d$). Also provided are proteins encoded by the novel DNA sequences. The proteins comprise the deduced amino acid sequences shown in SEQ.ID.NO.:2 ($\beta 2$), SEQ.ID.NO.:4 ($\beta 3a$), SEQ.ID.NO.:6 ($\beta 3b$), SEQ.ID.NO.:8 ($\beta 3c$), and SEQ.ID.NO.:10 ($\beta 3d$). Methods of expressing the novel subunit proteins in recombinant systems are provided as well as methods of identifying activators and inhibitors of potassium channels comprising the subunits.

The present invention also includes a genomic DNA fragment containing the 5' portions of the $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$ subunits, as well as the 5' portion of the core portion of the $\beta 3$ subunits. This genomic DNA fragment contains promoter elements for the subunits. Methods of screening for compounds which affect transcription of the gene encoding the $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$ subunits are also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A shows a DNA sequence encoding the $\beta 2$ subunit of the human calcium sensitive potassium channel (SEQ.ID.NO.:1). The start ATG codon is at position 271-273; the stop codon is at position 976-978. Figure 1B shows the deduced amino acid sequence (SEQ.ID.NO.:2) of the $\beta 2$ subunit.

Figure 2A shows a DNA sequence encoding the $\beta 3a$ subunit of a human calcium sensitive potassium channel (SEQ.ID.NO.:3). The start ATG codon is at position 341-343; the stop codon is at position 1172-1174. Figure 2B shows the deduced amino acid sequence (SEQ.ID.NO.:4) of the $\beta 3a$ subunit.

Figure 3A shows a DNA sequence encoding the $\beta 3b$ subunit of a human calcium sensitive potassium channel (SEQ.ID.NO.:5). The start ATG codon is at position 796-798; the stop codon is at position 1567-1569. Figure 3B shows the deduced amino acid sequence (SEQ.ID.NO.:6) of the $\beta 3b$ subunit.

Figure 4A shows a DNA sequence encoding the $\beta 3c$ subunit of a human calcium sensitive potassium channel (SEQ.ID.NO.:7). The start ATG codon is at position 869-871; the stop codon is at position 1694-1696. Figure 4B shows the deduced amino acid sequence (SEQ.ID.NO.:8) of the $\beta 3c$ subunit.

Figure 5A shows a DNA sequence encoding the $\beta 3d$ subunit of a human and calcium sensitive potassium channel (SEQ.ID.NO.:9). The start ATG codon is at position 457-459; the stop codon is at position 1294-1296. Figure 5B shows the deduced amino acid sequence (SEQ.ID.NO.:10) of the $\beta 3d$ subunit.

Figure 6 shows an alignment of the deduced amino acid sequences of the human calcium sensitive potassium channel $\beta 1$ (SEQ.ID.NO.:11), $\beta 2$ (SEQ.ID.NO.:2), $\beta 3a$ (SEQ.ID.NO.:4), $\beta 3b$ (SEQ.ID.NO.:6), $\beta 3c$ (SEQ.ID.NO.:8), and $\beta 3d$ (SEQ.ID.NO.:10) subunits.

Figure 7 shows the effect of the co-expression of the novel β subunits of the present invention on the electrophysiological properties of the ion channel formed by the α subunit of a human calcium sensitive potassium channel. Figure 7A shows the current-voltage relations recorded in inside-out patches expressing calcium sensitive potassium channel α or α and β subunits. α and β subunit cRNAs were co-injected in 1:10 molar ratio (β in excess) to detect maximum effects. The voltage clamp protocol consisted of a pre-pulse to -160 mV (200 ms), followed by 20 mV depolarizing steps from -80 to +80 mV (500 ms); holding potential was -80 mV; internal Ca^{2+} was 30 μM . Subunits $\beta 3b$ and $\beta 3d$ did not induce noticeable changes in

the kinetics and voltage dependence of the channels formed by α subunits, although they might decrease current density. Figure 7B: Boltzmann equations were fit to normalized conductances for the records shown in 7A, which were calculated from peak currents and plotted as function of test potential. $V_{1/2}$ values are: 20 mV (α subunit alone); -55 mV (α + $\beta 2$ subunit); 45.36 mV (α + $\beta 3a$ subunit); 20 mV (α + $\beta 3c$ subunit). Figure 7C shows that co-expression of $\beta 3$ subunit RNAs in molar excess of α subunit RNAs (up to 10X) reduced, but did not eliminate, a non-inactivating component of calcium sensitive potassium channel current. Inactivation rates and fractional inactivating current were calculated as described in Example 2.

Figure 8A-N shows the genomic sequence of GenBank accession number AC007823.4 (SEQ.ID.NO.:20). The different splice variants of the $\beta 3$ subunits are contained in nucleotides 1-40,467. The $\beta 3a$ -specific sequence is at positions 17,404-17,806; the $\beta 3b$ -specific sequence is at positions 24,710-25,507; the $\beta 3c/d$ sequence is at positions 32,590-33,514; the beginning of the $\beta 3$ core sequence is at positions 33,515-33,705. The sequences involved in tissue specific expression (*e.g.*, promoters, enhancers, repressors) are likely to be located in nucleotides 1-17,404.

DETAILED DESCRIPTION OF THE INVENTION

For the purposes of this invention:

"Substantially free from other proteins" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other proteins. Thus, a human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein preparation that is substantially free from other proteins will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. Whether a given human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein preparation is substantially free from other proteins can be determined by conventional techniques of assessing protein purity such as, *e.g.*, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with appropriate detection methods, *e.g.*, silver staining or immunoblotting.

"Substantially free from other nucleic acids" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other

208140-1691E001

nucleic acids. Thus, a human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit DNA preparation that is substantially free from other nucleic acids will contain, as a percent of its total nucleic acid, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit nucleic acids. Whether a given human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit DNA preparation is substantially free from other nucleic acids can be determined by conventional techniques of assessing nucleic acid purity such as, *e.g.*, agarose gel electrophoresis combined with appropriate staining methods, *e.g.*, ethidium bromide staining, Northern or Southern blotting, or by sequencing.

A "conservative amino acid substitution" refers to the replacement of one amino acid residue by another, chemically similar, amino acid residue. Examples of such conservative substitutions are: substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (*e.g.*, arginine for lysine; glutamic acid for aspartic acid); substitution of one aromatic amino acid (tryptophan, tyrosine, or phenylalanine) for another.

A polypeptide has "substantially the same biological activity as human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit" if that polypeptide is able to combine with a human calcium sensitive potassium channel α subunit thereby forming a functional potassium channel where the polypeptide confers upon the α subunit properties similar to those conferred by the $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits and where the polypeptide has an amino acid sequence that is at least about 50% identical to SEQ.ID.NO.:2, 4, 6, 8, or 10 when measured by such standard programs as BLAST or FASTA. For example, a polypeptide that is 50% identical in amino acid sequence to $\beta 3a$ (SEQ.ID.NO.:4) and is able to confer upon the α subunit properties such that electrophysiological measurements of the ion channel formed by the polypeptide and the α subunit result in graphs such as those shown in Figure 7A-C for the $\beta 3a$ subunit and the α subunit is a polypeptide that has "substantially the same biological activity as human calcium sensitive potassium channel $\beta 3a$ subunit."

The present invention relates to the identification and cloning of DNAs encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$

subunits, components of human calcium sensitive potassium channels. Expressed sequence tags (ESTs) (GenBank accession numbers AA904191, AI299145 and AI301175) were identified by searching databases for sequences with homology to the $\beta 1$ subunit. The cDNAs encoding the ESTs were purchased and sequenced in both
5 directions. The clone encoding AA904191 was determined to encode the entire $\beta 2$ subunit, since it contained in frame stop codons 5' to the start ATG of the open reading frame and the entire open reading frame.

The $\beta 2$ coding sequence was then used to search the databases for additional β subunits. Contigs were assembled from the identified ESTs and used to
10 search the database once again. Several ESTs were identified in this iterative manner (GenBank accession numbers AA195381, AA236930, AA236968, AA279911, AA761761 and AA934876). Available cDNAs encoding these ESTs were purchased and sequenced in both directions. None of these clones were full length. Because most were isolated in a preparation of tonsils enriched for B-cells, we performed 5'
15 RACE (rapid amplification of cDNA ends) using gene-specific oligonucleotides in the 3' untranslated region (UTR) and commercially prepared cDNA from human spleen, another tissue rich in B-cells (Clontech catalog # 7412-1), as the template. Multiple DNA fragments were amplified in this manner, cloned and sequenced in both directions. Sequencing revealed 4 subfamilies of full length clones, differing
20 only in their 5' ends: $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$.

The human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$ subunits of the present invention exhibit tissue specific patterns of expression. Northern blotting of mRNAs isolated from various tissues has shown that the $\beta 2$ subunit is expressed predominately in uterus, heart, ovary, thyroid, fetal
25 kidney, adrenal medulla, and pancreas; the $\beta 3a$ subunit is expressed predominately in heart and skeletal muscle; the $\beta 3b$ subunit is expressed in most tissues examined except for brain, skeletal muscle and testes. The $\beta 3c$ and/or $\beta 3d$ subunits have been found in pancreas.

The tissue specific expression patterns of the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$ subunits support the hypothesis that
30 these different subunits may contribute to the functional diversity of calcium sensitive potassium channels observed in different tissues. Activators and inhibitors of specific calcium sensitive potassium channels containing specific subunits may, therefore, have pharmacological efficacy in different pathological conditions, depending on the

subunit composition of the calcium sensitive potassium channels involved in the specific pathological condition.

Chromosomal mapping studies have shown that both the $\beta 2$ and $\beta 3$ subunits map to human chromosome 3q23-ter. The β subunits of the present invention have about 30-45% amino acid sequence identity to the previously known human $\beta 1$ subunit (GenBank accession no. U25138). The $\beta 2$ and $\beta 3$ subunits of the present invention have about 40% amino acid sequence identity to each other. The $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits differ only in their extreme N-terminal 1-20 amino acids, and are alternatively spliced variants of a single gene. Indeed, a genomic fragment of human DNA has been identified in the GenBank database that contains the 5' domains of $\beta 3a$, $\beta 3b$, $\beta 3c/d$, and the beginning of the conserved core in a contiguous fragment (accession number AC007823.4). See Figure 8. Additionally, two bacterial artificial chromosomes (BACs) have been isolated which contain the conserved core domain. One of these BACs also contains $\beta 3c/d$ specific sequence. Therefore, we have identified overlapping BAC clones that together encode the entire $\beta 3$ open reading frame. The $\beta 2$ subunit is encoded by a separate gene.

The present invention provides DNAs encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits that are substantially free from other nucleic acids. The present invention also provides isolated and/or recombinant DNA molecules encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits. The present invention provides DNA molecules substantially free from other nucleic acids comprising the nucleotide sequences shown in SEQ.ID.NO.:1, 3, 5, 7, or 9. cDNAs encoding each $\beta 3$ subunit have been isolated exhibiting a sequence polymorphism, encoding either a serine or an asparagine at the amino acid position that is equivalent to position 143 of $\beta 3b$. This represents amino acid 142 of the conserved core domain.

Accordingly, the present invention includes DNA substantially free from other nucleic acids as well as isolated and/or recombinant DNA encoding a polypeptide selected from the group consisting of: SEQ.ID.NO.:4; SEQ.ID.NO.:4 with an asparagine at position 163 instead of a serine; SEQ.ID.NO.:6; SEQ.ID.NO.:6 with a serine at position 143 instead of an asparagine; SEQ.ID.NO.:8; SEQ.ID.NO.:8 with an asparagine at position 161 instead of a serine; SEQ.ID.NO.:10; and SEQ.ID.NO.:10 with a serine at position 165 instead of an asparagine.

The present invention includes DNA substantially free from other nucleic acids as well as isolated and/or recombinant DNA encoding a polypeptide comprising the conserved $\beta 3$ core amino acid sequence, positions 2-246 of SEQ.ID.NO.:6.

5 The present invention includes isolated DNA molecules as well as DNA molecules that are substantially free from other nucleic acids comprising the coding regions of SEQ.ID.NOs.:1, 3, 5, 7, and 9. Accordingly, the present invention includes isolated DNA molecules and DNA molecules substantially free from other nucleic acids having a sequence comprising positions 271 to 975 of SEQ.ID.NO.:1,
10 positions 341 to 1171 of SEQ.ID.NO.:3, positions 796 to 1566 of SEQ.ID.NO.:5, positions 869 to 1693 of SEQ.ID.NO.:7, or positions 457 to 1293 of SEQ.ID.NO.:9.

Also included are recombinant DNA molecules having a nucleotide sequence comprising positions 271-975 of SEQ.ID.NO.:1, positions 341 to 1171 of SEQ.ID.NO.:3, positions 796 to 1566 of SEQ.ID.NO.:5, positions 869 to 1693 of
15 SEQ.ID.NO.:7, or positions 457 to 1293 of SEQ.ID.NO.:9. The novel DNA sequences of the present invention encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits, in whole or in part, can be linked with other DNA sequences, *i.e.*, DNA sequences to which human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits are not naturally linked, to
20 form "recombinant DNA molecules" encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits. Such other sequences can include DNA sequences that control transcription or translation such as, *e.g.*, translation initiation sequences, internal ribosome entry sites, promoters for RNA polymerase II, transcription or translation termination sequences, enhancer sequences, sequences that
25 control replication in microorganisms, sequences that confer antibiotic resistance, or sequences that encode a polypeptide "tag" such as, *e.g.*, a polyhistidine tract, the FLAG epitope, the myc epitope, GST, or maltose binding protein. The novel DNA sequences of the present invention can be inserted into vectors such as plasmids, cosmids, viral vectors, P1 artificial chromosomes, or yeast artificial chromosomes.

30 The present invention also includes DNA substantially free from other nucleic acids as well as isolated and/or recombinant DNA comprising genomic sequences of the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits. The present invention includes DNA substantially free from other nucleic acids as well as isolated and/or recombinant DNA comprising

SEQ.ID.NO.:20; positions 1-40,467 of SEQ.ID.NO.:20; positions 17,404-17,806 of SEQ.ID.NO.:20; positions 24,710-25,507 of SEQ.ID.NO.:20; positions 32,590-33,514 of SEQ.ID.NO.:20; positions 33,515-33,705 of SEQ.ID.NO.:20; or positions 1-17,404 of SEQ.ID.NO.:20.

5 Included in the present invention are DNA sequences that hybridize to at least one of SEQ.ID.NOs:1, 3, 5, 7, 9, or 20 under conditions of high stringency.

By way of example, and not limitation, a procedure using conditions of high stringency is as follows: Prehybridization of filters containing DNA is carried out for 2 hr. to overnight at 65°C in buffer composed of 5X SSC, 10X Denhardt's solution,
10 50% Formamide, 2% SDS and 100 µg/ml denatured salmon sperm DNA. Hybridization of 32P-labelled, random primed probe is carried out in 5X SSPE, 10X Denhardt's solution, 50% Formamide, 2% SDS, 100ug/ml salmon sperm DNA at 42°C overnight. Washing of filters is done in 2X SSC, 0.05% SDS at 42°C for 40 minutes, followed by 0.1X SSC, 0.05% SDS at 65°C for 40 minutes.

15 Other procedures using conditions of high stringency would include either a hybridization carried out in 5XSSC, 5X Denhardt's solution, 50% formamide at 42°C for 12 to 48 hours or a washing step carried out in 0.2X SSPE, 0.2% SDS at 65°C for 30 to 60 minutes.

Reagents mentioned in the foregoing procedures for carrying out high
20 stringency hybridization are well known in the art. Details of the composition of these reagents can be found in, e.g., Sambrook, Fritsch, and Maniatis, 1989, Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press. In addition to the foregoing, other conditions of high stringency which may be used are well known in the art.

25 The degeneracy of the genetic code is such that, for all but two amino acids, more than a single codon encodes a particular amino acid. This allows for the construction of synthetic DNA that encodes the human calcium sensitive potassium channel β2, β3a, β3b, β3c, or β3d subunit proteins where the nucleotide sequence of the synthetic DNA differs significantly from the nucleotide sequences of
30 SEQ.ID.NOs:1, 3, 5, 7, or 9 but still encodes the same human calcium sensitive potassium channel β2, β3a, β3b, β3c, or β3d subunit proteins as SEQ.ID.NOs:2, 4, 6, 8, or 10. Such synthetic DNAs are intended to be within the scope of the present invention.

5 Mutated forms of SEQ.ID.NOs:1, 3, 5, 7, or 9 are intended to be within the scope of the present invention. In particular, mutated forms of SEQ.ID.NOs:1, 3, 5, 7, or 9 which encode proteins that either do not interact with an α subunit or which when combined with α subunits give rise to calcium sensitive potassium channels having altered voltage dependence, calcium sensitivity, current kinetics (such as activation, inactivation or deactivation), or pharmacologic properties as compared to wild-type calcium sensitive potassium channels are within the scope of the present invention. Such mutant forms can differ from SEQ.ID.NOs:1, 3, 5, 7, or 9 by having nucleotide deletions, substitutions, or additions.

10 Also intended to be within the scope of the present invention are RNA molecules having sequences corresponding to SEQ.ID.NOs:1, 3, 5, 7, or 9. Antisense nucleotides, DNA or RNA, that are the reverse complements of SEQ.ID.NOs:1, 3, 5, 7, or 9, or portions thereof, are also within the scope of the present invention. In addition, polynucleotides based on SEQ.ID.NOs:1, 3, 5, 7, or 9 in which a small number of positions are substituted with non-natural or modified nucleotides such as inosine, methyl-cytosine, or deaza-guanosine are intended to be within the scope of the present invention. Polynucleotides of the present invention can also include sequences based on SEQ.ID.NOs:1, 3, 5, 7, or 9 but in which non-natural linkages between the nucleotides are present. Such non-natural linkages can be, *e.g.*, 15 methylphosphonates, phosphorothioates, phosphorodithionates, phosphoroamidites, and phosphate esters. Polynucleotides of the present invention can also include sequences based on SEQ.ID.NOs:1, 3, 5, 7, or 9 but having de-phospho linkages as bridges between nucleotides, *e.g.*, siloxane, carbonate, carboxymethyl ester, acetamidate, carbamate, and thioether bridges. Other internucleotide linkages that can be present include N-vinyl, methacryloxyethyl, methacrylamide, or ethyleneimine linkages. Peptide nucleic acids based upon SEQ.ID.NOs:1, 3, 5, 7, or 9 are also 20 included in the present invention.

25 Another aspect of the present invention includes host cells that have been engineered to contain and/or express DNA sequences encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. Such recombinant host cells can be cultured under suitable conditions to produce human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. Such recombinant host cells are also useful in the methods of identifying activators and inhibitors of calcium sensitive potassium channels described herein. An

expression vector containing DNA encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins can be used for the expression of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of human, bovine, porcine, monkey and rodent origin, amphibian cells such as *Xenopus* oocytes, and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Cells and cell lines which are suitable for recombinant expression of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins and which are widely available, include but are not limited to, L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), CPAE (ATCC CCL 209), Saos-2 (ATCC HTB-85), ARPE-19 human retinal pigment epithelium (ATCC CRL-2302), *Xenopus* melanophores, and *Xenopus* oocytes.

A variety of mammalian expression vectors can be used to express recombinant human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins in mammalian cells. Commercially available mammalian expression vectors which are suitable include, but are not limited to, pMC1neo (Stratagene), pSG5 (Stratagene), pcDNAI and pcDNAIamp, pcDNA3, pcDNA3.1, pCR3.1 (Invitrogen), EBO-pSV2-neo (ATCC 37593), pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pIZD35 (ATCC 37565), and pSV2-dhfr (ATCC 37146). Another suitable vector is the PT7TS oocyte expression vector.

Following expression in recombinant cells, human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins can be purified by conventional techniques to a level that is substantially free from other proteins. Techniques that can be used include ammonium sulfate precipitation, hydrophobic or hydrophilic interaction chromatography, ion exchange chromatography, affinity chromatography, phosphocellulose chromatography, size exclusion chromatography, preparative gel electrophoresis, and alcohol precipitation. In some cases, it may be

advantageous to employ protein denaturing and/or refolding steps in addition to such techniques.

Certain voltage-gated potassium channel subunits have been found to require the expression of other voltage-gated potassium channel subunits in order to be properly expressed at high levels and inserted in membranes. For example, co-expression of KCNQ3 appears to enhance the expression of KCNQ2 in *Xenopus* oocytes (Wang et al., 1998, Science 282:1890-1893). Also, some voltage-gated potassium channel α subunits require other related α subunits (Jegla and Salkoff, 1997, J. Neurosci. 17:32-44) or Kv β 2 subunits (Shi et al., 1995, Neuron 16:843-852).

Accordingly, the recombinant expression of the human calcium sensitive potassium channel β 2, β 3a, β 3b, β 3c, or β 3d subunit proteins may, under certain circumstances, benefit from the co-expression of other proteins and such co-expression is intended to be within the scope of the present invention. A particularly preferred form of co-expression is the co-expression of a human calcium sensitive potassium channel β 2, β 3a, β 3b, β 3c, or β 3d subunit protein (or combinations thereof) with a human calcium sensitive potassium channel α subunit protein. Such co-expression can be effected by transfecting an expression vector encoding a human calcium sensitive potassium channel β 2, β 3a, β 3b, β 3c, or β 3d subunit protein into a cell that naturally expresses a human calcium sensitive potassium channel α subunit protein.

Alternatively, an expression vector encoding a human calcium sensitive potassium channel β 2, β 3a, β 3b, β 3c, or β 3d subunit protein can be transfected into a cell in which an expression vector encoding a human calcium sensitive potassium channel α subunit protein has also been transfected. Preferably, such a cell does not naturally express human calcium sensitive potassium channel α or β subunits.

The present invention includes human calcium sensitive potassium channel β 2, β 3a, β 3b, β 3c, and β 3d subunit proteins substantially free from other proteins. The deduced amino acid sequences of the full-length human calcium sensitive potassium channel β 2, β 3a, β 3b, β 3c, and β 3d subunit proteins are shown in SEQ.ID.NOs.:2, 4, 6, 8, and 10, respectively. Thus, the present invention includes human calcium sensitive potassium channel β 2, β 3a, β 3b, β 3c, and β 3d subunit proteins substantially free from other proteins having the amino acid sequences SEQ.ID.NO.:2, SEQ.ID.NO.:4; SEQ.ID.NO.:4 with an asparagine at position 163 instead of a serine; SEQ.ID.NO.:6; SEQ.ID.NO.:6 with a serine at position 143 instead of an asparagine; SEQ.ID.NO.:8; SEQ.ID.NO.:8 with an asparagine at

position 161 instead of a serine; SEQ.ID.NO.:10; and SEQ.ID.NO.:10 with a serine at position 165 instead of an asparagine. The present invention also includes isolated human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$ subunit proteins having the amino acid sequences SEQ.ID.NO.:2, SEQ.ID.NO.:4;

- 5 SEQ.ID.NO.:4 with an asparagine at position 163 instead of a serine; SEQ.ID.NO.:6; SEQ.ID.NO.:6 with a serine at position 143 instead of an asparagine; SEQ.ID.NO.:8; SEQ.ID.NO.:8 with an asparagine at position 161 instead of a serine; SEQ.ID.NO.:10; and SEQ.ID.NO.:10 with a serine at position 165 instead of an asparagine.

- 10 Mutated forms of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$ subunit proteins are intended to be within the scope of the present invention. In particular, mutated forms of SEQ.ID.NOs:2, 4, 6, 8, and 10 that give rise to calcium sensitive potassium channels having altered electrophysiological or pharmacological properties when combined with α subunits are within the scope of the present invention.

- 15 As with many proteins, it is possible to modify many of the amino acids of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins and still retain substantially the same biological activity as for the original proteins. Thus, the present invention includes modified human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$ subunit proteins which have
20 amino acid deletions, additions, or substitutions but that still retain substantially the same biological activity as naturally occurring human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. It is generally accepted that single amino acid substitutions do not usually alter the biological activity of a protein (see, *e.g.*, Molecular Biology of the Gene, Watson *et al.*, 1987, Fourth Ed., The
25 Benjamin/Cummings Publishing Co., Inc., page 226; and Cunningham & Wells, 1989, Science 244:1081-1085). Accordingly, the present invention includes polypeptides where one amino acid substitution has been made in SEQ.ID.NOs:2, 4, 6, 8, or 10 wherein the polypeptides still retain substantially the same biological activity as naturally occurring human calcium sensitive potassium channel $\beta 2$, $\beta 3a$,
30 $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. The present invention also includes polypeptides where two or more amino acid substitutions have been made in SEQ.ID.NOs:2, 4, 6, 8, or 10 wherein the polypeptides still retain substantially the same biological activity as naturally occurring human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. In particular, the present invention includes embodiments

where the above-described substitutions are conservative substitutions. In particular, the present invention includes embodiments where the above-described substitutions do not occur in conserved positions. Conserved positions are those positions in which the human calcium sensitive potassium channel $\beta 1$, $\beta 2$, and any of the $\beta 3$ subunits all have the same amino acid (see Figure 6).

The human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins of the present invention may contain post-translational modifications, *e.g.*, covalently linked carbohydrate, phosphorylation, myristoylation, palmytoylation, *etc.*

The present invention also includes chimeric human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. Chimeric human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins consist of a contiguous polypeptide sequence of at least a portion of a human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein fused to a polypeptide sequence that is not from a human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein.

The present invention also includes isolated human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins and DNA encoding these isolated subunits. Use of the term "isolated" indicates that the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein or DNA has been removed from its normal cellular environment. Thus, an isolated human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that an isolated human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein is the only protein present, but instead means that the isolated human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein is at least 95% free of non-amino acid material (*e.g.*, nucleic acids, lipids, carbohydrates) naturally associated with the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein. Thus, a human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein that is expressed in bacteria or even in eukaryotic cells which do not naturally (*i.e.*, without human intervention) express it through recombinant means is an "isolated human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein."

It is known that certain potassium channels subunits can interact to form heteromeric structures resulting in functional potassium channels. For example, KCNQ2 and KCNQ3 can assemble to form a heteromeric functional potassium channel (Wang et al., 1998, Science 282:1890-1893). Accordingly, it is believed likely that the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins of the present invention will also be able to form heteromeric structures with other proteins where such heteromeric structures constitute functional potassium channels. Thus, the present invention includes such heteromers comprising human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. Preferred heteromers are those in which the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins of the present invention forms heteromers with calcium sensitive potassium channel α subunits.

DNA encoding the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins can be obtained by methods well known in the art. For example, a cDNA fragment encoding full-length human calcium sensitive potassium channel $\beta 2$ subunit protein can be isolated from human uterus, ovary or pancreas cDNA by using the polymerase chain reaction (PCR) employing suitable primer pairs. Such primer pairs can be selected based upon the DNA sequence encoding the human calcium sensitive potassium channel $\beta 2$ subunit protein shown in Figure 1A as SEQ.ID.NO.:1. Suitable primer pairs would be, *e.g.*:

5'-AAG ATG TTT ATA TGG ACC AGT GGC-3' (SEQ.ID.NO.:12)

and

5'-ACT CAT AAC AGA CTG CAC GTT AC-3' (SEQ.ID.NO.:13).

The above and subsequent primers are meant to be illustrative only; one skilled in the art would readily be able to design other suitable primers based upon SEQ.ID.NO.:1. Such primers could be produced by methods of oligonucleotide synthesis that are well known in the art.

In a similar manner, PCR primers can be selected and produced for the other human calcium sensitive potassium channel subunit proteins of the present invention. For example, for the human calcium sensitive potassium channel $\beta 3a$ subunit, suitable primer pairs would be, *e.g.*:

5'-GTC ATG CAG CCC TTC AGC ATC CC-3' (SEQ.ID.NO.:14)

and

5'-TTG CAG AAA TCA CAG ACA TCT GAA-3' (SEQ.ID.NO.:15).

A suitable cDNA template from which the human calcium sensitive potassium channel $\beta 3a$ subunit can be isolated is human heart, skeletal muscle or spleen cDNA.

5 For the human calcium sensitive potassium channel $\beta 3b$ subunit, suitable primer pairs would be, *e.g.*:

5'-GCA ATG ACA GCC TTT CCT GCC TC-3' (SEQ.ID.NO.:16)

and

5'-TTG CAG AAA TCA CAG ACA TCT GAA-3' (SEQ.ID.NO.:15).

10 A suitable cDNA template from which the human calcium sensitive potassium channel $\beta 3b$ subunit can be isolated is human spleen cDNA.

For the human calcium sensitive potassium channel $\beta 3c$ subunit, suitable primer pairs would be, *e.g.*:

15 5'-GAA ATG TTC CCC CTT CTT TAT GAG-3' (SEQ.ID.NO.:17)

and

5'-TTG CAG AAA TCA CAG ACA TCT GAA-3' (SEQ.ID.NO.:15).

20 A suitable cDNA template from which the human calcium sensitive potassium channel $\beta 3c$ subunit can be isolated is human pancreas or spleen cDNA.

For the human calcium sensitive potassium channel $\beta 3d$ subunit, suitable primer pairs would be, *e.g.*:

5'-GAG ATG GAC TTT TCA CCA AGC TCT-3' (SEQ.ID.NO.:18)

and

25 5'-TTG CAG AAA TCA CAG ACA TCT GAA-3' (SEQ.ID.NO.:15).

A suitable cDNA template from which the human calcium sensitive potassium channel $\beta 3d$ subunit can be isolated is human pancreas or spleen cDNA.

30 PCR reactions can be carried out with a variety of thermostable enzymes including but not limited to AmpliTaq, AmpliTaq Gold, or Vent polymerase. For AmpliTaq, reactions can be carried out in 10 mM Tris-Cl, pH 8.3, 2.0 mM $MgCl_2$, 200 μM for each dNTP, 50 mM KCl, 0.2 μM for each primer, 10 ng of DNA template, 0.05 units/ μl of AmpliTaq. The reactions are heated at 95°C for 3 minutes and then cycled 25 times using the cycling parameters of 95°C, 20 seconds, 62°C, 20

seconds, 72°C, 3 minutes. In addition to these conditions, a variety of suitable PCR protocols can be found in PCR Primer, A Laboratory Manual, edited by C.W. Dieffenbach and G.S. Dveksler, 1995, Cold Spring Harbor Laboratory Press; or PCR Protocols: A Guide to Methods and Applications, Michael *et al.*, eds., 1990,

5 Academic Press.

Since the calcium sensitive potassium channel subunits of the present invention are highly homologous to one another, and to other potassium channel subunits, it is desirable to sequence the clones obtained by the herein-described methods, in order to verify that the desired calcium sensitive potassium channel β subunits have in fact been obtained.

By these methods, cDNA clones encoding the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins can be obtained. These cDNA clones can be cloned into suitable cloning vectors or expression vectors, *e.g.*, the mammalian expression vector pcDNA3.1 (Invitrogen, San Diego, CA). Human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins can then be produced by transfecting expression vectors encoding the subunits or portions thereof into suitable host cells and growing the host cells under appropriate conditions. Human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins can then be isolated by methods well known in the art.

As an alternative to the above-described PCR methods, cDNA clones encoding the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins can be isolated from cDNA libraries using as a probe oligonucleotides specific for each human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit and methods well known in the art for screening cDNA libraries with oligonucleotide probes. Such methods are described in, *e.g.*, Sambrook *et al.*, 1989, *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K., Vol. I, II. Oligonucleotides that are specific for particular human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits and that can be used to screen cDNA libraries can be readily designed based upon the DNA sequences shown in Figures 1-5 and can be synthesized by methods well-known in the art.

Genomic clones containing the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit genes can be obtained from commercially

available human PAC, YAC, or BAC libraries available from Research Genetics, Huntsville, AL. Alternatively, one may prepare genomic libraries, *e.g.*, in P1 artificial chromosome vectors, from which genomic clones containing the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit genes can be isolated, using probes based upon the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit DNA sequences disclosed herein. Methods of preparing such libraries are known in the art (see, *e.g.*, Ioannou *et al.*, 1994, Nature Genet. 6:84-89).

The novel DNA sequences of the present invention can be used in various diagnostic methods. The present invention provides diagnostic methods for determining whether a patient carries a mutation in one or more of the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit genes. In broad terms, such methods comprise determining the DNA sequence of a region in or near one or more of the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit genes from the patient and comparing that sequence to the sequence from the corresponding region of the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit genes from a non-affected person, *i.e.*, a person who does not have the condition which is being diagnosed, where a difference in sequence between the DNA sequence of the gene from the patient and the DNA sequence of the gene from the non-affected person indicates that the patient has a mutation in one or more of the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit genes.

The present invention also provides oligonucleotide probes, based upon the sequences of SEQ.ID.NOs: 1, 3, 5, 7, 9, or 20 that can be used in diagnostic methods to identify patients having mutated forms of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits, to determine the level of expression of RNA encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits, or to isolate genes homologous to human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits. In particular, the present invention includes DNA oligonucleotides comprising at least about 10, 15, or 18 contiguous nucleotides of a sequence selected from the group consisting of: SEQ.ID.NOs: 1, 3, 5, 7, 9, and 20 where the oligonucleotide probe comprises no stretch of contiguous nucleotides longer than 5 of a sequence selected from the group consisting of: SEQ.ID.NOs: 1, 3, 5, 7, 9, and 20 other than the said at least about 10,

15, or 18 contiguous nucleotides. The oligonucleotides can be substantially free from other nucleic acids. Also provided by the present invention are corresponding RNA oligonucleotides. The DNA or RNA oligonucleotide can be packaged in kits for use as probes.

5 The present invention makes possible the recombinant expression of the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins in various cell types.

10 The $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$ subunits of the human calcium sensitive potassium channel have been expressed in *Xenopus* oocytes, both by themselves and in combination with an α subunit of a large-conductance calcium-sensitive potassium channel (maxi-K channel). The β subunits do not express currents on their own. However, when co-expressed with the α subunit, the $\beta 2$, $\beta 3a$, and $\beta 3c$ subunits induce inactivation of calcium sensitive potassium currents (Figure 7). The rates of inactivation produced by $\beta 2$, $\beta 3a$ and $\beta 3c$ are dependent upon
15 voltage and internal calcium concentration; inactivation time constants reach a maximum at high depolarizations and high micromolar calcium for $\beta 2$, $\beta 3a$ and $\beta 3c$, $\tau_{inact} \sim 30-40$ ms at 80 mV with 30 μM intracellular Ca^{2+} . Measurements of current-voltage dependence obtained in the presence of micromolar intracellular Ca^{2+} demonstrate that $\beta 2$ subunits induce a large shift in the voltage dependence of
20 activation (~ 80 mV towards negative potentials, with 30 μM Ca^{2+} in the bath; Figure 7B). This modulatory effect is similar to the one previously described for $\beta 1$ subunits, which do not induce inactivation. (McManus et al., 1995, Neuron 14:645-650). In contrast, $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$ subunits do not shift the voltage dependence when compared to channels containing only α subunits (Figure 7B).

25 The present invention also makes possible the development of assays that measure the biological activity of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. Such assays using recombinantly expressed human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins are especially
30 of interest. Such assays can be used to screen libraries of compounds or other sources of compounds to identify compounds that are activators or inhibitors of the activity of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. Such identified compounds can serve as "leads" for the development of pharmaceuticals that can be used to treat

patients having diseases in which it is beneficial to enhance or suppress calcium sensitive potassium channel activity.

In versions of the above-described assays, calcium sensitive potassium channels containing mutant human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins are used and inhibitors or activators of the activity of the mutant calcium sensitive potassium channels are identified.

Preferred cell lines for recombinant expression of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins are those which do not express endogenous potassium channels (*e.g.*, CV-1, NIH-3T3, CHO-K1, COS-7). Such cell lines can be loaded with ^{86}Rb , an ion which can pass through potassium channels. The ^{86}Rb -loaded cells can be exposed to collections of substances (*e.g.*, combinatorial libraries, natural products, analogues of lead compounds produced by medicinal chemistry) and those substances that are able to alter ^{86}Rb efflux identified. Such substances are likely to be activators or inhibitors of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins.

Activators and inhibitors of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins are likely to be substances that are capable of binding to calcium sensitive potassium channels. Accordingly, one type of assay determines whether one or more of a collection of substances is capable of such binding.

Accordingly, the present invention provides a method for identifying substances that bind to calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins comprising:

- (a) providing cells expressing a calcium sensitive potassium channel containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;
- (b) exposing the cells containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins to a substance that is not known to bind calcium sensitive potassium channels;
- (c) determining the amount of binding of the substance to the cells;
- (d) comparing the amount of binding in step (c) to the amount of binding of the substance to control cells where the control cells are substantially

identical to the cells of step (a) except that the control cells do not express human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

where if the amount of binding in step (c) is greater than the amount of binding of the substance to control cells, then the substance binds to calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins.

Another version of this assay makes use of compounds that are known to bind to calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. New binders are identified by virtue of their ability to potentiate, prevent, or displace the binding of the known compounds. Substances that have this ability are likely themselves to be inhibitors or activators of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins.

Accordingly, the present invention includes a method of identifying substances that bind calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins and thus are likely to be inhibitors or activators of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins comprising:

(a) providing cells expressing calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

(b) exposing the cells to a compound that is known to bind to the calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

(c) determining the amount of binding of the compound to the cells in the presence and in the absence of a substance not known to bind to calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

where if the amount of binding of the compound in the presence of the substance differs from that in the absence of the substance, then the substance binds calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins and is likely to be an inhibitor or

activator of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins.

Generally, the known compound is labeled (*e.g.*, radioactively, enzymatically, fluorescently) in order to facilitate measuring its binding to the calcium sensitive potassium channels.

Once a substance has been identified by the above-described methods, it can be assayed in functional tests, such as those described herein, in order to determine whether it is an inhibitor or an activator.

In particular embodiments, the compound known to bind calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins is selected from the group consisting of: charybdotoxin, iberiotoxin, and dehydrosoyasaponin.

The present invention includes a method of identifying activators or inhibitors of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins comprising:

(a) recombinantly expressing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins or mutant human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins in a host cell so that the recombinantly expressed human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins form calcium sensitive potassium channels by forming heteromers with other calcium sensitive potassium channel subunit proteins;

(b) measuring the biological activity of the calcium sensitive potassium channels formed in step (a) in the presence and in the absence of a substance suspected of being an activator or an inhibitor of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

where a change in the biological activity of the calcium sensitive potassium channels formed in step (a) in the presence as compared to the absence of the substance indicates that the substance is an activator or an inhibitor of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins.

It may be advantageous to recombinantly express other subunits of calcium sensitive potassium channels such as, *e.g.*, an α subunit. Alternatively, it may be advantageous to use host cells that endogenously express such other subunits.

In particular embodiments, the biological activity is the production of a calcium sensitive potassium current, a FRET signal, or the efflux of ^{86}Rb .

In particular embodiments, a vector encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins is transferred into *Xenopus* oocytes in order to cause the expression of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins in the oocytes. Alternatively, RNA encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins can be prepared *in vitro* and injected into the oocytes, also resulting in the expression of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins in the oocytes. Following expression of the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins in the oocytes, and following the formation of calcium sensitive potassium channels containing these subunits and other calcium sensitive potassium channel subunits (which other subunits may also be transferred into the oocytes), membrane currents are measured after the transmembrane voltage and/or internal calcium concentration is changed in steps. A change in membrane current is observed when the calcium sensitive potassium channels open or close, allowing or inhibiting potassium ion flow, respectively. Similar oocyte studies were reported for KCNQ2 and KCNQ3 potassium channels in Wang et al., 1998, Science 282:1890-1893 and this reference and references cited therein can be consulted for guidance as to how to carry out such studies.

Inhibitors or activators of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins can be identified by exposing the oocytes to collections of substances and determining whether the substances can block or diminish, or activate or enhance the membrane currents observed in the absence of the substance.

Accordingly, the present invention provides a method of identifying inhibitors or activators of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins comprising:

(a) expressing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins in a heterologous system such that calcium sensitive potassium channels containing the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins are formed;

(b) changing the transmembrane potential or internal calcium concentration of the heterologous system in the presence and the absence of a substance suspected of being an inhibitor or activator of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

(c) measuring membrane potassium currents following step (b); where if the membrane potassium currents measured in step (c) are greater in the absence rather than in the presence of the substance, then the substance is an inhibitor of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

where if the membrane potassium currents measured in step (c) are less in the absence rather than in the presence of the substance, then the substance is an activator of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins.

In particular embodiments, the heterologous system is selected from the group consisting of: *Xenopus* oocytes and a mammalian cell line.

The present invention also includes assays for the identification of activators and inhibitors of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins that are based upon fluorescence resonance energy transfer (FRET) between a first and a second fluorescent dye where the first dye is bound to one side of the plasma membrane of a cell expressing calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins and the second dye is free to shuttle from one face of the membrane to the other face in response to changes in membrane potential. In certain embodiments, the first dye is impenetrable to the plasma membrane of the cells and is bound predominately to the extracellular surface of the plasma membrane. The second dye is trapped within the plasma membrane but is free to diffuse within the membrane. At normal (*i.e.*, negative) resting potentials of the membrane, the second dye is bound predominately to the inner surface of the extracellular face of the plasma membrane, thus placing the second dye in close proximity to the first dye. This close proximity allows for the generation of a large amount of FRET between the two dyes. Following membrane depolarization, the second dye moves from the extracellular face of the membrane to the intracellular face, thus increasing the distance between

the dyes. This increased distance results in a decrease in FRET, with a corresponding increase in fluorescent emission derived from the first dye and a corresponding decrease in the fluorescent emission from the second dye. In this way, the amount of FRET between the two dyes can be used to measure the polarization state of the membrane. For a fuller description of this technique, see González & Tsien, 1997, Chemistry & Biology 4:269-277. See also González & Tsien, 1995, Biophys. J. 69:1272-1280 and U.S. Patent No. 5,661,035.

In certain embodiments, the first dye is a fluorescent lectin or a fluorescent phospholipid that acts as the fluorescent donor. Examples of such a first dye are: a coumarin-labeled phosphatidylethanolamine (*e.g.*, N-(6-chloro-7-hydroxy-2-oxo-2H--1-benzopyran-3-carboxamidoacetyl)-dimyristoylphosphatidyl-ethanolamine) or N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-dipalmitoylphosphatidylethanolamine); a fluorescently-labeled lectin (*e.g.*, fluorescein-labeled wheat germ agglutinin). In certain embodiments, the second dye is an oxonol that acts as the fluorescent acceptor. Examples of such a second dye are: bis(1,3-dialkyl-2-thiobarbiturate)trimethineoxonols (*e.g.*, bis(1,3-dihexyl-2-thiobarbiturate)trimethineoxonol) or pentamethineoxonol analogues (*e.g.*, bis(1,3-dihexyl-2-thiobarbiturate)pentamethineoxonol; or bis(1,3-dibutyl-2-thiobarbiturate)pentamethineoxonol). See González & Tsien, 1997, Chemistry & Biology 4:269-277 for methods of synthesizing various dyes suitable for use in the present invention. In certain embodiments, the assay may comprise a natural carotenoid, *e.g.*, astaxanthin, in order to reduce photodynamic damage due to singlet oxygen.

The above described assays can be utilized to discover activators and inhibitors of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. Such assays will generally utilize cells that express calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins, *e.g.*, by transfection with expression vectors encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins and, optionally, other calcium sensitive potassium channel subunits. In such cells, depolarization of the membrane potential as well as increases in intracellular calcium concentration will tend to open the calcium sensitive potassium channels. This will result in potassium efflux, tending to counteract the depolarization. In other words,

the cells will tend to repolarize. The presence of an inhibitor of the calcium sensitive potassium channel will prevent, or diminish, this repolarization. Thus, membrane potential will tend to become more positive (*i.e.*, depolarized) in the presence of inhibitors. Activators of the calcium sensitive potassium channel will open this channel and thus tend to hyperpolarize the membrane potential. Changes in membrane potential (depolarizations and hyperpolarizations) that are caused by inhibitors and activators of calcium sensitive potassium channels can be monitored by the assays using FRET described above.

Accordingly, the present invention provides a method of identifying activators of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins comprising:

(a) providing test cells comprising:

(1) an expression vector that directs the expression of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins in the cells so that calcium sensitive potassium channels containing human $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins are formed in the cells;

(2) a first fluorescent dye, where the first dye is bound to one side of the plasma membrane of the cells; and

(3) a second fluorescent dye, where the second fluorescent dye is free to shuttle from one face of the plasma membrane of the cells to the other face in response to changes in membrane potential;

(b) exposing the test cells to a substance that is suspected of being an activator of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

(c) measuring the amount of fluorescence resonance energy transfer (FRET) in the test cells that have been exposed to the substance;

(d) comparing the amount of FRET exhibited by the test cells that have been exposed to the substance with the amount of FRET exhibited by control cells;

wherein if the amount of FRET exhibited by the test cells is greater than the amount of FRET exhibited by the control cells, the substance is an activator of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ -subunit proteins;

where the control cells are either (1) cells that are essentially the same as the test cells except that they do not comprise at least one of the items listed at (a) (1)-(3) but have been exposed to the substance; or (2) test cells that have not been exposed to the substance.

5 The present invention also provides a method of identifying inhibitors of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins comprising:

(a) providing test cells comprising:

10 (1) an expression vector that directs the expression of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins in the cells so that calcium sensitive potassium channels containing human $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins are formed in the cells;

(2) a first fluorescent dye, where the first dye is bound to one side of the plasma membrane of the cells; and

15 (3) a second fluorescent dye, where the second fluorescent dye is free to shuttle from one face of the plasma membrane of the cells to the other face in response to changes in membrane potential;

(b) exposing the test cells to a substance that is suspected of being an inhibitor of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

20 (c) measuring the amount of fluorescence resonance energy transfer (FRET) in the test cells that have been exposed to the substance;

(d) comparing the amount of FRET exhibited by the test cells that have been exposed to the substance with the amount of FRET exhibited by control cells;

25 wherein if the amount of FRET exhibited by the test cells is less than the amount of FRET exhibited by the control cells, the substance is an inhibitor of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

30 where the control cells are either (1) cells that are essentially the same as the test cells except that they do not comprise at least one of the items listed at (a) (1)-(3) but have been exposed to the substance; or (2) test cells that have not been exposed to the substance.

In a variation of the assay described above, instead of the cell's membrane potential being allowed to reach steady state on its own, the membrane potential is artificially set at a potential in which the calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins are open. This can be done, *e.g.*, by variation of the external K^+ concentration in a known manner (*e.g.*, increased concentrations of external K^+). If such cells, having open calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins, are exposed to inhibitors, the calcium sensitive potassium channels will be blocked, and the cells' membrane potentials will be depolarized. This depolarization can be observed as a decrease in FRET.

In a variation of the assay described above, instead of the cell's membrane potential being allowed to reach steady state on its own, the membrane potential is artificially set at a potential in which the calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins are open by coexpression of another depolarizing current. If such cells, having open calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins, are exposed to inhibitors, the calcium sensitive potassium channels will be blocked, and the cells' membrane potentials will be depolarized. This depolarization can be observed as a decrease in FRET. If such cells, having open calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins, are exposed to activators, the balance of the calcium sensitive potassium current and the additional depolarizing current will shift (*i.e.*, the calcium sensitive potassium current will make a larger contribution to the total current) and the cell's membrane potential will be hyperpolarized. This polarization may be observed as an increase in FRET.

Accordingly, the present invention provides a method of identifying inhibitors or activators of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins comprising:

- (a) providing cells comprising:
 - (1) an expression vector that directs the expression of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit

proteins in the cells so that calcium sensitive potassium channels containing human $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins are formed in the cells;

(2) a first fluorescent dye, where the first dye is bound to one side of the plasma membrane of the cells; and

(3) a second fluorescent dye, where the second fluorescent dye is free to shuttle from one face of the plasma membrane of the cells to the other face in response to changes in membrane potential;

(b) adjusting the membrane potential of the cells such that the ion channel formed by the calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins is open;

(c) measuring the amount of fluorescence resonance energy transfer (FRET) in the test cells;

(d) repeating step (b) and step (c) while the cells are exposed to a substance that is suspected of being an inhibitor or activator of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

where if the amount of FRET exhibited by the cells that are exposed to the substance is different than the amount of FRET exhibited by the cells that have not been exposed to the substance, then the substance is an inhibitor or activator of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins.

In particular embodiments of the above-described methods, the cells contain an expression vector encoding a human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein. In particular embodiments of the above-described methods, the expression vector is transfected into the test cells.

In particular embodiments of the above-described methods, the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein has an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:2, 4, 6, 8, and 10.

In particular embodiments of the above-described methods, the first fluorescent dye is selected from the group consisting of: a fluorescent lectin; a fluorescent phospholipid; a coumarin-labeled phosphatidylethanolamine; N-(6-chloro-7-hydroxy-2-oxo-2H--1-benzopyran-3-carboxamidoacetyl)-dimyristoylphosphatidyl-

ethanolamine); N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-dipalmitoyl-phosphatidylethanolamine); and fluorescein-labeled wheat germ agglutinin.

In particular embodiments of the above-described methods, the second fluorescent dye is selected from the group consisting of: an oxonol that acts as the fluorescent acceptor; bis(1,3-dialkyl-2-thiobarbiturate)trimethineoxonols; bis(1,3-dihexyl-2-thiobarbiturate)trimethineoxonol; bis(1,3-dialkyl-2-thiobarbiturate)quatramethineoxonols; bis(1,3-dialkyl-2-thiobarbiturate)pentamethineoxonols; bis(1,3-dihexyl-2-thiobarbiturate)pentamethineoxonol; bis(1,3-dibutyl-2-thiobarbiturate)pentamethineoxonol); and bis(1,3-dialkyl-2-thiobarbiturate) hexamethineoxonols.

In a particular embodiment of the above-described methods, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, or *Xenopus* oocytes.

In particular embodiments of the above-described methods, the control cells do not comprise item (a)(1) but do comprise items (a)(2) and (a)(3).

In assays to identify activators or inhibitors of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins, it may be advantageous to co-express another calcium sensitive potassium channel subunit besides the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit. In particular, it may be advantageous to co-express a calcium sensitive potassium channel α subunit. Preferably, this is done by co-transfecting into the cells an expression vector encoding the other subunit. Suitable other subunits are, *e.g.*, the human calcium sensitive potassium channel α subunit *h-slo* (GenBank accession no. U11058), the mouse calcium sensitive potassium channel α subunit *m-slo* (GenBank accession no. U09383), the small conductance calcium sensitive potassium α subunits (GenBank accession nos. U69883, U69882, AF031815), or the intermediate conductance calcium sensitive potassium channel α subunit (GenBank accession no. AF022797).

Small regions of genomic sequences in proximity to a gene often regulate the transcription of that gene. These sequences are referred to as cis-acting elements. The proteins that bind these DNA sequences and directly affect the ability of the transcriptional machinery to bind or transcribe the gene are referred to as trans-acting elements. The cis-acting transcriptional regulatory elements are most often 5' of the transcription start site, but have been located within and 3' of the transcribed portion of genes as well. Depending on their effects on the rate of transcription, these sequences can be divided into three categories: promoters, enhancers, and repressors. A promoter independently allows transcription of the gene, while an enhancer increases the rate of transcription but is not capable of inducing transcription independently of the promoter. A repressor element inhibits transcription directed by a promoter element. Methods for identifying these elements are well known in the field and are described in Ausubel et al., eds., 1989, Current Protocols in Molecular Biology, sections 9.6-9.8, and 12.0-12.11, John Wiley & Sons, New York, NY.

Accordingly, the novel genomic sequences (SEQ.ID.NO.:20, Figure 8) and isolated BAC clones of the present invention make possible methods for identifying 1) DNA sequences required for transcriptional control of gene expression, 2) proteins involved in transcriptional regulation and 3) compounds which modulate the rate of transcription of the $\beta 3$ gene. Such assays utilize isolated and/or recombinant DNA comprising portions of SEQ.ID.NO.:20, positions 1 to 17,436, inserted into vectors upstream of the open reading frame of a reporter protein.

Useful reporter proteins are ones that are not expressed in the cells to be assayed (or are easily distinguished from endogenous proteins), have a linear relationship between the abundance of the transcript and the abundance of the reporter protein, and have a large window between the minimum detection level and saturation of detection system. Ideally, the abundance of the reporter protein is quickly measured by an enzymatic reaction, fluorescence detection, immunoassay or other means. Typical reporter proteins include, but are not limited to, the following: Chloramphenicol Acetyltransferase (CAT), firefly luciferase, Beta-Lactamase, Beta-Galactosidase, Secreted Alkaline Phosphatase (SEAP), human Growth Hormone (hGH), Green Fluorescent Protein (GFP) and GFP derivatives. Reporter vectors incorporating these proteins are commercially available, as are similar reporter vectors containing constitutive promoters, enhancers, or both (Clontech).

The present invention provides a method for identifying nucleotide sequences involved in transcriptional regulation of $\beta 3$ gene expression. Once a fragment of at least 6 contiguous nucleotides of DNA from SEQ.ID.NO.:20, positions 1-17,436, has been inserted upstream of the reporter cDNA in a promoter-reporter vector, the vector is then transfected into cells that either do or do not endogenously express one or more of the calcium sensitive potassium channel subunits $\beta 3a$, $\beta 3b$, $\beta 3c$ or $\beta 3d$. Promoter-reporter vectors may contain promoters, enhancers, both, or neither. Transfected cells are then assayed for the amount of reporter protein present. Because both transfection efficiency and transcription rate directly affect reporter protein level, it is useful in these assays to determine the transfection efficiency by co-transfecting a second vector (molar ratio 1:1) containing a distinct reporter behind a constitutive promoter, and determining the fraction of transfected cells.

In versions of the above assay, vectors are constructed with fragments of SEQ.ID.NO.:20 inserted upstream of a reporter cDNA with no other enhancer or promoter elements. These vectors (with and without fragments of SEQ.ID.NO.:20) are transfected into cells that endogenously express $\beta 3$ subunits. Calcium sensitive potassium channel $\beta 3$ subunit promoter elements are identified by the ability of these 5' gene fragments to stimulate reporter expression above the levels observed in the parent vector. The minimum required promoter sequence is then identified by successively deleting regions of the identified promoter fragment, and repeating the assay.

Another version of the assay incorporates fragments of SEQ.ID.NO.:20 inserted upstream of the reporter cDNA in a promoter-reporter vector containing an enhancer element. These vectors (with and without fragments of SEQ.ID.NO.:20) are transfected into cells that endogenously express $\beta 3$ subunits. Weak calcium sensitive potassium channel $\beta 3$ subunit promoter elements are identified by the ability of these 5' gene fragments to stimulate reporter expression above the levels observed in the parent vector. The minimum required weak promoter sequence can then be identified by successively deleting regions of the identified weak promoter fragment and repeating the assay.

A different version of the assay incorporates fragments of SEQ.ID.NO.:20 inserted upstream of the reporter cDNA in a promoter-reporter vector with a constitutive promoter upstream. These vectors (with and without fragments of SEQ.ID.NO.:20) are transfected into cells that do not endogenously express $\beta 3$

subunits. Calcium sensitive potassium channel $\beta 3$ subunit repressor elements are identified by the ability of these 5' gene fragments to prevent or reduce reporter expression below the levels observed in the parent vector. The minimum required repressor sequence is then identified by successively deleting regions of the identified repressor fragment and repeating the assay.

In view of the above, the present invention provides a method of identifying DNA sequences in the $\beta 3$ gene that promote, enhance, or repress gene transcription comprising:

- (a) constructing a promoter-reporter vector such that fragments of the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) precede the coding cDNA sequence of a reporter gene which encodes a reporter protein;
- (b) transfecting the vector into cells and measuring the abundance of the reporter protein encoded by the vector;
- (c) comparing the abundance of the reporter protein in the cells of step (b) to the abundance of the reporter protein in cells transfected with the vector without fragments of the promoter region of the $\beta 3$ gene;

where fragments of the promoter region of the $\beta 3$ gene which increase the abundance of the reporter protein in the absence of other promoter elements only in cells which endogenously express $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits are promoter elements; sequences which decrease the abundance of the reporter protein in the presence of an unrelated constitutive promoter element in cells which do not endogenously express $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits are repressor elements; and sequences which increase the abundance of the reporter protein in the presence of an unrelated constitutive promoter element in cells which endogenously express $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits are enhancer elements.

In particular embodiments, the vector contains promoter or enhancer sequence elements which function independently of the fragments of the promoter region of the $\beta 3$ gene.

In particular embodiments, the abundance of the reporter protein is normalized with respect to the fraction of transfected cells.

The binding of nuclear proteins to these sequences can be confirmed by gel-shift assays. A radiolabeled DNA fragment corresponding to the minimal sequence required to affect transcription is incubated with nuclear protein extracts from cells used to identify the regulatory DNA element, or tissues endogenously

expressing $\beta 3$ subunits. If a protein factor binds that sequence, the mobility in a gel will be altered, resulting in an apparent shift in the size of the radiolabeled fragment.

Transcription factors often are able to recognize more than one specific nucleotide sequence. As such, variations of sequences identified as minimal promoters, enhancers or repressors necessary for transcriptional regulation of the $\beta 3$ gene in SEQ.ID.NO.:20, positions 1-17,436, which retain the ability to influence transcription as detected in the above described assays are intended to be included in the present invention.

Minimal promoter, enhancer or repressor DNA fragments thus identified can then be used to identify and/or isolate proteins that influence transcriptional activity of the $\beta 3$ gene. Several methods are well known in the field, some of which are described in Ausubel et al., eds., 1989, Current Protocols in Molecular Biology, sections 12.0-12.11, John Wiley & Sons, New York, NY.

In one method, gel shift assays described above can be performed with cloned or purified known transcription factors, to determine if they are capable of binding sequences involved in transcriptional regulation. Alternatively, super-shift assays can be performed in which an antibody that recognizes a particular transcription factor is added to the transcription factor-DNA complex. If the antibody binds to the transcription factor, which in turn binds the radiolabeled DNA fragment, the mobility of the complex in a gel is further altered, resulting in a super-shift compared to the DNA alone. Using antibodies that recognize a specific transcription factor, or a class of transcription factors, allows identification of the factors involved in $\beta 3$ gene regulation. Variations of sequences identified as minimal promoters, enhancers or repressors necessary for transcriptional regulation of the $\beta 3$ gene in SEQ.ID.NO.:20, positions 1-17,436, which retain the ability to undergo gel shifts or super-shifts as described in the above assays are intended to be included in the present invention.

In view of the above, the present invention provides a method of identifying DNA sequences in the $\beta 3$ gene that promote, enhance, or repress gene transcription comprising:

- (a) incubating radiolabeled fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) with nuclear extracts from cells and separating the incubation on a gel;

where fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene that migrate differently in a gel ('undergo a shift') after incubation with nuclear extracts from cells are DNA sequences which bind nuclear factors which promote, enhance or repress $\beta 3$ gene expression.

5 In particular embodiments, the fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the method of claim 18.

In particular embodiments, the cells express $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits.

10 In particular embodiments, the cells do not express $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits.

The present invention provides a method of identifying nuclear factors involved in $\beta 3$ gene transcription regulation comprising:

(a) incubating radiolabeled fragments of double stranded DNA
15 corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) with cloned or purified transcription factors and separating the incubation on a gel;

where factors which bind $\beta 3$ gene promoter sequence elements will induce a shift in the migration of the radiolabeled DNA fragments, and are involved
20 in $\beta 3$ gene transcription regulation.

In particular embodiments, the fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the methods of claim 18 or 21.

The present invention provides a method of identifying nuclear factors
25 involved in $\beta 3$ gene transcription regulation comprising:

(a) incubating radiolabeled fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) with nuclear extracts from cells and separating the incubation on a gel;

30 (b) adding an antibody that specifically recognizes a single transcription factor or a family of transcription factors to the incubation of step (a), followed by separating the incubation on a gel;

where a super-shift in mobility of the double stranded DNA in step (b) as compared to step (a) indicates that a transcription factor recognized by the antibody binds the double stranded DNA.

In another method, the transcription factors that bind SEQ.ID.NO.:20, positions 1-17,436, and regulate transcription can be purified. DNA fragments corresponding to the minimal sequence required to affect transcription are covalently linked to a matrix (typically an agarose bead). This matrix is then incubated with nuclear extracts of cells that contain factors which bind the minimal element. The matrix is then washed free of non-specific proteins and the factor(s) are eluted with an excess of the DNA element, or by denaturation. Purified proteins can then be identified by immunoassay, protein sequencing, or other means.

Accordingly, the present invention provides a method of identifying nuclear factors involved in $\beta 3$ gene transcription regulation comprising:

- (a) attaching fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) to a stable matrix;
- (b) incubating nuclear extracts from cells with the matrix;
- (c) washing non-binding proteins from the nuclear extract from the matrix;
- (d) eluting bound proteins from the matrix with excess double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene;

where the eluted proteins from step (d) are nuclear factors involved in $\beta 3$ gene transcription regulation.

In particular embodiments, the method further comprises separating the eluted proteins from step (d) on a gel and staining the gel to test for purity of the eluted proteins.

In particular embodiments, the method further comprises sequencing the proteins that have been separated on the gel.

In particular embodiments, the method further comprises immunological analysis of the proteins that have been separated on the gel with antibodies directed towards known transcription factors to identify the eluted proteins by western blot or immunoprecipitation.

In particular embodiments, the fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the methods of claim 18 or 21.

5 In a different approach, cDNAs encoding the transcription factors that bind SEQ.ID.NO.:20; positions 1-17,436 can be cloned by several methods. In one version, the minimal DNA sequence is radiolabeled and used to screen an expression library made from tissues or cell lines that endogenously express the $\beta 3$ gene. Phage containing cDNA encoding the transcription factor are induced to express fusion proteins that target the transcription factor to its surface. Such phage plaques are
10 identified by their ability to bind radiolabeled DNA sequences containing the minimal DNA sequence.

Accordingly, the present invention provides a method of identifying clones encoding nuclear factors involved in $\beta 3$ gene transcription regulation by cloning comprising:

- 15 (a) screening an expression library with radiolabeled fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436)
- (b) determining which clones of the library bind the radiolabeled fragments of double stranded DNA;
- 20 (c) amplifying and sequencing the clones of step (b).

In particular embodiments, the fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the methods of claim 18 or 21.

Another cloning approach involves phage expressing transcription
25 factor fusion proteins at their surface. In this approach, the minimal DNA sequence is linked to a matrix. A phage expression library is then passed over the matrix and washed. Only phage containing the transcription factor bind the matrix. Bound phage are eluted with excess minimal DNA sequence and purified. cDNA encoding the transcription factor is then isolated from the phage and sequenced.

30 Accordingly, the present invention provides a method of identifying nuclear factors involved in $\beta 3$ gene transcription regulation by cloning comprising:

- (a) attaching fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) to a stable matrix;

(b) incubating phage expressing cDNA encoded fusion proteins at their surface with the matrix;

(c) removing phage that do not bind to the matrix by washing;

(d) eluting phage bound to the matrix with excess fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene;

where the phage eluted in step (d) encode nuclear factors involved in $\beta 3$ gene transcription regulation.

In particular embodiments, the DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the methods of claim 18 or 21.

In particular embodiments, the phage eluted at step (d) are amplified and sequenced.

A separate transcription factor cloning approach is the yeast 'one-hybrid' method (available in kit form from Clontech). In this method, yeast strains are made that contain several copies (three suggested) of the minimal element upstream of a reporter. A cDNA library is made such that each vector contains a cDNA that will be expressed as a fusion protein with the transcription activation domain of a yeast promoter. Thus, any fusion protein that specifically binds the DNA of interest will induce expression of the reporter protein. The vector containing the cDNA is then isolated from the yeast and sequenced.

Accordingly, the present invention provides a method of identifying nuclear factors involved in $\beta 3$ gene transcription regulation by cloning comprising:

(a) constructing a yeast strain that contains a few to several copies of a fragment of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) preceding a cDNA encoding a reporter protein;

(b) constructing a cDNA library from cells in a vector that allows formation of fusion proteins encoded by the inserted cDNA and a transcription activation domain;

(c) transforming the library of (b) into the yeast strain of (a) and isolating colonies of yeast displaying expression of the reporter protein.

In particular embodiments, the fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the methods of claim 18 or 21.

In particular embodiments, the method further comprises purifying the vectors from the isolated colonies and sequencing the cDNA in the vectors.

Since transcription factors often are able to recognize more than one specific nucleotide sequence, variations of sequences identified as minimal promoters, enhancers or repressors necessary for transcriptional regulation of the $\beta 3$ gene in SEQ.ID.NO.:20; positions 1-17,436, that can be bound by transcription factors as detected in the above described assays are intended to be included in the present invention.

Identification of nucleotide sequences involved in transcriptional regulation of $\beta 3$ gene expression by the methods described above allows for the development of assays that can be used to screen collections of substances to identify those substances that enhance or inhibit transcription of the $\beta 3$ gene. Fragments of the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) that have been shown to be involved in transcriptional regulation are linked to the coding sequence of a reporter gene in a suitable vector and are then transferred to appropriate cells. The abundance of the reporter protein in the cells is determined. The cells are then exposed to compounds that are suspected of being capable of enhancing or inhibiting the rate of transcription of the $\beta 3$ gene. If the compound actually is capable of enhancing the rate of transcription of the $\beta 3$ gene, then the abundance of the reporter protein will be increased when the cells are exposed to the compound. Conversely, if the compound actually is capable of inhibiting the rate of transcription of the $\beta 3$ gene, then the abundance of the reporter protein will be decreased when the cells are exposed to the compound.

Accordingly, the present invention provides a method of identifying substances that enhance or inhibit the rate of transcription of the $\beta 3$ gene comprising:

- (a) constructing a promoter-reporter vector such that fragments of the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) precede the coding cDNA sequence of a reporter gene which encodes a reporter protein;
- (b) transfecting the vector into cells and measuring the abundance of the reporter protein encoded by the vector in the presence and absence of a compound;

where (1) if the presence of the compound decreases the abundance of the reporter protein, then the compound is a substance that inhibits the rate of transcription of the $\beta 3$ gene; (2) if the presence of the compound increases the

abundance of the reporter protein, then the compound is a substance that enhances the rate of transcription of the $\beta 3$ gene.

In particular embodiments, the method further comprises a control in which the effect of the compound on the abundance of the reporter protein in control cells is measured, where the control cells are cells that are essentially the same as the cells of step (b) except that the control cells have been transfected with a vector that lacks fragments of the promoter region of the $\beta 3$ gene.

While the above-described methods are explicitly directed to testing whether "a" substance is an activator or inhibitor of the transcription the $\beta 3$ gene or the function of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins, it will be clear to one skilled in the art that such methods can be adapted to test collections of substances, *e.g.*, combinatorial libraries, to determine whether any members of such collections are activators or inhibitors of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. Accordingly, the use of collections of substances, or individual members of such collections, as the substance in the above-described methods is within the scope of the present invention. In particular, it is envisioned that libraries that have been designed to incorporate chemical structures that are known to be associated with potassium ion channel modulation, *e.g.*, dihydrobenzopyran libraries for potassium channel activators (International Patent Publication WO 95/30642) or biphenyl-derivative libraries for potassium channel inhibitors (International Patent Publication WO 95/04277) will be especially suitable.

The present invention includes pharmaceutical compositions comprising activators or inhibitors of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins that have been identified by the herein-described methods as well as activators or inhibitors of $\beta 3$ gene transcription. The activators or inhibitors are generally combined with pharmaceutically acceptable carriers to form pharmaceutical compositions. Examples of such carriers and methods of formulation of pharmaceutical compositions containing activators or inhibitors and carriers can be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain a therapeutically effective amount of the activators or inhibitors.

Therapeutic or prophylactic compositions are administered to an individual in amounts sufficient to treat or prevent conditions where human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein activity is abnormal. The effective amount can vary according to a variety of factors such as the individual's condition, weight, gender, and age. Other factors include the mode of administration. The appropriate amount can be determined by a skilled physician. Generally, an effective amount will be from about 0.01 to about 1,000, preferably from about 0.1 to about 250 and even more preferably from about 1 to about 50 mg per adult human per day.

Compositions can be used alone at appropriate dosages. Alternatively, co-administration or sequential administration of other agents can be desirable.

The compositions can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the compositions can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

Compositions can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three, four or more times daily. Furthermore, compositions can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

The dosage regimen utilizing the compositions is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal, hepatic and cardiovascular function of the patient; and the particular composition thereof employed. A physician of ordinary skill can readily determine and prescribe the effective amount of the composition required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of composition within the range that yields efficacy without

toxicity requires a regimen based on the kinetics of the composition's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a composition.

The inhibitors and activators of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins, or inhibitors and activators of $\beta 3$ subunit transcription will be useful for treating a variety of diseases involving excessive or insufficient calcium sensitive potassium channel activity. Accordingly, the present invention includes a method of treating asthma, diabetes, glaucoma, pregnant human myometrium, cerebral ischemia, and conditions where stimulation of neurotransmitter release is desired such as Alzheimer's disease and stimulation of damaged nerves by administering to a patient a therapeutically effective amount of a substance that is an activator or an inhibitor of a calcium sensitive potassium channel containing a human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein, or an activator or an inhibitor of $\beta 3$ subunit transcription.

The modulators of channel function or transcription activity of the present invention are also expected to be useful in conditions where currently marketed inhibitors of potassium channels such as glyburide, glipizide, and tolbutamide are useful, *e.g.*, as antidiabetic agents. Calcium sensitive potassium channels contribute to the repolarization, and thus the de-excitation, of neurons. Thus, inhibitors of calcium sensitive potassium channels are expected to act as agents that tend to keep neurons in a depolarized, excited state. Many diseases, such as depression and memory disorders are thought to result from the impairment of neurotransmitter release. As agents that contribute to neuronal excitability, the inhibitors of the present invention are expected to be useful in the treatment of such diseases since they will contribute to neuronal excitation and thus stimulate the release of neurotransmitters.

The activators of the present invention should be useful in conditions where it is desirable to decrease neuronal activity. Such conditions include, *e.g.*, excessive smooth muscle tone, angina, asthma, hypertension, incontinence, pre-term labor, migraine, cerebral ischemia, and Irritable Bowel Syndrome.

The calcium sensitive potassium channel subunits of the present invention are useful in conjunction with screens designed to identify activators and inhibitors of other ion channels. When screening compounds in order to identify

potential pharmaceuticals that specifically interact with a target ion channel, it is necessary to ensure that the compounds identified are as specific as possible for the target ion channel. To do this, it is necessary to screen the compounds against as wide an array as possible of ion channels that are similar to the target ion channel.

- 5 Thus, in order to find compounds that are potential pharmaceuticals that interact with ion channel A, it is not enough to ensure that the compounds interact with ion channel A (the "plus target") and produce the desired pharmacological effect through ion channel A. It is also necessary to determine that the compounds do not interact with ion channels B, C, D, *etc.* (the "minus targets"). In general, as part of a screening
- 10 program, it is important to have as many minus targets as possible (see Hodgson, 1992, *Bio/Technology* 10:973-980, at 980). Human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins, DNA encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins, and recombinant cells that have been engineered to express human calcium sensitive
- 15 potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins have utility in that they can be used as "minus targets" in screens designed to identify compounds that specifically interact with other ion channels. For example, Wang et al., 1998, *Science* 282:1890-1893 have shown that KCNQ2 and KCNQ3 form a heteromeric potassium ion channel know as the "M-channel." The M-channel is an important target for drug
- 20 discovery since mutations in KCNQ2 and KCNQ3 are responsible for causing epilepsy (Biervert et al., 1998, *Science* 279:403-406; Singh et al., 1998, *Nature Genet.* 18:25-29; Schroeder et al., *Nature* 1998, 396:687-690). A screening program designed to identify activators or inhibitors of the M-channel would benefit greatly by the use of potassium channels comprising human calcium sensitive potassium channel
- 25 $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins as minus targets.

- The present invention also includes antibodies to the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins. Such antibodies may be polyclonal antibodies or monoclonal antibodies. The antibodies of the present invention can be raised against the entire human calcium sensitive
- 30 potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins or against suitable antigenic fragments of the subunit proteins that are coupled to suitable carriers, *e.g.*, serum albumin or keyhole limpet hemocyanin, by methods well known in the art. Methods of identifying suitable antigenic fragments of a protein are known in the art. See, *e.g.*, Hopp & Woods, 1981, *Proc. Natl. Acad. Sci. USA* 78:3824-3828; and

Jameson & Wolf, 1988, CABIOS (Computer Applications in the Biosciences) 4:181-186.

For the production of polyclonal antibodies, human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins or antigenic fragments, coupled to a suitable carrier, are injected on a periodic basis into an appropriate non-human host animal such as, *e.g.*, rabbits, sheep, goats, rats, mice or chickens. The animals are bled periodically (or eggs collected) and sera obtained are tested for the presence of antibodies to the injected subunit or antigen. The injections can be intramuscular, intraperitoneal, subcutaneous, and the like, and can be accompanied with adjuvant.

For the production of monoclonal antibodies, human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins or antigenic fragments, coupled to a suitable carrier, are injected into an appropriate non-human host animal as above for the production of polyclonal antibodies. In the case of monoclonal antibodies, the animal is generally a mouse. The animal's spleen cells are then immortalized, often by fusion with a myeloma cell, as described in Kohler & Milstein, 1975, Nature 256:495-497. For a fuller description of the production of monoclonal antibodies, see Antibodies: A Laboratory Manual, Harlow & Lane, eds., Cold Spring Harbor Laboratory Press, 1988.

Gene therapy may be used to introduce human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins into the cells of target organs. Nucleotides encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins can be ligated into viral vectors which mediate transfer of the nucleotides by infection of recipient cells. Suitable viral vectors include retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, lentivirus, and polio virus based vectors. Alternatively, nucleotides encoding human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins can be transferred into cells for gene therapy by non-viral techniques including receptor-mediated targeted transfer using ligand-nucleotide conjugates, lipofection, membrane fusion, or direct microinjection. These procedures and variations thereof are suitable for *ex vivo* as well as *in vivo* gene therapy. Gene therapy with human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins will be particularly useful for the treatment of diseases where it is beneficial to elevate calcium sensitive potassium channel activity. cDNAs encoding mutant calcium

sensitive potassium channel subunits, that display a dominant negative phenotype, may be particularly useful for gene therapy treatment of diseases where it is beneficial to decrease calcium sensitive potassium channel activity.

The present invention includes processes for cloning orthologues of human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits from non-human species. In general, such processes include preparing a PCR primer or a hybridization probe based upon SEQ.ID.NO.:1, 3, 5, 7, 9, or 20 that can be used to amplify a fragment containing the non-human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit (in the case of PCR) from a suitable DNA preparation or to select a cDNA or genomic clone containing the non-human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit from a suitable library. A preferred embodiment of this process is a process for cloning the calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit from mouse.

By providing DNA encoding mouse calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits, the present invention allows for the generation of an animal model of human diseases in which calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit activity is abnormal. Such animal models can be generated by making transgenic "knockout" or "knockin" mice containing altered calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit genes. Knockout mice can be generated in which portions of the mouse calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit gene have been deleted. Knockin mice can be generated in which mutations that have been shown to lead to human disease are introduced into the mouse gene. Such knockout and knockin mice will be valuable tools in the study of the relationship between calcium sensitive potassium channels and disease and will provide important model systems in which to test potential pharmaceuticals or treatments for human diseases involving calcium sensitive potassium channels.

Accordingly, the present invention includes a method of producing a transgenic mouse comprising:

- (a) designing PCR primers or an oligonucleotide probe based upon SEQ.ID.NO.:1, 3, 5, 7, 9 or 20 for use in cloning the mouse calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit gene or cDNA;
- (b) using the PCR primers or the oligonucleotide probe to clone at least a portion of the mouse calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$,

or $\beta 3d$ subunit gene or cDNA, the portion being large enough to use in making a transgenic mouse;

- (c) producing a transgenic mouse having at least one copy of the mouse calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit gene altered from its native state.

Methods of producing knockout and knockin mice are well known in the art. One method involves the use of gene-targeted ES cells in the generation of gene-targeted transgenic knockout mice and is described in, *e.g.*, Thomas et al., 1987, Cell 51:503-512, and is reviewed elsewhere (Frohman et al., 1989, Cell 56:145-147; Capecchi, 1989, Trends in Genet. 5:70-76; Baribault et al., 1989, Mol. Biol. Med. 6:481-492).

Techniques are available to inactivate or alter any genetic region to virtually any mutation desired by using targeted homologous recombination to insert specific changes into chromosomal genes. Generally, use is made of a "targeting vector," *i.e.*, a plasmid containing part of the genetic region it is desired to mutate. By virtue of the homology between this part of the genetic region on the plasmid and the corresponding genetic region on the chromosome, homologous recombination can be used to insert the plasmid into the genetic region, thus disrupting the genetic region. Usually, the targeting vector contains a selectable marker gene as well.

In comparison with homologous extrachromosomal recombination, which occurs at frequencies approaching 100%, homologous plasmid-chromosome recombination was originally reported to only be detected at frequencies between 10^{-6} and 10^{-3} (Lin et al., 1985, Proc. Natl. Acad. Sci. USA 82:1391-1395; Smithies et al., 1985, Nature 317: 230-234; Thomas et al., 1986, Cell 44:419-428). Nonhomologous plasmid-chromosome interactions are more frequent, occurring at levels 10^5 -fold (Lin et al., 1985, Proc. Natl. Acad. Sci. USA 82:1391-1395) to 10^2 -fold (Thomas et al., 1986, Cell 44:419-428) greater than comparable homologous insertion.

To overcome this low proportion of targeted recombination in murine ES cells, various strategies have been developed to detect or select rare homologous recombinants. One approach for detecting homologous alteration events uses the polymerase chain reaction (PCR) to screen pools of transformant cells for homologous insertion, followed by screening individual clones (Kim et al., 1988, Nucleic Acids Res. 16:8887-8903; Kim et al., 1991, Gene 103:227-233). Alternatively, a positive genetic selection approach has been developed in which a

marker gene is constructed which will only be active if homologous insertion occurs, allowing these recombinants to be selected directly (Sedivy et al., 1989, Proc. Natl. Acad. Sci. USA 86:227-231). One of the most powerful approaches developed for selecting homologous recombinants is the positive-negative selection (PNS) method developed for genes for which no direct selection of the alteration exists (Mansour et al., 1988, Nature 336:348-352; Capecchi, 1989, Science 244:1288-1292; Capecchi, 1989, Trends in Genet. 5:70-76). The PNS method is more efficient for targeting genes which are not expressed at high levels because the marker gene has its own promoter. Nonhomologous recombinants are selected against by using the Herpes Simplex virus thymidine kinase (HSV-TK) gene and selecting against its nonhomologous insertion with herpes drugs such as gancyclovir (GANC) or FIAU (1-(2-deoxy 2-fluoro-B-D-arabinofluranosyl)-5-iodouracil). By this counter-selection, the percentage of homologous recombinants in the surviving transformants can be increased.

Other methods of producing transgenic mice involve microinjecting the male pronuclei of fertilized eggs. Such methods are well known in the art.

The present invention includes a transgenic, non-human animal in which the animal's genome contains DNA encoding at least a portion of a human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit.

The following non-limiting examples are presented to better illustrate the invention.

EXAMPLE 1

Identification of the human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits and cDNA cloning

DNA sequence encoding the $\beta 1$ subunit was used to search the GenBank database for homologous sequences encoding novel subunits. This search yielded an EST with similarity to $\beta 1$ (AA904191). A cDNA encoding the EST was purchased (Genome Systems) and sequenced in both directions. Synthetic oligonucleotide primers (SEQ.ID.NOs.:12 and 13) were used to amplify the coding region and a small portion of the 3' untranslated region (UTR) of this gene ($\beta 2$). The

coding region was then subcloned into a modified vector (pSP64T) containing an expanded polylinker between the 5' and 3' translation enhancer sequences (MVpl(+)).

The sequence of $\beta 2$ was then used to search the GenBank database for additional novel beta subunits. The sequences from identified EST's were then used to search the database again. Several EST's were obtained in this iterative approach: AA195381, AA236930, AA236968, AA279911, AA761761, AA934876, AA195511, AA917510. The alignment of these sequences suggested they encoded the C-terminal portion of a novel β subunit, here designated $\beta 3$. Available cDNAs encoding these ESTs were purchased (Genome Systems) and sequenced in both directions. None of these clones encoded full length protein based on the lack of 5' in-frame stop codons and amino acid alignments only to the middle of the first transmembrane segments of $\beta 1$ and $\beta 2$.

Unique and conserved portions of the individual subunits were used separately to search the databases for genomic sequences encoding these transcripts. A single 180 kilobase fragment of unidentified genomic sequence was identified using $\beta 3a$, $\beta 3b$ and $\beta 3c$ specific fragments (GenBank accession number AC007823, version 2). Later versions of this entry contained a 40.4 kilobase contiguous fragment that contained all three specific fragments in the following order $\beta 3a$, $\beta 3b$ and $\beta 3c$. $\beta 3c$ is contiguous with the 5' end of the core sequence. See Figure 8.

A synthetic oligo, 5'-TTT ACA TTG TTA GTT TGC AGA CAG G-3' (SEQ.ID.NO.:19), annealing 3' of the $\beta 3$ stop codon was used in a 5' RACE reaction as described in Clontech's Marathon Ready Spleen cDNA kit (catalog # 7412-1). This reaction yielded multiple products of varying sizes. Several fragments separated by electrophoresis were extracted from gel slices and cloned. Three distinct subunits were identified ($\beta 3a$, $\beta 3b$ and $\beta 3c$) in this manner.

To ensure novel subunits were not overlooked, the unfractionated product of the PCR amplification reaction was cloned directly into a TA cloning vector (pCR2.1, Invitrogen), without any attempt to isolate specific fragments. Colonies were then screened using a probe derived from EST AA761761 by the 'colony filter hybridization protocol' as described in *Current Protocols in Molecular Biology*, sections 6.1.1 and 6.3.1. DNA was prepared from hybridizing colonies. cDNAs with restriction digest patterns distinct from the original clones were sequenced in both directions. The open reading frames were determined and

amplified using synthetic oligonucleotide primers (SEQ.ID.NO.s.:14 through 18), and subcloned into MVpl(+). One additional unique subunit was identified: β 3d.

EXAMPLE 2

5 Analysis of expression of human calcium sensitive potassium channel β 2, β 3a, β 3b, β 3c, or β 3d subunits

Northern blot analysis: Northern blots containing poly(A+)-RNA from human heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testes, ovary, small intestine, colon, and peripheral blood
 10 leukocytes were purchased from Clontech, Palo Alto, CA. The blots were probed with ^{32}P -labeled, randomly primed cDNA probes from β 2 (nucleotides 268 to 1080 of SEQ.ID.NO.:1), β 3a (nucleotides 70 to 384 of SEQ.ID.NO.:3), β 3b (nucleotides 463 to 797 of SEQ.ID.NO.:5), and β 3c/d (nucleotides 311 to 912 of SEQ.ID.NO.:7). The hybridization was carried out in 5X SSPE, 10X Denhardt's solution, 50%
 15 Formamide, 2% SDS, 100ug/ml salmon sperm DNA at 42°C overnight. The washes were carried out stepwise in 2X SSC, 0.05% SDS at 42°C for 40 minutes, followed by 1X SSC, 0.05% SDS at 50°C for 40 minutes. High stringency washes were carried out at 0.1SSC, 0.05% SDS at 65°C for 40 minutes. Hybridization was detected either by exposure of the washed blots to X-ray film or by electronic detection using a
 20 phosphorimager.

Electrophysiological analysis: cRNAs were synthesized in vitro from plasmids encoding human *Slowpoke* α or the β 2, β 3a, β 3b, β 3c, or β 3d subunits and injected into *Xenopus* oocytes (1.5 ng/oocyte of α subunit RNA +/- β subunit RNA at 1, 5, or 10X molar excess). Calcium sensitive potassium currents were recorded in
 25 inside-out patches. Recordings were performed under ionic conditions of symmetrical potassium. The standard pipette and bath solutions contained 116 mM potassium gluconate, 4 mM potassium chloride, 10 mM HEPES, pH 7.2. CaCl_2 was added to the bath solution to give final concentrations of free ionized calcium of 3-30 μM , taking into account the stability constant for calcium gluconate (15.9 M^{-1}).
 30 Currents were recorded using an EPC-7 amplifier (HEKA). The pClamp6.0 program (Axon Instruments) was used to generate voltage-clamp commands for data acquisition, and for analysis. NP_o - voltage relations were determined at 3, 10 and 30

μM bath calcium using two methods: (1) calculation of macroscopic conductance from peak or steady-state currents at test potentials (-80 to 80 mV), or (2) measurement or calculation of tail currents peaks (-80 mV) at test potentials. Boltzmann functions were fit to the data and used to derive the half-maximal activation parameter ($V_{1/2}$). Maximal inactivation parameters (30 μM Ca^{2+} and 80 mV) were calculated from current traces or averaged current traces. Inactivation rates were determined from single exponential fits. Fractional non-inactivating current was calculated as steady-state/peak current; fractional inactivating current was estimated as peak current minus steady-state current divided by peak current.

10

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

15

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

WHAT IS CLAIMED IS:

1. An isolated DNA comprising nucleotides encoding a human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein.
2. The DNA of claim 1 comprising nucleotides encoding a polypeptide having an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:2; SEQ.ID.NO.:4; SEQ.ID.NO.:4 with an asparagine at position 163 instead of a serine; SEQ.ID.NO.:6; SEQ.ID.NO.:6 with a serine at position 143 instead of an asparagine; SEQ.ID.NO.:8; SEQ.ID.NO.:8 with an asparagine at position 161 instead of a serine; SEQ.ID.NO.:10; SEQ.ID.NO.:10 with a serine at position 165 instead of an asparagine; and positions 2-246 of SEQ.ID.NO.:6.
3. The DNA of claim 1 comprising a nucleotide sequence selected from the group consisting of: SEQ.ID.NO.:1, 3, 5, 7, 9, and 20.
4. The DNA of claim 1 comprising a nucleotide sequence selected from the group consisting of: positions 271-975 of SEQ.ID.NO.:1, positions 341 to 1171 of SEQ.ID.NO.:3, positions 796 to 1566 of SEQ.ID.NO.:5, positions 869 to 1693 of SEQ.ID.NO.:7, and positions 457 to 1293 of SEQ.ID.NO.:9.
5. An isolated DNA that hybridizes under stringent conditions to the DNA of claim 2.
6. An expression vector comprising the DNA of claim 1.
7. A recombinant host cell comprising the DNA of claim 1.
8. An isolated human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein.
9. The protein of claim 8 having an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:2; SEQ.ID.NO.:4; SEQ.ID.NO.:4 with an asparagine at position 163 instead of a serine; SEQ.ID.NO.:6; SEQ.ID.NO.:6 with a

serine at position 143 instead of an asparagine; SEQ.ID.NO.:8; SEQ.ID.NO.:8 with an asparagine at position 161 instead of a serine; SEQ.ID.NO.:10; SEQ.ID.NO.:10 with a serine at position 165 instead of an asparagine; and positions 2-246 of SEQ.ID.NO.:6.

5 10. The protein of claim 8 containing a single amino acid substitution.

 11. The protein of claim 8 containing two or more amino acid substitutions where the amino acid substitutions do not occur in conserved positions.
10

 12. A polypeptide having at least 80% sequence identity to the protein of claim 9 when measured by BLAST or FASTA.

 13. An antibody that binds specifically to a human calcium
15 sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit protein; or that binds specifically to the $\beta 3$ subunit family of proteins by binding to the conserved core.

 14. A DNA or RNA oligonucleotide probe comprising at least 15 contiguous nucleotides of at least one of a sequence selected from the group
20 consisting of: SEQ.ID.NO.:1, 3, 5, 7, 9, and 20.

 15. A method for identifying substances that bind to calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins comprising:
25

- (a) providing cells expressing a calcium sensitive potassium channel containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;
- (b) exposing the cells to a substance that is not known to bind calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;
30
- (c) determining the amount of binding of the substance to the cells;
- (d) comparing the amount of binding in step (c) to the amount of binding of the substance to control cells where the control cells are substantially

identical to the cells of step (a) except that the control cells do not express human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

- where if the amount of binding in step (c) is greater than the amount of binding of the substance to control cells, then the substance binds to calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins.

16. A method of identifying substances that bind calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins and thus are likely to be inhibitors or activators of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins comprising:

- (a) providing cells expressing calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;
- (b) exposing the cells to a compound that is known to bind to the calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;
- (c) determining the amount of binding of the compound to the cells in the presence and in the absence of a substance not known to bind to calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

- where if the amount of binding of the compound in the presence of the substance differs from that in the absence of the substance, then the substance binds calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins and is likely to be an inhibitor or activator of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins.

17. A method of identifying activators or inhibitors of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins comprising:

- (a) recombinantly expressing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins or mutant human calcium

sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins in a host cell so that the recombinantly expressed human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins form calcium sensitive potassium channels by forming heteromers with other calcium sensitive potassium channel subunit proteins;

5 (b) measuring the biological activity of the calcium sensitive potassium channels formed in step (a) in the presence and in the absence of a substance suspected of being an activator or an inhibitor of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins;

10 where a change in the biological activity of the calcium sensitive potassium channels formed in step (a) in the presence as compared to the absence of the substance indicates that the substance is an activator or an inhibitor of calcium sensitive potassium channels containing human calcium sensitive potassium channel $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunit proteins.

15 18. A method of identifying DNA sequences in the $\beta 3$ gene that promote, enhance, or repress gene transcription comprising:

(a) constructing a promoter-reporter vector such that fragments of the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) precede the coding cDNA sequence of a reporter gene which encodes a reporter protein;

20 (b) transfecting the vector into cells and measuring the abundance of the reporter protein encoded by the vector;

(c) comparing the abundance of the reporter protein in the cells of step (b) to the abundance of the reporter protein in cells transfected with the vector without fragments of the promoter region of the $\beta 3$ gene;

25 where fragments of the promoter region of the $\beta 3$ gene which increase the abundance of the reporter protein in the absence of other promoter elements only in cells which endogenously express $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits are promoter elements; sequences which decrease the abundance of the reporter protein in the presence of an unrelated constitutive promoter element in cells which do not endogenously express $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits are repressor elements; and sequences which increase the abundance of the reporter protein in the presence of an unrelated constitutive promoter element in cells which endogenously express $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits are enhancer elements.

19. The method of claim 18 where the vector contains promoter or enhancer sequence elements which function independently of the fragments of the promoter region of the $\beta 3$ gene.

5

20. The method of claim 18 where the abundance of the reporter protein is normalized with respect to the fraction of transfected cells.

21. A method of identifying DNA sequences in the $\beta 3$ gene that promote, enhance, or repress gene transcription comprising:
(a) incubating radiolabeled fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) with nuclear extracts from cells; and
(b) separating the incubation on a gel;
where fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene that migrate differently in a gel ('undergo a shift') after incubation with nuclear extracts from cells are DNA sequences which bind nuclear factors which promote, enhance or repress $\beta 3$ gene expression.

10

22. The method of claim 21 where the fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the method of claim 18.

25

23. The method of claim 21 where the cells express $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits.

24. The method of claim 21 where the cells do not express $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits.

30

25. A method of identifying nuclear factors involved in $\beta 3$ gene transcription regulation comprising:

(a) incubating radiolabeled fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene

(SEQ.ID.NO.:20, nucleotides 1 to 17,436) with cloned or purified transcription factors and separating the incubation on a gel;

5 where factors which bind $\beta 3$ gene promoter sequence elements will induce a shift in the migration of the radiolabeled DNA fragments, and are involved in $\beta 3$ gene transcription regulation.

26. The method of claim 25 where the fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the methods of claim 18 or 21.

10

27. A method of identifying transcription factors involved in $\beta 3$ gene transcription regulation comprising:

15 (a) incubating radiolabeled fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) with nuclear extracts from cells and separating the incubation on a gel;

(b) adding an antibody that specifically recognizes a single transcription factor or a family of transcription factors to the incubation of step (a), followed by separating the incubation on a gel;

20 where a super-shift in mobility of the double stranded DNA in step (b) as compared to step (a) indicates that a transcription factor recognized by the antibody binds the double stranded DNA.

28. A method of identifying clones encoding nuclear factors involved in $\beta 3$ gene transcription regulation by cloning comprising:

25 (a) screening an expression library with radiolabeled fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436)

30 (b) determining which clones of the library bind the radiolabeled fragments of double stranded DNA;

(c) amplifying and sequencing the clones of step (b).

29. The method of claim 28 where the fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the methods of claim 18 or 21.

5 30. A method of identifying nuclear factors involved in $\beta 3$ gene transcription regulation by cloning comprising:

(a) attaching fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) to a stable matrix;

10 (b) incubating phage expressing cDNA encoded fusion proteins at their surface with the matrix;

(c) removing phage that do not bind to the matrix by washing;

(d) eluting phage bound to the matrix with excess fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene;

15 where the phage eluted in step (d) encode nuclear factors involved in $\beta 3$ gene transcription regulation.

20 31. The method of claim 30 where the DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the methods of claim 18 or 21.

25 32. The method of claim 30 where the phage eluted at step (d) are amplified and sequenced.

30 33. A method of identifying nuclear factors involved in $\beta 3$ gene transcription regulation comprising:

(a) attaching fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) to a stable matrix;

(b) incubating nuclear extracts from cells with the matrix;

(c) washing non-binding proteins from the nuclear extract from the matrix;

(d) eluting bound proteins from the matrix with excess double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene;

5 where the eluted proteins from step (d) are nuclear factors involved in $\beta 3$ gene transcription regulation.

34. The method of claim 33 further comprising separating the eluted proteins from step (d) on a gel and staining the gel to test for purity of the eluted proteins.

10

35. The method of claim 34 further comprising sequencing the proteins that have been separated on the gel.

36. The method of claim 34 further comprising immunological
15 analysis of the proteins that have been separated on the gel with antibodies directed towards known transcription factors to identify the eluted proteins by western blot or immunoprecipitation.

37. The method of claim 33 where the fragments of double
20 stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the methods of claim 18 or 21.

38. A method of identifying nuclear factors involved in $\beta 3$ gene transcription regulation by cloning comprising:

25 (a) constructing a yeast strain that contains a few to several copies of a fragment of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) preceding a cDNA encoding a reporter protein;

(b) constructing a cDNA library from cells in a vector that allows
30 formation of fusion proteins encoded by the inserted cDNA and a transcription activation domain;

(c) transforming the library of (b) into the yeast strain of (a) and isolating colonies of yeast displaying expression of the reporter protein.

39. The method of claim 38 where the fragments of double stranded DNA corresponding to sequences found in the promoter region of the $\beta 3$ gene are identified by the methods of claim 18 or 21.

5 40. The method of claim 38 further comprising purifying the vectors from the isolated colonies and sequencing the cDNA in the vectors.

41. A method of identifying substances that enhance or inhibit the rate of transcription of the $\beta 3$ gene comprising:

10 (a) constructing a promoter-reporter vector such that fragments of the promoter region of the $\beta 3$ gene (SEQ.ID.NO.:20, nucleotides 1 to 17,436) precede the coding cDNA sequence of a reporter gene which encodes a reporter protein;

(b) transfecting the vector into cells and measuring the abundance of the reporter protein encoded by the vector in the presence and absence of a
15 compound;

where (1) if the presence of the compound decreases the abundance of the reporter protein, then the compound is a substance that inhibits the rate of transcription of the $\beta 3$ gene; (2) if the presence of the compound increases the abundance of the reporter protein, then the compound is a substance that enhances the
20 rate of transcription of the $\beta 3$ gene.

42. The method of claim 41 further comprising a control in which the effect of the compound on the abundance of the reporter protein in control cells is measured, where the control cells are cells that are essentially the same as the cells of
25 step (b) except that the control cells have been transfected with a vector that lacks fragments of the promoter region of the $\beta 3$ gene.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05828 A1

(51) International Patent Classification⁷: **C07K 14/47**,
16/18, G01N 33/53, 33/567, C12N 5/10, 15/12, 15/63,
15/64

(21) International Application Number: PCT/US00/19585

(22) International Filing Date: 18 July 2000 (18.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/144,764 20 July 1999 (20.07.1999) US

(71) Applicant (for all designated States except US): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **UEBELE, Victor** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-

0907 (US). **SWANSON, Richard** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **LIU, Yuan** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **LAGRUTTA, Armando** [PA/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(74) Common Representative: **MERCK & CO., INC.**; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(81) Designated States (national): CA, JP, US.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL HUMAN CALCIUM SENSITIVE POTASSIUM CHANNEL SUBUNITS

(57) Abstract: The present invention is directed to novel human DNA sequences encoding calcium sensitive potassium channel subunits $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, and $\beta 3d$, the proteins encoded by the DNA sequences, vectors comprising the DNA sequences, host cells containing the vectors, and methods of identifying inhibitors and agonists of calcium sensitive potassium channels containing human $\beta 2$, $\beta 3a$, $\beta 3b$, $\beta 3c$, or $\beta 3d$ subunits and inhibitors and agonists of $\beta 3$ gene transcription.

2001-01-25

WO 01/05828 A1

FIGURE 1A

1 CTTAATCCTA TCCAAGTATG CAGTACGCTC TTGGGTCGTC TCATGAGACC CAGGGGCATG
61 TTGGAAAGAA CTGAGAGAAA GAGCAACAAA GCGGCGAGTG GTGTGAGAGG GCAGCACGCG
121 CTGTGGGGCC CTTCCAGAGA AATGTACTGA AAAAGTCTAC GCAATGTCTG GGATTTGCTA
181 AACAATACCT GGAAAGCAGA CAGGTTTTTT TGCCATTCCCT CCAGGACATC CACCATAAGG
241 AAAGGAGACC CTGGACCAAC ATTCTCTAAG ATGTTTATAT GGACCAGTGG CCGGACCTCT
301 TCATCTTATA GACATGATGA AAAAAGAAAT ATTTACCAGA AAATCAGGGA CCATGACCTC
361 CTGGACAAAA GGAAAACAGT CACAGCACTG AAGGCAGGAG AGGACCGAGC TATTCCTCTG
421 GGACTGGCTA TGATGGTGTG CTCCATCATG ATGTATTTTC TGCTGGGAAT CACACTCCTG
481 CGCTCATACA TGCAGAGCGT GTGGACCGAA GAGTCCTAAT GCACCTTGCT GAATGCGTCC
541 ATCACGGAAA CATTTAACCTG CTCCTTCAGC TGTGGTCCAG ACTGCTGGAA ACTTCTCTAG
601 TACCCCTGCC TCCAGGTGTA CGTTAACCTG ACTTCTTCCG GGGAAAAGCT CCTCCTCTAC
661 CACACAGAAG AGACAATAAA AATCAATCAG AAGTGCCTCT ATATACCTAA ATGTGGAAAA
721 AATTTTGAAG AATCCATGTC CCTGGTGAAT GTTGTCTATG AAAACTTCAG GAAGTATCAA
781 CACTTCTCCT GCTATTCTGA CCCAGAAGGA AACCAGAAGA GTGTTATCCT AACCAAACTC
841 TACAGTTCCA ACGTGCTGTT CCATTCACTC TTCTGGCCAA CCTGTATGAT GGCTGGGGGT
901 GTGGCAATTG TTGCCATGGT GAAACTTACA CAGTACCTCT CCCTACTATG TGAGAGGATC
961 CAACGGATCA ATAGATAAAT GCAAAAATGG ATAAAATAAT TTTTGTATAA GCTCAAATAC
1021 TGTTTTCTTT CATTCTTCAC CAAAGAACCCT TAAGTTTGTA ACGTGCAGTC TGTATGAGT
1081 TCCCTAATAT ATTCTTATAT GTAGAGCAAT AATGCAAAAG CTGTTCTATA TGCAAACATG
1141 ATGTCCTTAT TATTCAGGAG AATAAATAAC TGTTTTGTGT TGAA

FIGURE 1B

1 MFIWTSGRTS SSYRHDEKRN IYQKIRDHDL LDKRKTVTAL KAGEDRAILL GLAMMVCSIM
61 MYFLLGITLL RSYMOSVWTE ESQCTLLNAS ITETFNCSFS CGPDCWKLSQ YPCLQVYVNL
121 TSSGEKLLLY HTEETIKINQ KCSYIPKCGK NFEESMSLVN VVMENFRKYQ HFSCYSDPEG
181 NQKSVILTKL YSSNVLFHSL FWPTCMMAGG VAIVAMVKLT QYLSLLCERI QRINR

FIGURE 2A

1 GCTCCCGGCT GCCGAGGCGG AAACACAGGT GATGAGGTGG CCGCAAGCAC AGTGCAAAGA
61 GAGAGAAGCA GCTTCGGCTG CAGCAAACCA CGCAGGTCCCT TCTTGATCAT CTAGAACTGA
121 CCGCTCCGCC TTGCCAGGAG TCTGCAGAAC CACGTGGCTG GCCTGCCCTGA AGTTCTCACC
181 TCTCTAGGAA GGCGGGGGGC TTCTAATGGC TGCAGCTGCG CTGGGGGGCTG GGGGCTCCCG
241 CTGGGACTCC ACTTCCGTGG ATGTCTAAGC TTCACCTTTC TTGCGCCCGC AGGGGCGATGA
301 CTCAGGTGAA AGGGAGCCAT TTTCTCAGAC CCCTGGCCTC ATGCAGCCCT TCAGCATCCC
361 CGTGCAAATC ACAC TTCAGG GCAGCCGGAG GCGCCAGGGG AGGACAGCCT TTCCTGCCTC
421 AGGGAAGAAG AGAGAGACAG ACTACAGTGA TGGAGACCCA CTAGATGTGC ACAAGAGGCT
481 GCCATCCAGT ACTGGAGAGG ACCGAGCCGT GATGCTGGGG TTTGCCATGA TGGGCTTCTC
541 AGTCCTAATG TTCTTCTTGC TCGGAACAAC CATTTCTAAAG CCTTTTATGC TCAGCATTCA
601 GAGAGAAGAA TCGACCTGCA CTGCCATCCA CACAGATATC ATGGACGACT GGCTGGACTG
661 TGCCTTCACC TGTGGTGTGC ACTGCCACGG TCAGGGGAAG TACCCGTGTC TTCAGGTGTT
721 TGTGAACCTC AGCCATCCAG GTCAGAAAGC TCTCCTACAT TATAATGAAG AGGCTGTCCA
781 GATAAATCCC AAGTGCTTTT ACACACCTAA GTGCCACCAA GATAGAAGTG ATTTGCTCAA
841 CAGTGCTCTG GACATAAAAG AATTC TTCGA TCACAAAAAT GGAACCCCTT TTTTCATGCTT
901 CTACAGTCCA GCCAGCCAAT CTGAAGATGT CATTC TTATA AAAAAAGTATG ACCAAATGGC
961 TATCTTCCAC TGTTTATTTT GGCTTTCAC TACTCTGCTA GGTGGTGCCC TGATTGTTGG
1021 CATGGTGAGA TTAACACAAC ACCTGTCTT ACTGTGTGAA AAATATAGCA CTGTAGTCAG
1081 AGATGAGGTA GGTGGAAAAG TACCTTATAT AGAACAGCAT CAGTTCAAAC TGTGCATTAT
1141 GAGGAGGAGC AAAGGAAGAG CAGAGAAATC TTAAGACGGT GGCCAAATTA AAGTGCTGGC
1201 CTTCAGATGT CTGTGATTTT TGCAACTCGA GTATGCG

FIGURE 2B

1 MQPFSIPVQI TLQGSRRRQG RTAFPASGKK RETDYSDDP LDVHKRLPSS TGEDRAVMLG
61 FAMMGFSVLM FLLGTTILK PFMLSIQREE STCTAIHTDI MDDWLDCAFT CGVHCHGQK
121 YPCLQVFNVL SHPGQKALLH YNEEAVQINP KCFYTPKCHQ DRSDLLNSAL DIKEFFDHKN
181 GTPFSCFYSP ASQSEVILI KKYDQMAIFH CLFWPSLTLL GGALIVGMVR LTQHLSLLCE
241 KYSTVVRDEV GGVVPYIEQH QFKLCIMRRS KGRAEKS

FIGURE 3A

1 AAGAGAAAGA ACAAGAAAAA GAAAAAGAAG AGGAAAAAAT CCCCAGTACC CATAGAAACC
61 CTTAAAGATG TTTAAAAAGA GTTAACTTAT CAGAACACAG ATTTAAGTGA AATTAAGGAA
121 GAAGAGCAGG TAAAGTCTAC TGACAGAAAAG TCAGCAGTGG AAGCCCCAAA CGAGGTGACT
181 GAAAAATCCAA AACAGAAAAAT TGCAGCAGAA AGCAGTGAAA ATGCTGATTG TCCAGAGAAT
241 CCTAAAATGA AGTTGGATGG AAAACTTGAC CAAGAAGGCA ATGATGTAAA AACAGCAGCT
301 GAGGAGGTAC TAGCTGGTAG AGACACATTA GATTTTGAGG ATGTCACAGT TCAATCATCA
361 GGCCCAGGG CTGGTGGTGA AGAATTAGAT GAAGGTGTTG CAAAAGATAA TGCTAAAATA
421 GCTGGTGCCA CTTAAAGCAA TCCTGAAGAA CCAGAGAGTG AAGATGCAGA TCACTGCACC
481 GTACCCAAAA ATGAAAGTCC CTCACAGGAC ATTAGTGATG CCTGTGAAGC AGAAAGTACA
541 GAGAGGTGCG GGATGTCAGA ACATCCAAGT CAGACCATCA GGAAAGCTTT AGACAGCAAT
601 AGCCTAAAAA ACCATGACTT GTTGGCACCA GGAGGAGAGC CGGGGGACTT CAATCCAGAA
661 AGCAGAGAAG ATACCAGAGG AGGGAACGAG AAGGGCAAAA GCAAAGAAGA CCGTACCATG
721 TCCTAAGCTG AGGCAGGCGG CAGGCGTGGT GCACAGGAAG TCTGAGTGTG AGGGGCTCTT
781 TTCTCTCCAC TGCCAATGAC AGCCTTTCCT GCCTCAGGGA AGAAGAGAGA GACAGACTAC
841 AGTGATGGAG ACCCACTAGA TGTGCACAAG AGGCTGCCAT CCAGTACTGG AGAGGACCGA
901 GCCGTGATGC TGGGGTTTGC CATGATGGGC TTCTCAGTCC TAATGTTCTT CTTGCTCGGA
961 ACAACCATTG TAAAGCCTTT TATGCTCAGC ATTCAGAGAG AAGAATCGAC CTGCACTGCC
1021 ATCCACACAG ATATCATGGA CCACTGGCTG GACTGTGCCT TCACCTGTGG TGTGCACTGC
1081 CACGGTCAGG GGAAGTACCC GTGTCTTCAG GTGTTTGTGA ACCTCAGCCA TCCAGGTCAG
1141 AAAGCTCTCC TACATTATAA TGAAGAGGCT GTCCAGATAA ATCCCAAGTG CTTTTACACA
1201 CCTAAGTGCC ACCAAGATAG AAATGATTTG CTCAACAGTG CTCTGGACAT AAAAGAATTC
1261 TTCGATCACA AAAATGGAAC CCCCTTTTCA TGCTTCTACA GTCCAGCCAG CCAATCTGAA
1321 GATGTCATTG TTATAAAAAA GTATGACCAA ATGGCTATCT TCCACTGTTT ATTTTGGCCT
1381 TCACTGACTC TGCTAGGTGG TGCCCTGATT GTTGGCATGG TGAGATTAAC ACAACACCTG
1441 TCCTTACTGT GTGAAAAATA TAGCACTGTA GTCAGAGATG AGGTAGGTGG AAAAGTACCT
1501 TATATAGAAC AGCATCAGTT CAAACTGTGC ATTATGAGGA GGAGCAAAGG AAGAGCAGAG
1561 AAATCTTAAG ACGGTGGCCA AATTAAAGTG CTGGCCTTCA GATGTCTGTG ATTTCTGCAA
1621 CTCGAGTATG CG

FIGURE 3B

1 MTAFPASGKK RETDYSDDGP LDVHKRLPSS TGEDRAVMLG FAMMGFSVLM FLLGTTLK
61 PFMLSIQREE STCTAIHTDI MDDWLDCAFT CGVHCHGQK YPCLOVFNL SHPGKALLH
121 YNEEAVQINP KCFYTPKCHQ DRNDLLNSAL DIKEFFDHKN GTPFSCFYSP ASQSEDVILI
181 KKYDQMAIFH CLFWPSLTLL GGALIVGMVR LTQHLSLLCE KYSTVVRDEV GGKVPYIEQH
241 QFKLCIMRRS KGRAEKS

2003140-1691E001

FIGURE 4A

1 CCCAGCTACT CGGGAGGCTG AGGCAGGAGA ATCGCTTGAA CCTGGGAGGC GGAGGAGGTT
 61 GCAGTGAAC T GAGATCGTAC CCAGCCTGGG CAACAGTGCG AGGCTCCGTC TCAAAAAAAAA
 121 ACCAAAAAAC ACAAAAAACA AAAACGACAG AGAAGGCCAA ACAAACACA TCTGTGGGCT
 181 GGATGCCGCC ATGCCACCG GTTTGCGACC TTTGTGTTGG ACTCTTCTGT TCACCAGACA
 241 CCCTGCCCTG CGAGAATGTA TCTCATCCTT TGCTGGAGCA GGTTTGCAGG CACAGTGGAG
 301 AGAGGAGAGA AGAAATGAAG GGACACTTAT GCAGAACCAT GAGTGGCCAG AGAGGAGGAG
 361 AAGGAGGGTG AGAGGAGCAA AGAAGCCATG ACAACTTCAT AATTCTGAGT GGACTGGGCA
 421 GTGGCCAGAA ATTCTGGTGG TGGATATGCT GCCTTTCCAA CAGGTGAATA TGAAAGAATA
 481 AGTCAAACCC TGTTCCAGGAC GCTGTTAATT CCAAATGTGA ACTTTTGTAG TCATTCTTTT
 541 CATGTGGAAT TCAAAGGAGA ATGTAAACAA ATTTTCAGGA GGGACGTGCA ATATCCCTGA
 601 AAGATAACAG AGTTCCGTAA ACTTATTTAC ATACAACATT CTCTAGTTAT TGATTAAACA
 661 GATCTCTACA GACTTGCATG AGGCAACATT TCTTAGGCTT GTTTGCTACA ATATCTTTAA
 721 AAATACTTGA TTACACATCA CTTTAGCTTA TTTAGATGGA CTTTTCACCA AGCTCTGAAC
 781 TGGGATTTCA TTTTGTGCA TTCATCCTGC TCACGAGACA CAGGTAGGCA GCAAATGAGA
 841 TTATCCCTCC AGTCCCCATG GATTGGAAAT GTTCCCCCTT CTTTATGAGC TCACTGCAGT
 901 ATCTCCTTCT CCCTTTCCCC AAAGGACAGC CTTTCCTGCC TCAGGGAAGA AGAGAGAGAC
 961 AGACTACAGT GATGGAGACC CACTAGATGT GCACAAGAGG CTGCCATCCA GTACTGGAGA
 1021 GGACCGAGCC GTGATGCTGG GGTTCGCCAT GATGGGCTTC TCAGTCCTAA TGTTCTTCTT
 1081 GCTCGGAACA ACCATTCTAA AGCCTTTTAT GCTCAGCATT CAGAGAGAAG AATCGACCTG
 1141 CACTGCCATC CACACAGATA TCATGGACGA CTGGCTGGAC TGTGCCTTCA CCTGTGGTGT
 1201 GCACTACCAC GGTCCAGGGA AGTACCCGTG TCTTCAGGTG TTTGTGAACC TCAGCCATCC
 1261 AGGTCAGAAA GCTCTCCTAC ATTATAATGA AGAGGCTGTC CAGATAAATC CCAAGTGCTT
 1321 TTACACACCT AAGTGCCACC AAGATAGAAG TGATTTGCTC AACAGTGCTC TGGACATAAA
 1381 AGAATTCCTC GATCACAAAA ATGGAACCCC CTTTTCATGC TTCTACAGTC CAGCCAGCCA
 1441 ATCTGAAGAT GTCATTCTTA TAAAAAGTA TGACCAAATG GCTATCTTCC ACTGTTTATT
 1501 TTGGCCTTCA CTGACTCTGC TAGGTGGTGC CCTGATTGTT GGCATGGTGA GATTAACACA
 1561 ACACCTGTCC TTACTGTGTG AAAAATATAG CACTGTAGTC AGAGATGAGG TAGGTGGAAA
 1621 AGTACCTTAT ATAGAACAGC ATCAGTTCAA ACTGTGCATT ATGAGGAGGA GCAAAGGAAG
 1681 AGCAGAGAAA TCTTAAGACG GTGGCCAAAT TAAAGTGCTG GCCTTCAGAT GTCTGTGATT
 1741 TCTGCAACTC GAGTATGCG

FIGURE 4B

1 MFPLLYELTA VSPSPFPQRT AFPASGKKRE TDYSDGDPLD VHKRLPSSTG EDRAVMLGFA
61 MMGFSVLMFF LLGTTILKPF MLSIQREEST CTAIHTDIMD DWLDCAFTCG VHCHGQ GKYP
121 CLQVFVNLSH PGQKALLHYN EEAVQINPKC FYTPKCHQDR SDLLNSALDI KEFFDHKNGT
181 PFSCFYSPAS QSEDEVILIKK YDQMAIFHCL FWPSLTLLGG ALIVGMVRLT QHLSLLCEKY
241 STVVRDEVGG KVPYIEQHOF KLCIMRRSKG RAEKS

FIGURE 5A

1 CGCCGCGGAT CCGAAATGAA GGGACACTTA TGCAGAACCA TGAGTGGCCA GAGAGGAGGA
61 GAAGGAGGST GAGAGGAGCA AAGAAGCCAT GACAACTTCA TAATTCTGAG TGGACTGGGC
121 AGTGGCCAGA AATTCTGGTG GTGGATATGC TGCCTTTCCA ACAGGTGAAT ATGAAAAGAT
181 AAGTCAAACC CTGTTCAAGG CGCTGTAAAT TCCAAATGTG AACTTTTTGA GTCATTCTTT
241 TCATGTGGAA TTCAAAGGAG AATGTAAACA AATTTTCAGG AGGGACGTGC AATATCCCTG
301 AAAGATAACA AAGTTCGTAA CACTTATTTA CATAACAACAT TCTCTAGTTA TTGATTAAAC
361 AGATCTCTAC AGACTTGCAT GAGGCAACAT TTCTTAGGCT TGTCTGCTAC AATATCTTTA
421 AAAATACTTG ATTACACATC ACTTTAGCTT ATTTAGATGG ACTTTTCACC AAGCTCTGAA
481 CTGGGATTTT ATTTTGTGTC ATTCATCCTG CTCACGAGAC ACAGGACAGC CTTTCCTGCC
541 TCAGGGAAGA AGAGAGAGAC AGACTACAGT GATGGAGACC CACTAGATGT GCACAAGAGG
601 CTGCCATCCA GTACTGGAGA GGACCGAGCC GTGATGCTGG GGTTTGCCAT GATGGGCTTC
661 TCAGTCCTAA TGTTCCTCTT GCTCGGAACA ACCATTCTAA AGCCTTTTAT GCTCAGCATT
721 CAGAGAGAAG AATCGACCTG CACTGCCATC CACACAGATA TCATGGACGA CTGGCTGGAC
781 TGTGCCTTCA CCTGTGGTGT GCACTGCCAC GGTGAGGGGA AGTACCCGTG TCTTCAGGTG
841 TTTGTGAACC TCAGCCATCC AGGTCAGAAA GCTCTCCTAC ATTATAATGA AGAGGCTGTC
901 CAGATAAATC CCAAGTGCTT TTACACACCT AAGTGCCACC AAGATAGAAA TGATTTGCTC
961 AACAGTGCTC TGGACATAAA AGAATTCTTC GATCACAAAA ATGGAACCCC CTTTTCATGC
1021 TTCTACAGTC CAGCCAGCCA ATCTGAAGAT GTCATTCTTA TAAAAAGTA TGACCAAAATG
1081 GCTATCTTCC ACTGTTTATT TTGGCCTTCA CTGACTCTGC TAGGTGGTGC CCTGATTGTT
1141 GGCATGGTGA GATTAACACA ACACCTGTCC TTACTGTGTG AAAAAATATAG CACTGTAGTC
1201 AGAGATGAGG TAGGTGGAAA AGTACCTTAT ATAGAACAGC ATCAGTTCAA ACTGTGCATT
1261 ATGAGGAGGA GCAAAGGAAG AGCAGAGAAA TCTTAA

208740-165FED01

FIGURE 5B

1 MDFSPSSELG FHFVAFILLT RHRTAFPASG KKRETDYSDG DPLDVHKRLP SSTGEDRAVM
61 LGFAMMGFSV LMFFLLGTTI LKPFMLSIQR EESTCTAIHT DIMDDWLDCA FTCGVHCHGQ
121 GKYPCLQVFV NLSHPGQKAL LHYNEEAVQI NPKCFYTPKC HQDRNDLLNS ALDIKEFFDH
181 KNGTPFSCFY SPASQSEVI LIKKYDQMAI FHCLFWPSLT LLGGALIVGM VRLTQHLSSL
241 CEKYSTVVRD EVGGKVPYIE QHQFKLCIMR RSKGRAEKS

FIGURE 6





BKb1MVK.KLVM
 BKb2MFIWTSGR TSSSYRHDEKRN IYQKIRDHDL LDKRKT V T
 BKb3aMQPFSIPVQITLQGSRRRQGR TAFPASGKKRETDYS...DGDPLDVHKRLP
 BKb3bMTAFPASGKKRETDYS...DGDPLDVHKRLP
 BKb3cMFPLLYELTAVSPSPFPQRTAFPASGKKRETDYS...DGDPLDVHKRLP
 BKb3d MDFSPSSELGFHFVAFILLTRH.....RTAFPASGKKRETDYS...DGDPLDVHKRLP

BKb1 AQRGETRALCLGVTMVVCAVITYIILVTTVLPLYQKSVW TQESKCHLI.....ET.NI
 BKb2 ALKAGEDRAILLGLAMMVCSINMYFLLGITLLRSYMQSVWTEESQCTLLNASIT.ETFNC
 BKb3a SS.TGEDRAVMLGFAMMGFSVLMFFLLGTTILKPFMLS IQREESTCTAIHTDIMDDWLDC
 BKb3b SS.TGEDRAVMLGFAMMGFSVLMFFLLGTTILKPFMLS IQREESTCTAIHTDIMDDWLDC
 BKb3c SS.TGEDRAVMLGFAMMGFSVLMFFLLGTTILKPFMLS IQREESTCTAIHTDIMDDWLDC
 BKb3d SS.TGEDRAVMLGFAMMGFSVLMFFLLGTTILKPFMLS IQREESTCTAIHTDIMDDWLDC

BKb1 RDQEELKGKKVPQYPC L..WVNVS.AAGRWA VLYHTEDTRDQ NQQCSYIPGSV..DNYQT
 BKb2 SFSCGPD CWKLSQYPC LQVYVNL TSS.GEKL LLYHTEETIKINQKCSYIPKCG..KNFEE
 BKb3a AFTCGVHCHGQGKYPCLQVFVNLS.HPGQKALLHYNEEAVQINPKCFYTPKCHQDRNDLL
 BKb3b AFTCGVHCHGQGKYPCLQVFVNLS.HPGQKALLHYNEEAVQINPKCFYTPKCHQDRNDLL
 BKb3c AFTCGVHCHGQGKYPCLQVFVNLS.HPGQKALLHYNEEAVQINPKCFYTPKCHQDRSDLL
 BKb3d AFTCGVHCHGQGKYPCLQVFVNLS.HPGQKALLHYNEEAVQINPKCFYTPKCHQDRSDLL

BKb1 ARADVEKVRAKFQEQQVFYCF SAPRGNETSVL FQRLYGPQALLFSLFWPTFLLTGGLLI
 BKb2 SMSLVNVVMENFRKYQH FSCYSDPEGNQKSVILTKLYSSNVLFHSLFWPTCMMAGGVAIV
 BKb3a NSALDIKEFFDHKNGTPFSCFYSPASQSEDVILIKKYDQMAIFHCLFWPSLTLLGGALIV
 BKb3b NSALDIKEFFDHKNGTPFSCFYSPASQSEDVILIKKYDQMAIFHCLFWPSLTLLGGALIV
 BKb3c NSALDIKEFFDHKNGTPFSCFYSPASQSEDVILIKKYDQMAIFHCLFWPSLTLLGGALIV
 BKb3d NSALDIKEFFDHKNGTPFSCFYSPASQSEDVILIKKYDQMAIFHCLFWPSLTLLGGALIV

BKb1 AMVKSNOYLSILAAQK.....
 BKb2 AMVKLTQYLSLLCERIQRINR.....
 BKb3a GMVRLTQHLSLLCEKYSTVVRDEVGGKVPYIEQH QFKLCIMRRSKGRAEKS
 BKb3b GMVRLTQHLSLLCEKYSTVVRDEVGGKVPYIEQH QFKLCIMRRSKGRAEKS
 BKb3c GMVRLTQHLSLLCEKYSTVVRDEVGGKVPYIEQH QFKLCIMRRSKGRAEKS
 BKb3d GMVRLTQHLSLLCEKYSTVVRDEVGGKVPYIEQH QFKLCIMRRSKGRAEKS

A hslo α hslo $\alpha + \beta 2$ hslo $\alpha + \beta 3A$ hslo $\alpha + \beta 3C$ 

4 nA

200 ms



B**C**

Figure 7

FIGURE 8A

1 aatcatgtga gttcatcatt ataaaacagc tgatttataa caactgattt taaagtgggt
 61 tgtagcttg aagataaatg agatagggca tgattcaggt ttctgtgtac acactatatt
 121 ctaatgaaag taattacaat tatcttctaa acagctgcag atattttttc tataaacaat
 181 ttttagatgtt acattgttaa atgttagctt tcaaattctt cacattttta ctcaatgaag
 241 tccttttttag caaactttaca ggaatcattg tatcattcag ctattaaata aggaattggt
 301 ctaattcaca tcttaattaa gaactttact aggttatatc ttttgcaagt atgagaataa
 361 tctagataga aggactagaa ttggattaaa ggtgatccag ataaaaatag taattctaatt
 421 gaggaaattt ttttaacattg aaaatagtag cctgtttatt ttttttaattg ttagagtcaa
 481 accattgcac attactgtgt aaaaatacac aaagatggta acttgctgct aaagcccttt
 541 ttacttttga atctttgtat ttttttcacc ttgttaattt taagttgtgc ttttttact
 601 catttgtttt ctacttttat ttctgtttgg gttaaagtta caaacagcaa gtttttgggt
 661 ttaaatttct gaaaatgttg cgatggaatt acagtaatgt gttacggctt gggccctcg
 721 caggagtgtg tctcgcagtc agcagtgaac acaaagtctg aacagcacac tatcagagct
 781 aaacagatac tagctactgt gaaaaacata atggattcag taaacctggc agctgaagat
 841 aaaaggatg agttcatttt gttgcaacat aaaaatgtta gttttttgt cagacttttg
 901 ttaagatgag gttttaaatt gttgtactat aaatactttt tacttgaaa tcaaccttgt
 961 gggtttaact gatgcctact tctatatatt taagtgcgta tttgaaagtg tcgatattta
 1021 ttctgcaacc ttgcacacat catttatatc ccctggacct cactattcct gtgtatgaat
 1081 tgtgattttt aaaatgtttt gtggctttta aatatctttg aagcagtgga agaaccattt
 1141 cttcaagcag atttttatga agaagtccaa aacaggatgat cctctttctg cattcaacct
 1201 acgacctatt ttttaatatg gtcatacatt ggtattttga aatcactatt ttatactagt
 1261 tgtgtttgtt tattgcctgg tgaacaaaca aggcgatgct acctgccaac cagaaagtgt
 1321 atttggttaag cagtaccctt tatgtttatc tgtacggcat tatttttatac tatttggtac
 1381 cttgtaaagg tggcaatgaa tacatgaaaa taccagcatt atcgatacaa agtataattt
 1441 tcacaaactt ggtatgcttg aaacacagat cgggatgtta ttagatgtga caaaagctaa
 1501 tgatgttaag cctcgatagg accttcagtg gacttaagcc agttgaagga aacataaacg
 1561 catcaaagct taagtccaag atgacataac attggaattt taaatgtatt tgctctttca
 1621 gggacaaaga ccccttcattg tccctgtctg ttgctttata atggctattt cttaggaatg
 1681 aattaagtct aaatgcagag aattgccagc atataaaacg caaggatcag aaccttgagt
 1741 ttgaactcag cccctgtgta cagcctccgt gtggcctctg tttaattaga tctgtctgct
 1801 atagcagttc cttctagctc agttgctttg atgtagtacc caaattttgg cctaaaagtgt
 1861 atttaattag taataatttt taaagatata ggatgttgaa caaagtatag cacaagaag
 1921 atgtgatttg aggattgtat aatcataatg tcctgggaac ttcttaagta aaagatcttc
 1981 ttaaatggat ctcaggtctt tatttttctg tatcagccag agttgaacaa acttttggtt
 2041 aaaaaaagag ccagatagta aatattctag gctttatggg ccataaagtc tcttgagct
 2101 actcatttct acagtttttag agcaaaagca gccatagata gataataggt aaatgaatgg
 2161 gtgtggctgt gtttcaagaa aactttaaca aaagctggca gctggctaga tttggcttgt
 2221 aagggtgctat atgctgacct ctgcttatta actaaagtca gtattgcatt ctgttttgcc
 2281 tgttcatatc tatgaagact tagaattctt attcatcctt tctgggattc aggtgccaca
 2341 tgggcagaga aacgtgggtt ctatcaaata atctatataa aatactttat aagtgaata
 2401 ttacttgaat cctttgagat gttacaagtt ttttttttcc ttgagtcag ctaatagatg
 2461 gttcaatata tgaatgagtc ccttgctgaa atgcttttagg acttcagact accctgaacg
 2521 ttgattactc tttatactga aataggcatt attcagtgga agagagggaa gaccaaatgt
 2581 atagactgga ctttattcga aaccagatga accttttaac actggatgtt aagaaaaaaa
 2641 tcaaggaggt taccgaggag gtggcaaaaa aagtgggtaa cagtagcttc atgattaaaa
 2701 taacctggat ggaaattatt tttgataatg ctaaaaatgt tattcctgtt actttaaaag
 2761 aatgttttca gatttttcaa ttttaatttt ttgaataatt gataatcttg ttttaattat
 2821 ttaactccaa aattttcata ttttcagggt tcatgtgcaa tgacagatga aatttgctga
 2881 ctgtctgttt tgggtgatga attttgttca gagtttcatc ctaatccaga tgtattaaaa
 2941 atatatataa gtgtaagtta aagtatagat aaaattatc agagacagtt tcttattatt
 3001 ctataccctc atttatttca tggtttggca tttcagtgtg tcagtacaaa atgaaactgt

FIGURE 8B

3061 tagatctctt gtgccctctt gtaataaatg taaactgtct tgtataaaaa gtaaatagaa
 3121 aatttatact tagaattgaga taaagatcat tttaggacga ggcacagtgg ctcatgcctg
 3181 taatctcaac actttgggag gccgaggtgg gaggatcagt tgggccccag agttcgagac
 3241 cagcctgggc aacacagtga gaactctaact ctacaaaaaa cagttaggct gggtgcggtg
 3301 gctcccgctt ttaatcccag cactttggga ggctgaggcg gacggatcac gaggtcagga
 3361 gttcgagacc agcctgacca acatgggtgaa accctgtcta ctaaaaaatac aaaaaaaaaa
 3421 ttagccggtg gcaggcgctt gtaataccag ctactctgga ggctgaggcg ggagaatcgc
 3481 ttgaaaccgg aaggcagaag tggcagtgag ccaagatcac accactgcac tccaacctgg
 3541 gcaacaagag caaaactcta tctcaaaaaa aataaaaaat agccaagcat ggcgacacgc
 3601 ttctatagtc ccagttactc aggagtctga ggcaggagga tcgctgagc agaccggtc
 3661 aaggctacag tgagtcaaga tcaaaagcact ccagcctagg caacaaagca agacctgtc
 3721 tcaaaaaaaa aaaaaaagtc aaattaaaaa gaccattttg gcattttactg aatattttat
 3781 gtctttataa aaactacata ctttctggag aaaaaataat atggatattt accattgtta
 3841 acaggaatta aataagcaca tagaggatgg tatgggaaga aatttggctg atcgatgcac
 3901 cgatgaagta aacgccttag tgcttcagac ccagcaagaa attattggta atattttatgt
 3961 ctacaaggct atgtctggtt tgttttttca ttcattgactg gtgaagagct tattttcctt
 4021 taggcattcc attgaaggta aaacatttac cattcttatc ttaagtgttg taattttgtt
 4081 ctttctagaa aatttgaagc cattacttcc agctggtata caggataaac tacatacact
 4141 gatcccttgc aagaaatttg atctcagta taatctaaat taccacaagt tatgttcaga
 4201 ttttcaagag gatattgtat ttcccttttt cccttgggct ggtcttccct tgtacatcga
 4261 tttttgggcc tagaaatgct caaagggtgc tcctaggatt atcagagcct atctttcagg
 4321 tatgtatctt tgaatctacc aattaagact ctcttttatt attttgttta tgtggttttt
 4381 ctataataaa actagcttta caaatctgc acatttaaaa gctagtatct atctcttaga
 4441 gccatttctg aggtagatat ttagtttgag catctccaat ctgaaaatcc ttaaagggtcc
 4501 aaaatgaaaa acttttttag tacggtgaca ccacaggtgg aaaattccac accagacctc
 4561 aatgagggtca tagtaaaaaac gcaggcacac aacacacagt ttattcagtg tcctcaaggg
 4621 aaaaaagact cagcctcttc tagctgcaat atatcttttc cacgtatgcc caaattcccc
 4681 cacacaagca cacctatgaa ggttactaaa atggcacatg tgcaggtcca gtgcaccaac
 4741 agcattttcc ccattgatgcc ccacaagggg ccaagacctt tgtgcattac ccagtatggg
 4801 cttctttact tcctgtcttt tctctggtgt aaagatactg tttaaaaaaa attttttttt
 4861 gagtggggat gcgtttgaga cagagacctg cgctgtggct caggctggag tgcagtgggtg
 4921 caatcttggc tcaactgcaac ctccacctcc cgggttcatt cgattctcct gcctcagcct
 4981 cctgagcagc tgggattata cgcacccacc accacacca gctaattttt gtatttttag
 5041 tagacatggg tttcacctg ttggccagac tggctctgaa ctctgacct caagtatcc
 5101 acctgcctca gcctcccaaa gtgttgggtg tacaggcgtg agccacagca cccaggctgt
 5161 ttaaaatggt taaaaggcct acagataccc ttgtgggtga cattgataag aaaaagaaga
 5221 ggcattttatt tttattttata acacataaat ttaagctgtt ggaaaaactg gacaataatg
 5281 taagtgaaga acttcttaca gaagaatgat gttggaatga acaccatata tgacctaaaa
 5341 gaaagaacaa ctttcctaaa gttgttcttt aggactaaac tgttgaagtt ccattgctaaa
 5401 aatgatgaca gaagttaatg aaaaaaacaa aaacactgca gaaagttaaa aacgaagatc
 5461 ttgatcatgc attgaaagag tggatccatc agcattgcag tgaacacgtg ccacttaagg
 5521 acatgctgat catgaaataa acatctatta aaatgaactg aaaatcgaag ggaactgtga
 5581 gtattcaata ggctggttag agaaatttaa ggtaagatag cattaacttt tctaaagggt
 5641 tgtggtggtt aagcatcttg atcacaaaaa agcagagaaa ttcattgatg aatttggcaa
 5701 gattgtctct gatgaaaatc tgactccaga acaagtctat aatgctgatg aaacatcact
 5761 gttttgccat tattgaccca gaaagacact gactacagct gaggagacag cccctacaag
 5821 aataaaggat gcaaagaaca gaataactgt gctgggatgt gctaattgcag caggcataaa
 5881 tgtgaactta ctgtgatagg caaaagcttg catcctcact gttttcaagg aatgcatttt
 5941 ttttactagt ccattattgt actaacaaaa aggcattggat ccctagggac atcttttctg
 6001 attggtttca caaacatttt ataccagctt gtgtgcactt gcagggaagc taggccggat
 6061 gatgactgca agattttgtt attccttgac aactattctg ctcatcgtct agctgaaatt
 6121 cttattaaaa aaagtgtttc attatttcaa ccttgtgacc aggtatttct agcatcaatg
 6181 aagagtaaat acaaaaacct tttttgggca gcatgctagc agcagtgaac tgaggcctgg

FIGURE 8C

6241 gtgtggaagg ttttcagaag gagtttagaa tgaaagatgc catagatgct tttagccagca
 6301 caaggagttt aggatgaagg atgccatata tgccagcact tggaagacag tgactcagtt
 6361 gtgtatgcct gcagcctctg cctgtcacta cttttattga tgatgaggag caaattgggtg
 6421 actttgaagt atgtcaagt agctccttat gcaaaaaata atatcttcag agtccatccg
 6481 taagctggaa gaaggatata tcaaaagaag gtttgacatt gataatgagg tttcagttgt
 6541 tcattcatta actgatggca aaatagctaa aatgcttcta aatcaagggtg attatgataa
 6601 tgggtgataat gaagatgatt tcattgacct cgcagaacaa ctgcctatag gcagcatggt
 6661 gatgggctta ttgaagcact agagcagcat gtattcataa cagaacaaga aatagggtta
 6721 taaaatcaag gagagacttc aacaaaaacc attgttaaag aggcaagtag gtggtagtgc
 6781 aggaaacatt ttaaaaggcc attcagcaca atgtcttatt atgccgagag gaccacttc
 6841 ttgggtccctc aactgcttct gatgtttctt ctacctaac aaagtactgt gtaccggaac
 6901 tttttaatca aaacataaca ttgtaggtag agactgaaag cctgccattg ttgctgttta
 6961 acagctgata cagggtgttct ggtgatgcca ctgtgctgct tagtttgaat acgttatttt
 7021 tcaactgttat taatgggtgtg tcttatattt ttactattaa gttcctttgt gtgaatccgt
 7081 gtaagaaaat gattgcttgt cagtagtatg taaattcaat caagaatgat ggtgatgcca
 7141 aacaaccata gagtggtcac atgggtgggt gacatagcaa cacctgtgtt ttctgataag
 7201 tcagtgtaca caacctttgt ttcatgcaca aaattattta aatattggat aaaattacct
 7261 tcaggctatg catataaggt atatgaagca taaatgaatt ttgtgtttgg acttgggtcc
 7321 catcctcaag atagctcatt atatctatga actattcaaa aatcctaaaa aatctgaaat
 7381 ctgaaacact tctggtccca agcattttgg ataaagggaca ctcaacctgt agtatgctta
 7441 agggaaaagct tatcctaaag ctttcgtcca atactgttgc aggtgggtgct acattcattt
 7501 ttgaaacatt tctgttttct taaaagattt gggtttcaca tttcaataaa actagcataa
 7561 atacaagcat ttttttaatt ttttttatt atacttttaa gttctagggg acatgtacac
 7621 aacgtgcagg tttgtttacat atgtatacat gtgccatgtt agtgtgctgc acccattaac
 7681 tcatcattta cattaggtat atctccta atctcctc ctccctcctc ccatcccaca
 7741 acaggccccg ggggtgtgat tccccctcc tgtgtccaag tgttctcatt gttcaattcc
 7801 caccatagag tgagaacatg cagtgtttgg tttttgtcc ttgcaatagt ttgctgagaa
 7861 tgatgggttc cagcttcacg gatgtcccta caaaggacat gaactcatca ttttttatgg
 7921 ctgcatagta ttccatgggt tatatgtgcc acattttctt aatccagtct atcattgttg
 7981 gacatttggg ttggttccaa gtctttgcta ttatgagtag tgctgcagta aacatatgtg
 8041 tgcatgtgtc tttatagcac catgatttat attcctttgg gtatataccc agtaatggga
 8101 tggctgggtc agatagtatt tctagtctta gatccctgag gaatcaccac actgtcttcc
 8161 acaatgggtt aactagttaa cagtcaccac aacagtgtaa aagtgttccct atttctccac
 8221 atcctctcca gcacctgtt tttcctgact ttgtaatgat tgccattcta actggtgtga
 8281 gatgatatct cattgtgggt ttgatttgca tttctctgat ggccagtgat gatgaacatt
 8341 ttttcacgtg tctattggct gcataaatgt cttcttttga gaagtgtctg ttcatatcct
 8401 tcgcccactt tttgatgggg ttgttttttt cttgtaaatt tgtttgagtt ctctgtagat
 8461 tctcgatatt acccctttgt cagatgagta gattgcaaaa attttctccc attctgtagg
 8521 ttgctgttcc actctgatgg tagtttcttt tgctgtgcag aagctcttta gtttaatgag
 8581 atcccatatt tcaattttgg cttttgttgc cattgccttt ggtgttttag acatgaagtc
 8641 cttgcccatt cctgtgtcct gaatgatatt gcctagggtt tcttctaggg tttttatggt
 8701 tttagggtcta acatttaagt ctttaatgca tcttgaatta atttttgtat aagggtgaag
 8761 gaagggatcc agtttcagct ttgtacatat agctagccag ttttcccagc accatttgtt
 8821 aaatagggaa tcctttcccc atttcttgtt tttgtcaggt ttgtcaaaga tcagatagtt
 8881 gtagatgtgt ggtattattt ctgagggtc tgttctgttc cattgggtcta tatctctgtt
 8941 ttggtaccag taccatgctg ttttggttag ttgttggttag ttagtatag tttgaagtca
 9001 ggtagcgtga tgccctccagc tttgttcttt tggcttagga ttgacttggc aatgcgggct
 9061 ctttttttgt tccatatgaa ctttaaagta gtttttttcc aattctgtga agaaagtcac
 9121 tggtagcttg atggggatgg cattgaatct ataaattacc ttgggcagta tggccatttt
 9181 catgatattg attcctccta tccatgagca tggaatgttc ttccatttca cccattcaca
 9241 attgcttcga agagagtaaa atacctagga atccaactta caaaggatgt gaaggacctc
 9301 ttcaaggaga actacaaacc actgctcatc gaaataaaaag agaatacaag cattttaaaa
 9361 gaaaaacttt aaaaaattta tcaattcagt aatttttttag gaaattttgt aaattgtaaa
 9421 accatcacca caatttagtt ttagtttttg tcacctcaaa gctgttttac tcatgttag
 9481 tcaattatga tttccacctc cagcctcacc actaatctgc cttctgttta tggatttggc
 9541 ctttctggag gtttcttata aatgcaatca tatagaatgt ggccttatat gactgggttc
 9601 tttcacttag tataatgttt tcaagggtta tcatcatggt atcagtgttg taggatgtat
 9661 cagtacttca tttcttatta cggctgagga atattccatt atagatacaa cactatccat

FIGURE 8D

9721 tcaccagttg atggacatta gggtagtttg tagtttttgg ccattatgaa tactgctata
 9781 aatattcatg tacatgtttt ttatgtggac gtgcgttttc atttctcttg agtatatacg
 9841 taggttctaa tgggtataga gtagtattcg ttgtagggtt gatttgcatt tccctaataga
 9901 ccaatgattt taaacatctt ttttgtgtgc tcactagcca tttgtgtatc ttcttttgtg
 9961 aaatgtctat tcaaagcttt tacctatttt taaattattt gggctctata gagttgcagg
 10021 atttctttgc atattctgga tcaaactctt tctcacatat atgatttcca aatatgtttc
 10081 tttatttttt gagacaagga cttgctatgc ccaagctgga gtatgggtgg gtgatcacag
 10141 ttcactgcca cctctgcttc caaggagctg ggaccacagg catgtgccac cacacctagc
 10201 taatttaaaa gaaatttttg tagacacaag gtctcactgt gctgtgctgg ctggtttcaa
 10261 actcctggtc tcaagctatc ctccctgcat ggccctccag agtgctggga ctacaggcat
 10321 aagtcactgc acccagcccc aaatatattt ctcttgctg tggctgtgtg ttttgaagtt
 10381 taagagggtt ttattttgaa gtcccttttt tttttttttt tttttttgag actgagtttc
 10441 actctgttgt ccagactgga gtgcagtggg gcaatctcgg ctccactgca gctctgcctc
 10501 ctgggttcac gccattctcc tgcctcagcc tcccaagtag ttgggactac aggcattccac
 10561 cacctcgctg ggctaatttt ttttttttat gtatttttat tagagacagg gtttactgtt
 10621 gttagccagg atggtctcga tctcctgacc tcgagatcca tccacctcgg cctcccaaag
 10681 tgctgggatt acaggcgtga gccaccgcgc ccggccgaag tccttttttt tttttttagt
 10741 ttatcatttt ttgttgttgt ttgtttcaag gattgtgctt ttgttgttag tttttttaaa
 10801 aacacacttt gttcctcttg agagttgagg gcctactggt acatttagac cccattgtat
 10861 attatgaaaa tttattgttc atgatatcat tgggtccatat tgtagataag aatttccaaa
 10921 ttatttttat tttctacata tatttgtggg gtactcatca ttttagggtaa ttttccctc
 10981 atagatgtgc tactataatt tttaggtttt ataaagataa ctttatagtt gtttaagtgt
 11041 aatctttttt ctttctctct tttttttggc agctccctag atcttttagt tctactccca
 11101 ctgctcctac cactccagca acgccagata atgcatcaca ggaagaactc atgattacat
 11161 tagtaacagg attggcgtcc gttacatcta gaacttctat gggcatcatt attgttggag
 11221 gagtggtaag aaacattact ttttagtataa ttaaaatcga aatgtttgca aggctgcctg
 11281 ttagctcaca aaagaaaagg tatacagtat ttacttctat ttataggatc tgtaaaatag
 11341 tatgaaaatt tgcaggttaa aagtagtgaa ttaaatatca caagtttcat cttaaatttt
 11401 taaaaaacat acatctttag gaatgaacta tcaccaccta gctgggtctt aataacttct
 11461 aagcattttt acatcacagc acacaaaagaa atatttgtac gttgaggtaa taagaaaacc
 11521 ccagggtccc tatctagcct tctctgaata tcaaggggat ctgtcttaag tattaatgt
 11581 tatttttagt agtagttctt atttgtttct ttaaaaaatg tatatcatta acagcatgga
 11641 tatgcttggt ttgggttttg aaaggctctga cctacaatat ttaacattgt tttatttttg
 11701 agatacattg aatcaggata agtctggcag cttataaagc tctccctcat ttgtgtgctg
 11761 atccctttta agcctgattg atttctggta acttcagggt ttctcatgga gaaggaatat
 11821 acatttttag aaaatgtatc taactcaaag atccataggg aactaaaatg cttttaaatg
 11881 tactctccaa agtgggtgtt ttccctctca gactaaagcta tgactttatc ttacagattt
 11941 ggaataactat aggcgtgaaa cctctatctg tttcattaac tatgtatgga gctttgtatc
 12001 tttatgaaag actgagctgg accaccccat gccaaaggag cgagccttta aacagcagtt
 12061 tgtaaaactat gcaactgaaa aactgaggat gattgttagc tccacgagtg caaactgcag
 12121 tcaccaagta aaacagtaag ttggaagggt catctttcct ttaaaaaaaa gttactgaaa
 12181 tatgacatac atgcagaaaa agcacaaaat aagtgtattg ctcaaagaat tatcacaaaa
 12241 tgaacatggt tcgtgatggc cataaatgag aaaaaataga acaatactaa acctactgc
 12301 tgccctttct cctcctaata cactattctt ctttccattc tctgataga ttaggtttga
 12361 acattagaaa attggtagat aggaactctc aagaactctg gaggggttta aaaagatagt
 12421 tcttaatttt ttttcttttt tttcagagat agggctctctg tcgcccaggc tggagggcag
 12481 tggcacaatc tggctcactg cagcctcgaa tcttgggctc aagtgatctt actgcctcag
 12541 cctcccacgt agctgggacc acagggtgtg gccaccacac caggataatt ttttaatttt
 12601 ttttttttct ttgagacagg gactcaatat gttgcccggt ttggtcttga ccacctgggc
 12661 tcaagtaatc ctccctcctc aagcctcctg agtagctgag attataggca tgagccacca
 12721 tgcccaactc aaaagatctt cagcagacct attctaaatt tatgtacctg gctgggcaag
 12781 gtggctcagc cctataatcc cagcacattg ggaggctgag gcaggcggat cacttgaggt
 12841 cgggagttcg agaacagcct ggccaacatg gtgaaacccc atctctacta aaaacacaaa
 12901 aattagccgg gcatggttagc acatgctctg aatctcagct agttgggagg ctgaggcaca
 12961 agaatacgct gaccctggaa ggcagaggtt gtagtggcc gagatcacat cactgaactc
 13021 cagcctgggc gacagagtga gactctgtca cacatacaaa aaaaattaag cactggatat
 13081 agatttattt ttctattctt tgtctttttc tccttagaaa gtgaaacaga aaaaaacaa
 13141 aataaaaataa cttctaattg attaagaatt cagggttatt gtgttcttat taataggggt

FIGURE 8E

13201 tattctataaa catttaggaa tgcatacaaaa ttcatagatca gatatacactt gccaaagaatg
 13261 ggggcttcat cagatccgga atagaatttta tctaaaagt atcaagacat gcagacttat
 13321 aaaaagctat gaacatcctg tctgtataac aacttggcca gcaacattcc tggcgcaaaag
 13381 ggctaaggct ccttcaagcc ttgagaataa gacacttaaa agaataagcc caagctcctc
 13441 ctgagcgagg aggccgaata ttgtcagtag aagcatggac ttttggatgt gatctgttct
 13501 ggagccccgg acctagccct tgttactttg tgatttttgc acaagttcct cggactctct
 13561 ggtcttctgt gtctctcatct gctgaatgcg caaaaagttc ctacctctc aagtctctgtg
 13621 tctgaaggac attatgttct catagcactg agcacaatcc ctggcacatg gttactcagg
 13681 gcaccaagt tatcattatg tgtctaggga aagttgggtt gggcatgcag ttgttgaatt
 13741 ctcttctttc tgggtgagcg ctgcctctca gcagctgatg ggggaatcct tgcattattg
 13801 tcaactccagg agagaagata cctgcttcct gcaagcaaac ttacggtttc atacacttta
 13861 ttggatctca aaggcagatc tttttttgtt ttgttttgc ttcttgagat ggagtttcgc
 13921 tctcgttgcc caggctggag tgcaatggca cgatctgatc gtggctcact gcaatctctg
 13981 cctcctgggt tcaagtgatt ctctgcgtc agcctcccaa gtatctggga tgacaggcat
 14041 gcgccactat ggccagctaa tttttagtatt ttagtagaga tgggtttcac catgttggtg
 14101 aggctggtct cgaactcctg acttcaggag atctacctgc gtcagcctcc taaagtgtg
 14161 ggattacggt ggtgagccac cacaccggc ttaaaggcag atcttaaaag cacattaaat
 14221 catctgtctt aactcccaca ttgcacagag aaataagctg agttccaagg aggcagcata
 14281 acctgagact agaaatggtg cttaggttcc taagcccagg cctccaaggt ctatttactg
 14341 tataatgtga gctgatgtct cccaaagtat aaatgtaggg tcacctgtgt taggatcata
 14401 tgaagggtct tttaaaatgc aagttcttgg gtcctttacc ctaattgttt tatcagaatc
 14461 tctagagatg ggacctggga atctgtatctt aacagaggat cacacctgag ttcaagaacc
 14521 actcatgtag tagaacaatt acctcaactt aaaatatgaa atgtatctgt agcaagtgcc
 14581 acctggtaaa gacttgatca cagtggattt caaacaagac aaagtattga gggctgttga
 14641 actgtcaaag aatttcagct attatttcta ttagtttctg cctcactatc catcgagtgtg
 14701 tttgtatgcc aggataggcc agatttctga gctcttgtga gcttgtgtaa gattgtgtag
 14761 ctctctgctc ttgaaaaagc ccaaaaagtg aattaacatt tgtatagact tagaactgta
 14821 actagctcat aaatagtagc cactagtatt atcactcaga gcaggaaaag catctgcaca
 14881 gaggtgacgc tgggttctct gatgtgagcc tagttcaggc agtcagggtc ccatttgatt
 14941 agcaagatgg ctggagataa taatcagggt aaaggaaaagg aaagatccca tcgaaggctc
 15001 cagaagtttg tggcacagat catacttcct tgttgtttgt tttcctgcaa agagaatgta
 15061 agatcagatg tgactttact tttgacagtt tgaattcttg ctcacatcag caaaaattct
 15121 ccatattgga ataactgtcc agtttaggggt ttacttattc tcctacgaac aaatatagat
 15181 agtcacgcaa agaacaatag ctggttgtga aatttttaggt tgttgtcaat gatttgtgca
 15241 tctctaaatt ggaaaacaca gacatagttt tcatgaacat ggagaatttc agctacaaaa
 15301 taattcttag ccataatagg tattgtatat ttaattgaga gaatgtgaaa aacaatgagg
 15361 aagtagtttc tccagtatgg tgaaaggcaa agagggttct tttttttccc ctaagtaaag
 15421 catctactaa atgcaaaaga aatgattgtg gactctggaa tctggaatcc acgatgctag
 15481 cactttgcag taatagcctc tttcatatat agatctcaca acagtttgta gacactaagt
 15541 ttttccatgc tctgcaact cacactgagt ttttatttac tcccttttta ctctggaaaa
 15601 gcagggcagg aagtttttaa agggttcctt gcagttacaa agctagaatt tgaaccaggt
 15661 gtcaaagcct ctgggtcaga ttgggagggg gccacggtg tgaacttgac agttaattca
 15721 tgggtgctgt tttatggagc aggaagtgc ctttagtgac tcagaggaag gaataagctg
 15781 agggaggggtc caggagacca gaggtacagt gcctggcatc tcttatcact gcattctaag
 15841 tggcttagcc ttgctgtgtt cctgaatgca cacattggga ttgcaactca caccgaccac
 15901 ttttaggttct tcttgagaga taggctgtga gtctgaatg gagtgtgtgt gtgtaggggg
 15961 cttggctttc aggccaaagag tggagtgaat gtggtacttg gtggacagag aggccagttg
 16021 gttatcaagt gaaggggctg tagggaaaaa gttcagaggg caaaaagcta tgttgtctct
 16081 tctcacttat tgtccatgag tattttcttt taaatggaac cggaatcata agataagaat
 16141 gaccaggagg ctctggtaaa ggcagggtgca agttttgtgt gacaagatcc tcatggacta
 16201 aaaaatgatc atatttctga ggttgaatca aatacataaa agcagcagca aatcacacac
 16261 ttcttcgaag agagttacca agttgcaggg gaaatttatt agcacaata agtctgaaaa
 16321 ggaaaagcta tccatatata caaggtttaag ttggaagaag gaggcagaaa gaagaaattc
 16381 cagttgttat cattattttt tattccaaat tgcactgtt cactaaaaata cttcggaactg
 16441 ggtgcagtgg cttacaccta taatcccagc actttgggag actaggcggg cagatcactt
 16501 gaggtcaggc attcgagacc agcctgggtc acatgatgaa accctgtctt tactaaaaat
 16561 acaaaaatta gccagtcgtg gtggcacatg cctgtaatcc cagctactcg ggaggctgag
 16621 gcaggagaat cgcttgaacc tgggaggtgg aggttgcagt gagccaagat tgagccagtg

FIGURE 8F

16681 cactccggcc tgggtgacag agggagactc catctcaaaa aaacccaaac aaatatttta
 16741 taaaatagaa atagaaaaat aatacaaatg aaaagtctat taagtatata tttttattaa
 16801 gcaatattaa aatgactgca agtaagagtt tatatagcta tatgtacatg gatatttata
 16861 gatgagatta cgcttacatt cttgcccaca ccatcttgga aaatgttaag ataatatcgc
 16921 cttgactgaa aaacatacag caaacatggt ctctttggca ttctgtcatc cacatctaca
 16981 ggtgcctgta gcaatgtgtg gtactataat ataatggtaa ttgatgttcc taatttggga
 17041 gtgtggaaag atccccaat gtcttttaag tcatcagaga aagataaaat aatatttgat
 17101 acagcttttc ttaaaaattg agataatttt aatggcgagt tattttatgg ccctttgtat
 17161 cttgaaaaat tgggaaatca catatggttt aaaagcgaat tatcttaatt ggaacatgcc
 17221 attaaactaga aaacccatta tttcagcttg cactctaaca gacaatacgt ggaaaaggaa
 17281 acgcgccag ggcaaaacat ttctcttct tataaacctt gaactgagta cgtccctcac
 17341 caattataga ggggtcccctt gggcctcaga actttccaca agcgttgagg tctctatggc
 17401 gatgctccc gctgccgagg cggaacaca ggtgatgagg tggcggcaag cacagtgcaa
 17461 agagagagaa gcagcttcgg ctgcagcaaa ccacgcaggt ccttcttgat catctagaac
 17521 tgaccgtcc gccttgccag gagtctgcag aaccacgtgg ctagcctgcc tgaagtctc
 17581 acctctccag gaaggcggg ggcttctaag ggctgcagct gcgctggggg ctgggggctc
 17641 ccgctgggac tccacttccg tggatgtcta agcttcacct ttcttgccg ccgaggggca
 17701 tgactcaggt gaaagggagc cattttctca gaccctggc ctcatgcagc ccttcagcat
 17761 ccccggtgcaa atcacacttc agggcagccg gaggcgccag gggaggtaag tcacttccg
 17821 aagctctgcc ggtagtggga atctggctga acaagcagtt gcaagaagag gggacatctc
 17881 gagcttggg agtgagtgtt tccttttct ctgaggatgc ccacttgcca tgctcccag
 17941 ggtaccagc aggtctcccc agtagcactc acatcacggg gctgcagcct ttctgttg
 18001 ctctatctc taggttgcca gttcttgag actggagacc ttttaaactc acctgtagct
 18061 ccccgact gatcatagcc cagcccatag ttggtgctca agaattgatct gttggtgaa
 18121 tgaggaatga agaaattaga ccagcatttg gtcccatttg tgaagccctg gactcacagc
 18181 ccttggttc aaacccagct caccacttaa tcagccatat gactgggcag gtcccatttg
 18241 tgaagccctg gactcacagc ccttggttc aaacccagct caccacttaa tcagccatat
 18301 gactgggcaa gtcacttaac ttctctggtt gcctcatctc cttatctgtg aaatgcagat
 18361 agtaagagcc cctgcgtgtc tcagcagagt ataccacatc ctctctaaac tatactgtta
 18421 taccgggtat acgctctaca cctccctaaa ctctagcctt ttagctattg ttattacca
 18481 cctactctt ctctttaaag ggggaagtga gagattattt tcaggaccctg ttttctccc
 18541 agggaaatga aaagcaaaga agctgaaagc ctctagtac ctgcaccct tttgctgct
 18601 ctagggttg ggcatggggc agtcaatgtg ggaacaaaaa tggagagaag agtgatgct
 18661 gaggggttg gacaaatggg atactaaaac cttttgtgct agggcggtg gctcacact
 18721 gtaatcccag cactttggga ggccgaggtg agtggatcac ctgaggctcag gacttcgaga
 18781 gcagcctggc caacatgggt aaacccgctc tctactaaaa atacaaaaat tagctgggca
 18841 tgggtggggc gcgcctgtaa tcccagctac tcaggaggct gaggctggag aattgcttga
 18901 acctgggagg aggaggttg agtgagcaga gattgtgcca ttgactcca gcctgggca
 18961 caagagccaa actctgtctc aaacaaagaa aaacctgttg ggaggggtac atttcagaac
 19021 caggttcact cactatctgg aaatatgcat gatttattat tggctctagt ggagttggga
 19081 gctgagaatt ggaaaacatt aaagatggta atggctatca tggtactcac ttccattatc
 19141 acttaactgc actcaggggt atttgagagg gagcatgagg agagtgaat acaggagttt
 19201 ggataagatg ggggttcagg gaagaaggac cagacagact acagaggaaa gaaaggtgtt
 19261 cttctcgcta gacatgaacc aatttttttg tgaacagaca attaaaatga attactttat
 19321 ggcaaaagat caaatgacaa acatgcaagc aaacaagttt tagtgtcca tacgtcacac
 19381 aattaactag atataaaggc agttgtgttg tcatcaaagc aaactactgt atcccatttt
 19441 catttctgaa atgcacaact gaattattgc tatttctctt tgctgaactt gatgaactat
 19501 gttgacttaa ctttatttgc tgtttcaaaa taagttgtta aataatgttg taattaaaaa
 19561 atagaagagt aaaaataatt accaagggtc tctctgtaa ccaaacgaa ttacagggaa
 19621 atattaatat agtgacttc atgttttagac attcatttca catacaccg tgaatgaat
 19681 gtcagatgaa ttatgaagtt ttgatgagcc acagcatgtt tctaaggaa acttcttgca
 19741 aaagtttcag tgctggaggg agaggctgt ggcttctgtg gggatcacac ccaggtgagt
 19801 gtgttcaggc tgtttgtaat tgagtttgc tcaggctaag ccagaagctg cctgtagcca
 19861 tgtgtcgta tgggctggg tgggaaagtc agtctatct gcagtgaaga gaatagaagg
 19921 tgggtgatatt tgccttgatt atgaataaaa cagctcaagg taatacactg gttagaagcg
 19981 gacatgtatt actggcagaa aaaggaatca atatgctttt tatccatctt cctgactaga
 20041 aagcaacta gatcatactt aagtgtttg aggtccttg atgaaagatg cttgtaataa
 20101 caacaaagtt aattacaagg ctgtttatgg tctgagaaaa ctggaaacaa cctaataata

FIGURE 8G

20161 ttcaataata aggaaatggt taaggaaata tggcatatct aattgatgga acattatgta
 20221 gccaatagga ttacaaagaa ttgttaatga catgggaaag tgcttattat gttaagtga
 20281 aaagataaga ttaacaaaaa aatctcaaat catatctaata gtgatctcat tctgtttaa
 20341 acaatatagg ccagggtgagg tggattatgc ctataatctc agcacttttg gaggccgagg
 20401 cagggtggatc acctgagggtc aagatttcga gactagcctg gccaacatgg tgaaccccg
 20461 tttctactaa aaacaaaaaa attagctggg cgtggtagcc ggccgctata atcccagcta
 20521 cttggggaggc tgaggcagga gaattgcttg aaccgggaa gcagagggtg tagtgagctg
 20581 agatcatgcc actgcactgc agcctggatg acagagtga actccatctc aaaaaaaaa
 20641 aaaaaaaaaa aaagaaaaga aaaagaaaaa caaacagaa acaaaaaaca aaaaacaaaa
 20701 aacctaatat agagcaggag gggattaacc cagcaacca agtgacacaa cattaccttt
 20761 aagtgtgtg ggtgagtttt tgttctcttc tgtacatttt ttttgtatt tttcaagttt
 20821 catacaatga gcatataaaa atatatattc ttcataaatc atttgacatt tgttgaggaa
 20881 tttctttgtg ctaagtttgt agtcagggtc tgagagggtg caacgtgctg gcagcccttg
 20941 cagccctcgc tcgctctccg cgctctctcg gccttggcgc ccactctggc cgccctgag
 21001 gagcccttt ctgggctggc caaggctaga gccggctccc tcagcttgca gggagggtggg
 21061 gaggagagg cgccggcggg aaccggggt gtgcgaggag cttgcgggccc agtccgagtt
 21121 ccagggtggc gtggactcag cgggccagca ctccgagtgg ccgaccggcc tacaagccac
 21181 ggacagtga gggcttagca cctgggcccag cagctgctgt gctcaatttc tcacagggccc
 21241 ttaggtgcct ccccgcgggg cagggtcttg gacctgcagc ccgccatacc tgagcgctgc
 21301 cccgctcgc tgggctctcg tgccgccga gcctccctga tgagcgctgc cccctgctcc
 21361 acggcaccga gtcccattca ccactcaagg tctgaggagt gcgggcacac gcacaggact
 21421 ggcaggcagc tccacctgtg gcccgggtgc gggatccact ggggtgaagcc agctgggctc
 21481 ctgagtctgg tggggacttg gagaacgttt atgttttagt aagagattgt aaatacacca
 21541 attggtactg tgtatctagc tcaaggttta taaacacacc aatcagcacc ctgtatctag
 21601 ctgagggttt gtgaatgcac caatcgacac tgtatctagc tactctggtg gggacttggg
 21661 aaacgtttgt gtccacactc tgtatctagc taatctagt gggatgtgga gaacctttgt
 21721 gtctagctca gggattgtaa acgcaccaat cagcacctg tcaaatggg ccaattagct
 21781 ctctgtaaaa tggaccaatc ggtctctgtg aaaatggacc aatcagcagg atgtgggtg
 21841 ggccagataa gagaataaaa gtaggctgcc ccagccagca gtggcaacct gctcaggtcc
 21901 ctttccagc tgtggaggat ttgttcttt gctctttgca ataaatcttg gtactgctcg
 21961 ttctttgggt ccacgctgcc tttatgagct gtaacactca ctgcaaggt ctgcagcttc
 22021 actcctgaag ccaggggagac cacgaacca tcggggaggaa tgaacaactc cagaggcgcc
 22081 gccttaagag ctataacact cactgccaag gtcccgggct tcattcttga agtcgggtgag
 22141 accaagaacc caccaattcc ggacacagtt tcataaatgt tccatacatg cttgagaata
 22201 atatatattc tgtagaagt gattattctt atttatcatt tagataaaa tagttaattg
 22261 ctttacttaa atctattacc ctactggttt gttcagggtc agctatctaa attactggg
 22321 gagtgtataa aaatacatca taactctgata gtggattttg tctatttctt cttgtagttt
 22381 aatcagtgaa acaatgctat caggtaacct caaattagca ttgttacatt tccgtgtga
 22441 attgagcctt taatcagttg taaaacactt atttttaaat ttctaataaa gctttttaat
 22501 ttttaacatt catgtttgct ttttgttaca ttttgctat aaatttcacc ctttttgtat
 22561 ctgtgtttta gatgtatctt ttgtaaaaac atgcatatag atagttctcc atttacagtg
 22621 ggattacatc ctgacaaatc catcataagt ggaaaatact gtaagttgaa aacttcagag
 22681 tattagctat ttacctcat gattgtgtgg cagactggga actatggctg gctgccactg
 22741 cccagcatct caagagagta gggtagctga tctgctagc ccaggaaata atgcaaatc
 22801 aaaatttgag gtacagtttc tactgaattc atattgcttt cacaccatag taatgtaaaa
 22861 aaattgcaag tgtggggcgg cgccggccat gggggcgggc gaggcgcccg agccccgctt
 22921 ccccgcgccc attccacccc cgccagaggt cagcccgcgg ccacctacgc cccgcccctg
 22981 cgggctgcgc ccgagcccag tcccgcgagc cgctccccgg cggtctggct cttggccccg
 23041 gaagcgcgag cgttcacttc gcggcgagtg gctccgtctc cgcgacaga gcgcgcccc
 23101 cctggcccg cgccgggggg ggggctcccg cacggtcccc gagcgtttcc cgccgggtgg
 23161 agcgggcccga gccagcagg ttgaccagcc ccgcgccac gcagagccgg gagatctact
 23221 gtttgagcgc ggaagcgag aggtggcg agggccggct cgccgcaaaa cgggaggccc
 23281 gcgaggaggc tcgtgagatc cccatgaagg agctggagcg gcagcagaag gaggtagaag
 23341 agagaccaga aaaatatttt actgtaagg ggtctctgaa catgctgggc ccgtctgcag
 23401 ccacgctggc ctttctgggt gggacttctc ctgagagagg cagcggagac acctctatat
 23461 ccacgacac cgaggcgtcc atcagggaaa tcaaggactc tctagcagaa gttgaagaga
 23521 aatgtaagaa ggctatgttt tccaatgctc agttagacaa tgaacacaca aacttcattt
 23581 accaagttga caccctgaaa gatatgttgc tggagattga agaacagctg gctgaatata

FIGURE 8H

23641 ggcggcagta cgaagagaaa aacaaataat ttgaaagggg aaaacacgcc cacagtatac
 23701 tgcagtttca gtttgctgaa gtcaaggagg ccctgaagca aacagaggaa atgctcgaga
 23761 aacatggaat aatcctaaat tcagaaatag ttaccaatgg agagacttcc gacactctca
 23821 gtaatgtttg ataccaagat cctaccaaga tgacgaaaga agagttaa at ggcctcaagt
 23881 cgacagggga tgggacccta ggaaagccag tgaggtggag gtgaagaatg aaatcgtggc
 23941 gaatgtgggg aaaagagaaa tcttgcacaa tactgagaaa gaacaacaca cagaggacac
 24001 agtgaaggat tgtgtggaca tagaggtatt cactgctggg gagaataccg aggaccagaa
 24061 atcctctgaa gacactgccc cattcctagg aaccttagca ggtgctacct atgaggaaca
 24121 ggttcaaagc caaattcttg agagcgcttc tctccctgaa aacacagcac aggttgagtc
 24181 aaatgagggtc atgggtgcac cagatgacag gaccagaact ccccttgagc catccaactg
 24241 ttggagtgcac ttagatgggtg ggagccacac agagaatgtg ggagaggcag cggtgactca
 24301 ggttgagagag caggcagaca cagtggcctc atgtccttta gggcatagtg atgacacagt
 24361 ttatcatgat gacagatgta tggtagaggt cccccaacag ttagagacaa gcatagggca
 24421 tagtttagag aaagaattca ccaaccagga agcagctgag cccaaggagg ttccagtgc
 24481 gagtacagaa gcaggtaggg atcacaacga agaagagggg gaagaaaaag gattaagggg
 24541 tgagaaacca atcaagacag aagttcctgg ttctccagca ggaactgaga gcaagggtca
 24601 ggaggcgaca ggtccaagta cagtagacac tcaaagtga ccctcagata tgaaagagcc
 24661 agatgaagaa aagaatgacc aacagggaga ggcattggac tcattgcaga agagaaagaa
 24721 caagaaaaag aaaaagaaga ggaaaaaatc cccagtacc c atagaaacc ttaaagatgt
 24781 ttaaaaaagag ttaacttatc agaacacaga tttaagtga attaaggga aagagcaggt
 24841 aaagtctact gacagaaagt cagcagtggg agcccaaaac gaggtgactg aaaatccaaa
 24901 acagaaaaat gcagcagaaa gcagtgaaaa tgttgattgt ccagagaatc ctaaatgaa
 24961 gttggatgga aaacttgacc aagaaggcaa tgatgtaaaa acagcagctg aggaggtact
 25021 agctggtaga gacacattag attttgagga tgtcacagtt caatcatcag gcccgagggc
 25081 tgggtggtgaa gaattagatg aaggtgttgc aaaagataat gctaaaaatag ctgggtgccac
 25141 ttaaagcaat cctgaagaac cagagagcga agatgcagat cactgcaccg tacccaaaaa
 25201 tgaaagtccc tcacaggaca ttagtgatgc ctgtgaagca gaaagtacag agaggtgtgg
 25261 gatgtcagaa catccaagtc agaccatcag gaaagcttta gacagcaata gcctaaaaaa
 25321 ccatgacttg ttggcaccag gaggagagcc gggggacttc aatccagaaa gcagagaaga
 25381 taccagagga gggaaacgaga agggcaaaaag caaagaagac cgtaccatgt cctaagctga
 25441 ggcaggcggc aggcgtggtg cacaggaagt ctgagtgtga ggggctcttt tctctccact
 25501 gccaatgtaa gtagaatgtt ctaaattcat agagatgcac tgtatgccaa tcaccaggtg
 25561 atctactgct ttaagttata gactgttact tgtagatttc catgtaatca ttgaggttat
 25621 caccagatt agaaagacat atttgttact agtgtacatt ctaattgaga gcatatatcc
 25681 agtagtatca aacaataatg tctactgttt atagtccact taataaaaaa agaagcattt
 25741 accatttgcc ttaggctgat aggaatgtga atattcttga ccaaatatat cagcatctaa
 25801 ttgaaatgac caaatagcat tcttagactt ctgtattatg aatataattg atatttaaat
 25861 taatgtcttg ttcatatatg tctactttca tatttgattt taaaatatac attataacct
 25921 gtatggtatt ttatttaaag gagataaacc gccaaatagc aaataggtca ctgaaaagat
 25981 ttgcacctta gaacaataat cattttaagg ataacaagta aaggtctgaa agcatgaggg
 26041 gctttatttg ccttcacctc atataagtct ttgattttga accaatgctt ttggatctca
 26101 ttgttgatga tacttgaatt tactttgtag gagattttaa cttcatgctg atgatgtatc
 26161 aaattcattt tatacaaagt ttaaagattt tttctggaag tgatacatgt caaattacat
 26221 ttcctactgc agtatttgag cagggacagt cattttttaa atgtttttgg ccgggtgtgg
 26281 tggctcacgc ctgtaatctc agcacgttgg gaggccaagg cggttgatc acctgaggtc
 26341 agaagttcaa ggccagcctg gccaacatgg tgaaaccctg tctctacgaa aaatacaaaa
 26401 aattggccag gcgtggtggt gggcgctgt aatcccagcc actccggagg ctgaggcagg
 26461 agaatcgctt gaacctgcga ggcggagatt gcagtcagcc aagatcaagc cattgtactc
 26521 cagcctggac aacgagcgaa actctgtcta aaaaacacac acacacacac acacacacac
 26581 aaaacaatgt tttcatgcct gtaaccctag cacattggga agccaagttt ggaggatcgc
 26641 ttgaggccag gagttcaagg ctgcagttag ctatgattgc accactatac tctagcctgg
 26701 gagacagagt gagaccctgt ctctaaaaaa aagaaaaagt ttttgaacct taaaattact
 26761 tctctttgtt tgaatttcta atcatcattc aaaagaacag ttaaaaaagg ttaactgttc
 26821 ttgtgcaact acaaattaga ctggagtagg atatttttaa gagctgaatc acttttggtg
 26881 ttttgttata aatgttttca tttgttatgt cccagtatat tcttattgga aaattcttgt
 26941 tttgatctgc ctgaagaaaa tatctgtttt ctatataaag aaacatttaa aaataattgt
 27001 aaagttagat ttaattgtaa aatataaaat caciaaggaa tgtaccttat gaatgttgac
 27061 attttatgaa attatgtaga ttcataattac tgttacaaga tagaattgaa tgcaaaaaa

FIGURE 8I

27121 ccaaactctc attaaaaattt gaggaataaca taagtgttat tatgtaattg aaataaaaac
 27181 atttttatagt tgtaaaaaaa attgcaagtg gaaccatctt aagttggggg acatctatat
 27241 gtattttaa atagttctgac aatctttata tttgaaaaac agttttttta gagatagggg
 27301 ctacactatc actgaggctg gagtgcagtg gcacaatcaa gcttattgca gcctcaaaca
 27361 cctgggctca agcaactctc ctgggtcagc ctcttgagta gctaggacta taggtgtgcc
 27421 actacaactg gatgggtgtt taatttttat tgtgtagaga caggggtctg ctatgttgcc
 27481 cagggtggtc tcgaactcct ggggttcaagt gattctccca cgttggtttc ccaaagtgtt
 27541 gggactatag gcatgagcac cacagcctgc cctactctct atcttttaac tggatcattt
 27601 actccattta gttttattgt aattactgat atactgatgc aataacatta ttctatcatg
 27661 ttattctgtg ctatttgtcc tgacttnttc atgagttttt ccctcatctt tattgccttt
 27721 tttggattga ttttttccct ttccattctt tgtttctcta ctagtgttga atttctggag
 27781 tatcacctaa aagagtagag aaagggtgata tttctattta gcatgcata tttgaactttt
 27841 caacatgaaa ttaatgtctt tatttttccc catggaaaaa ttatcactgt tactccctct
 27901 aaatttatatt ctcttgtcat gtatttatct tttcttttaa cccacaaga cataatagta
 27961 ataagataat tactattatt attattttgt agaattaata tctttttttt tctttgagat
 28021 ggagtctttc tctgttgccc aggtctggagt gcagtgggtg gatcttggtt tactgcaacc
 28081 tctgcctcct ggggttaggt gattctcctg tttcagcctt ccgagtagct gggattacag
 28141 gtgtgtgcca ccacgtccag ctaatttttg tattttttgt agagatgggg tttcgccatg
 28201 ttgggagctc tgggtctggaa ctcttgacgt cagggtgatct gccacactgg gcctcccaaa
 28261 gtgttgggat tacaggcgtg agccactgtg tccagcctag agttaatct tttacttacc
 28321 tgtttacttc tgtatttgcct ctccatttct ggttaaatat cagctggtat ctggattttt
 28381 ttcgttctgc cttgagtaaa tacttgacct ttttcttcca gtgagggtct atcaaggaca
 28441 aactcagttt tgtgtttgaa atgtctttgt ctgaaatgtc tttattcatt gagaggattt
 28501 tttttagtag atagaattct gtggttactt tttctcagta tattgataat attcttgctt
 28561 tatggcttct agtcttgtta cagagaagta agctctcagc caaattgtca ttactttgaa
 28621 gtttaattgtc tttttctttg gcgactgtta agatttcctc ttgtctttgt agctgtgcaa
 28681 tatactctgt atgtgtttta gtgtgggttc tctttatttt atcccatggg cttctggagt
 28741 ctgggaactg gtcttcaatc agttctagaa tttgactatc tttttaaaat attgcttctg
 28801 acttattgtc cttttcttct ggaattctga atagatatta tgttactata tttaatctat
 28861 ctttcatgtc tctgaacctc tctttaatac tttccattta aaaatctctc tgtattatac
 28921 tctggctatt tttgcagatc cagctctgtg ttcactaatt atcttctcag atgtatctaa
 28981 ttgagtgtta tgtctgttca ttaaattttt actttcaatt attttatttt tgatttctat
 29041 aaattctttt ttaaataatta gctctacatt ttagaattcc ttgatttctg acattttgga
 29101 tccttctttt atttctttta atatgttaca gatgtgtatt ttatattcta tgcaaatatc
 29161 tgaaattttt cgtggatctc attttgtggt ctattttttt tgcactcaaa cgccttgatt
 29221 tcttgtgtgt tttatgactt tttttttatt ttttattatg tattatttta ttcatttttt
 29281 tttgagatag agtcttgctc tgtgtcccag actgaagtgc agtggcacga tctcagctca
 29341 ctgcaacatc caccttcttg gttcaagtga ttgtcccacc tcagcctccc gagtagctgg
 29401 gattacaggt gcctgccact acacctgggt aattttttgt tttttaatag agacagggct
 29461 tagccatgtt ggccgggctc gtctcaaact cctgacctca ggtgatccac ctgccttagc
 29521 ctctgaaagt gctgggatta tagccatgaa ctacctcgcc tggctgttgt gtgttttatg
 29581 acttctaaat gagtgcata actccttggg catttatata cgtcttcttt ttttatttta
 29641 ttttatttga gacgagtctt gctctgtcgc taggctggag tgcagtggcg caatcttggc
 29701 tccactgcaac ctccgactcc ttgttcaaag gattctcctg ccgagcagc tagaattaca
 29761 ggcacgtgcc accacgcccga gctaattttt tgtgttttta gtagagatag ggtttctcac
 29821 catgtaggcc aggatggtct cgatctcctg acttcatgat tcgcccacct cgacctccaa
 29881 aagtgtctgg attacaggcg tgagccattg cgcctggcct atagaattct ttttaaggcct
 29941 aagttaaatg tgtgtgccta cagagaacat acgtatttaa atttgccagg ttgcagaggg
 30001 cactacctac ttaaacaaca ttacacgaaa ttcttagctt gagatttttg tattaccag
 30061 gtagtatgaa ttcaggctgt aaactccctt gaggatcccc ttgaggatta tctaaaattt
 30121 caggggagat ttagattttc ctcttttagt cagtgttaag gtttgagaaa ggcatttttc
 30181 ttgccatttc ctatggagtg gtacgggtg ggtgaagga gaggggctat tccagttca
 30241 acctgacact gacttttaag tcctttgggg tccagctct agttggatgg tatattaaac
 30301 tacatactc ggatagaccc tggacattgt ctctgtccc tgtgacctta taaactgtga
 30361 aacaaaagct caagttcacc aagttccgca aatgccctca agttaaaact tgacttctgt
 30421 ccaccttctt ttctgggttc ctactttcac atagtttttg tcttttgagt atttccaatt
 30481 ctttttaagc tttggccaga agtttttagt gtctgtagtt agagtgggtg tctagtgtac
 30541 cataccactg aaacagaagc ctgttacttt tacaataata aaaacatct tatgtgggct

FIGURE 8J

30601 ttttaaaaaa attttttaa attttttattt actttttttt ttgagatgga gtctcactct
 30661 gtcgcccagg ctggagtgcga gtggcatgat cttggctcac tgcaacctct gccaccggg
 30721 ttcaagcgat ttctctgcct cagcctcctg agaagctgtg attacaggcg catgccaccg
 30781 tgccctggcta aattttgtat ttttaggaga gacaggtttc accatgttgg tcaggctggg
 30841 ctcaaaactcc tgagctcagg tgatctgccc accttggcct cccaaagtgc tgggattaca
 30901 agcatgagcc actgcacctg gccaaacctt tctatgtttt agttttttat gattatttta
 30961 tattatccct tccccacaca tgaaataact tctttccaag tgacttatga agttgtcaac
 31021 ttttcataaa gccttggaaac aaagtgggca gaaaaattat aaataaaaaag tcttgtctag
 31081 gacagtacag gtctgtctta ttcttaaatt agatcagaat cgggttatgc cgggttttta
 31141 taacatacca ttataattgg gtatgttaaa gaatgtatta gagatgcatt agaagagcga
 31201 cctcattata agcctcttca cccatggatt ccaaggatat cttacaataa acctctggga
 31261 tacctttacgc tacagagcaa ctaaagttcca gctttagagc acaagggaaa atgcaggata
 31321 ttgggtcctg gaaactacaa aaaccatcaa actctacttt aggggctaaaa ctttctttta
 31381 atcaatctgt catatttatt gataaattag aaaatgtggc tgggtgcagt ggctcacacc
 31441 tgtaatccta gcagtttggg aggccgaggt ggggtggatca cgaggtcagg agatggagac
 31501 cattctggct aacacagtga aaccctgtct tactaaaaat acaaaaaatta gccgggcgtg
 31561 gtggtgggag cctgtagtcc cagctactca ggaggcggag gcaggagaat ggctgaacc
 31621 cgggagacgg aggttgcagt gagccgagat tgccccactg cactccagcc tgggtgacag
 31681 agggagacgc catctcaaaa aaaaagtaaac gttcaaatct cattaaattt
 31741 tttttccatg ccccttctct ggtggttagga tgatagggga tgagtaaaat atcaaagaca
 31801 actaaaaaatt cctaaactag atcctcgggt cccaaagaag tgtaaacat ggagtcccc
 31861 accttctgag gttggtgctt cctggcacag gctcttggaa cattctggat tgtctgacat
 31921 tccttttact cgcttttagaa cctaaagatg ttgctggggg aaaagggagc tagggagagg
 31981 gaaggggaag gatgtgggat aaggcataaa ctatgcttgt gggaaaaaaa caaccagtaa
 32041 tttccttgat ggggtttttg cttgacttta aaatgcagta agcttttagg aagcttgatg
 32101 gagcctgtgt ttctaccatt agtgtctgat ttgtttggct taagatttca ttaagcttct
 32161 taaaatggag atacttctgg aactcaaatg gctactgagc agggaatggc aaatcagtga
 32221 actgttagga agtggaggga ttttggcaaa ctagagaaca cacttccac aggggcagcc
 32281 actgctctgc tggggccgct gttcactctg agggacgtgc atcttgggat tatttccaaa
 32341 gtcagaactc agcattttta tgagaaatgt catgattttt aaggctttaa caagttatcc
 32401 cacattaaaa aaataataat aaaccaggcc ggggtgcagt gctcacgcct gtaatcccaa
 32461 cattttggga ggctgaggtg ggtggatcat gaggtcaggc gttcgagacc attatggcca
 32521 acatggtgaa acactgtctc tacttaaaat acaaaaaatta gctgggcatg gtggccggcg
 32581 cctgtaatcc cagctactag ggaggctgag gcaggagaat cgcttgaacc tggggaggcg
 32641 agggaggtgc agtgaactga gatcgtacc agcctgggca acagtgcgag gttccgtctc
 32701 aaaaaaaacc aaaaaacaca aaaaacaaaa acgacagaga aggccaaaca aaacacatct
 32761 gtgggctgga tgccgccatg cccaccgggt tgccgacctt gtgttggact cttctgttca
 32821 ccagacaccc tgccctgcga gaatgtatct catcctttgc tggagcaggt ttgcaggcac
 32881 agtggagaga ggagagaaga aatgaaggga cacttatgca gaaccatgag tggccagaga
 32941 ggaggagaag gaggtgaga ggagcaaga agccatgaca acttcataat tctgagtgga
 33001 ctgggcagtg gccagaaatt ctggtggtgg atatgctgcc tttccaacag gtgaatatga
 33061 aagaataagt caaacctgt tcaggacgct gttaattcca aatgtgaact ttttgagtca
 33121 ttctttccat gtggaattca aaggagaatg taacaaaatt ttcaggaggg acgtgcaata
 33181 tccctgaaag ataacaaagt tcgtaacact tatttacata caacattctc tagttattga
 33241 ttaaacagat ctctacagac ttgcatgagg caacatttct taggcttgtt tgctacaata
 33301 tctttaaaaa tacttgatta cacatcactt tagcttattt agatggactt ttcaccaagc
 33361 tctgaactgg gatttcattt tgttgcattc atcctgctca cgagacacag gtaggcagca
 33421 aatgagatta tccctccagt ccccatggat tggaaatgtt ccccttctt tatgagctca
 33481 ctgcagtatc tccttctccc tttccccaaa ggacagcctt tcctgcctca gggaagaaga
 33541 gagagacaga ctacagtgat ggagaccac tagatgtgca caagaggctg ccatccagtg
 33601 ctggagagga ccgagccgtg atgctggggt ttgccatgat gggcttctca gtccaatgt
 33661 tcttcttgct cggaacaacc attctaaagc cttttatgct caggtaagaa acagagggaag
 33721 gaaatctaga gtttcaatt cagataagat ccaggcacag cggtaaaagg ggagaggctg
 33781 gctttgggtt ctcaatctgt gactctctgc catggtctag aaaaagaaaa atacaattcc
 33841 tcttccgctg tcagtgtggt gggcagctgg gtgtggagga agaggtggcg agaaggtcaa
 33901 agatatttcc ctgactgcc tcctcccac tcataatcta tatatacctc caaacacgta
 33961 atccacaaat tatagtttct tcatttaggt cataaatcct ccccttaaaa tgttgggtatt
 34021 ccaagagaga gttaaaccct gtatgtgagc acaataaaaag ttttttgagt ctgaattttt

FIGURE 8K

34081 tgagtttgac agtgtctacc tggcacatag tagttgctca atacatatta gtttccttcc
 34141 ttttaattag gttctttatt caatatatgt agtgatacag ttgacctttg aacaacatgg
 34201 gtttgaactt cgggaatcca cttataaatg gattttcttc tgtgcctgcc acccctgaga
 34261 cagtaagatc aatccctcct ctttctcttc ctctcagcc tactcaacat gaagaggaca
 34321 gggagaggac ctttatgatg atccacttcc atttagtaaa tagtaaacat gttttctctt
 34381 ccttatgatt ttttttcttc aatttttggt ttaagttccg gggtagatgt acagaatgtg
 34441 caggtttggt acaaaggtaa acgtgtgcca tgggtggttg cagcacagat caacccatca
 34501 cctgggtatt aagcccagca tgcattagct attcttctctg atgctctccc tccccctact
 34561 ccactgagag gccccagtg gtgttgctcc cctctagggtg tccatgtgtt ctcatcattc
 34621 agctcccact ttttaagtga aacattcagt gtttggttct ctgtttctgc attagtttgc
 34681 tgaggataat ggcttccagc ttcatttcat ctatgtcccc gcaaatagaca tgatcttggt
 34741 cttccttatg attttctttc ctttctttt ttctgagacg gagtcttgct ctgtcaccca
 34801 ggctgaagtg cagtggcacg atcttggtc actgcaacct ctgcctcccg aattcaagca
 34861 gttctcctgc ctacgcctcc caagtagctg ggaccacagg tgtgtgccac catacttggc
 34921 taatttttaa attgttggtg gagatgggat cccctatgt tgcacaggct ggctgtgaac
 34981 tcctaagctc aagtcactct tctaccttg tctcccaaag tgctgggatt acaggcatga
 35041 gccaccatgc ctgaccagta gttaaatttt tgaggagtca aaagttatat gcaaattttc
 35101 gactgcagggt ttgggggtgt ggtgttgga cccctaacc ctgaattgtt caagggtcaa
 35161 ctttagttgc tactatttaa gtatatgctg tatgtcaat acatactata ttttatccta
 35221 cttaaacccta cagcagccca tgatggaagt gttattttag ttttcatatt ataaatgaga
 35281 aagctgaggg tcagaaaggc caagtaactt gcccaagttc acatagccgg taaataatat
 35341 gcctgtcatt ctgacgtaag acttgcttct taatacctaa atgatgtttg ctgaaatgag
 35401 ggggaatggg gttctgatta ggggaagggga ggggctatatt aattttgtag gatggccac
 35461 acaacatgtg gtactctggg gccagggtcag ttcagggtaa aaggaaggca aggggtgctt
 35521 tttggacatt gctttatttt tggacagccc tttttttttt ggacagccaa agagcaacag
 35581 gaggcccagg gggagtggaa gagggaaggcc taggagttca gtgagggaaa ggggtcataa
 35641 aaaaggaaga gagtggccta cttctgttat ttatgattca tctctgcca tctctagggt
 35701 accattgtta tgacaaagat gtagaagtca ccatttacta tagcacacag tgccactgtt
 35761 ggaagaattc cgcggatcct ctccctatag tgagtcgtat tagcggccgc aaatttatta
 35821 gagcaatata gtccatacat gtcaagctcg accgatgcc ttgagagcct tcaaccaggt
 35881 cagctccttc cgggtggcgc ggggcatgac tattggcgcg ccggatcgat ccttaattaa
 35941 gtctactaga taacttcgta taatgtatac tatacgaagt tattatctat gtcgggtgcg
 36001 gagaaagagg taatgaaatg tgccccgctt acgcagggca tccattttatt actcaaccgt
 36061 aaccgatatt gccagggttac gcggtgagc gcattgcaagc tttggcgcgc cgtcgaccac
 36121 ttctctgtta tgacagctta tcatcgaatt tctgccattc atccgcttat taccatttat
 36181 tcaggcgtag caaccaggcg ttttaaggga ccaataactg ccttaaaaaa attacgcccc
 36241 gccctgccac tcatcgaggt actgttgtaa ttcattaagc attctgccga catggaagcc
 36301 atcacaaacg gcatgatgaa cctgaatcgc cagcggcatc agcaccttgt cgccttgctg
 36361 ataataattt gccatggtga aaacgggggc gaagaagtgt tccatatttg ccacgtttaa
 36421 atcaaaactg gtgaaactca cccagggtatt ggctgagacg aaaaacatat tctcaataaa
 36481 cccttttaggg aaataggcca ggttttcacc gtaacacgcc acatcttgcg aatatatgtg
 36541 tagaaactgc cggaaatcgt cgtggtattc actccagagc gatgaaaacg tttcagtttg
 36601 ctcatggaaa acggtgtaac aagggtgaac actatcccat atccagct caccgtcttt
 36661 cattgccata cggaaactcg gatgagcatt catcaggcgg gcaagaatgt gaataaaggc
 36721 cggataaaac ttgtgcttat ttttctttac ggtcttttaa aaggccgtaa tatccagctg
 36781 aacgggtctg ttataggtac attgagcaac tgactgaaat gcctcaaaat gttcttttac
 36841 atgccatttg gatatatcaa cgggtggtata tccagtgtat ttttctcca ttttagcttc
 36901 cttagctcct gaaaatctcg ataactcaaa aaatacgcgc ggtagtgtat tttttcatt
 36961 atgggtgaaag ttggaacctc ttacgtgcgc atcaacgtct cttttctgcc aaaagtggc
 37021 ccagggtctc ccggtatcaa cagggaacac aggatttatt tattctgca agtgatcttc
 37081 cgtcacagggt atttattcgc gataagctca tggagcggcg taaccgtgc acaggaagga
 37141 cagagaaagc gcggatctgg gaagtgcgg acagaacggt caggacctgg attggggagg
 37201 cgggttgccgc cgctgctgct gacgggtgtga cgttctctgt tccggtcaca ccacatacgt
 37261 tccgccattc ctatgcgatg cacatgctgt atgccggtat accgctgaaa gttctgcaaa
 37321 gcctgatggg acataagtc atcagttcaa cggaggtcta cacgaagggt tttgctgctg
 37381 atgtggctgc ccggcaccgg gtgcagtttg cgatgccgga gtctgatgcg gttgctgctg
 37441 tgaaacaatt atcctgagaa taaatgcctt ggcctttata tggaaatgtg gaactgagtg
 37501 gatatgctgt ttttgtctgt taaacagaga agctggctgt tatccactga gaagcgaacg

FIGURE 8L

37561 aaacagtcgg gaaaatctcc cattatcgta gagatccgca ttattaatct caggagcctg
 37621 tgtagcgttt ataggaagta gtgttctgtc atgatgcctg caagcggtaa cgaacacgat
 37681 ttgaatatgc cttcaggaac aatagaaatc ttcgtgcggg gttacgttga agtggagcgg
 37741 attatgtcag caatggacag aacaacctaa tgaacacaga accatgatgt ggtctgtcct
 37801 ttacagcca gtatgtctcg ccgcagttga gcgacagggc gaagccctcg agtgagcgag
 37861 gaagcaccag ggaacagcac ttatatattc tgcttacaca cgatgcctga aaaaaattcc
 37921 cttgggggta tccactttat cacgggggata tttttataat tttttttttt atagttttta
 37981 gatctttctt tttagagcgc cttgtaggcc tttatccatg ctggttctag agaaggtgtt
 38041 gtgacaaatt gccctttcag tgtgacaaat caccctcaaa tgacagtcct gtctgtgaca
 38101 aattgccctt aaccctgtga caaattgccc tcagaagaag ctgttttttc acaaagttat
 38161 ccctgcttat tgactctttt ttattttagt tgacaatcta aaaacttgct acacttcaca
 38221 tggatctgtc atggcggaaa cagcggttat caatcacaag aaacgtaaaa atagcccgcg
 38281 aatcgctccag tcaaacgacc tcaatgaggg ggcataatagt ctctcccggg atcaaaaaacg
 38341 tatgctgtat ctgttcgttg accagatcag aaaatctgat ggcacctac aggaacatga
 38401 cggatctgtc gagatccatg ttgctaaata tgctgaaata ttcggattga cctctgcgga
 38461 agccagtaag gatatacggc aggcattgaa gagtttcgcg gggaaggaag tggtttttta
 38521 tcgccctgaa gaggatgccg gcgatgaaaa aggcattgaa tcttttcctt ggtttatcaa
 38581 acgtgcgcac agtccatcca gagggcttta cagtgtacat atcaacccat atctcattcc
 38641 cttctttatc gggttacaga accggtttac gcagtttcgg cttagtgaac caaaagaaat
 38701 caccaatccg tatgccatgc gttttatcga atccctgtgt cagtatcgta agccgtaggg
 38761 ctcaggcatc gtctctctga aaatcgactg gatcatagag cgttaccagc tgcctcaaag
 38821 ttaccagcgt atgcctgact tccgcgcgcg ctctctgcag gtctgtgta atgagatcaa
 38881 cagcagaact ccaatgcgcc tctcatacat tgagaaaaag aaaggccgcc agacgactca
 38941 tatcgtatct tcttccgcg atataccttc catgacgaca ggatagtctg agggttatct
 39001 gtcacagatt tgagggtggt tcgtcacatt tgttctgacc tactgagggt aatttgtcac
 39061 agttttgctg tttccttcag cctgcatgga ttttctcata ctttttgaac tgtaattttt
 39121 aaggaagcca aatttgaggg cagtttgta cagttgattt ctttctctt ccttctgta
 39181 tgtgacctga tatcggggtg tagttcgta tcattgatga gggttgatta tcacagttta
 39241 ttactctgaa ttggctatcc gcgtgtgtac ctctacctgg agtttttccc acggtgagata
 39301 tttcttcttg cgctgagcgt aagagctatc tgacagaaca gttcttctt gcttctctgc
 39361 cagttcgctc gctatgctcg gttacacggc tgccggcgagc gctagtata ataagtgact
 39421 gaggtatgtg ctcttcttat ctctttttgt agtgttgctc ttatttttaa caactttgcg
 39481 gttttttgat gactttgcga tttgtgtgtt gctttgcagt aaattgcaag atttaataaa
 39541 aaaacgcaaa gcaatgatta aaggatgttc agaataaaac tcatggaaac acttaaccag
 39601 tgcataaacg ctggatcatg aatgacgaag gctatcgcca ttgcacagtt aatgatgac
 39661 agcccggaag cgaggaaaat aaccggcgcg tggagaatag gtgaagcagc ggatttgatt
 39721 ggggtttctt ctcaggctat cagagatgcc gagaaagcag ggcgactacc gcacccggat
 39781 atggaaattc gaggacgggt tgagcaacgt gttgggtata caattgaaca aattaatcat
 39841 atgcgtgatg tgtttggtac gcgattgcga cgtgctgaag acgtatttcc accggtgatc
 39901 ggggttgctg ccataaaagg tggcgtttac aaaacctcag tttctgttca tcttgctcag
 39961 gatctggctc tgaaggggct acgtgttttg ctcgtggaag gtaacgacct ccagggaaca
 40021 gcctcaatgt atcacggatg ggtaccagat cttcatattc atgcagaaga cactctctctg
 40081 cctttctatc ttggggaaaa ggacgatgtc acttatgcaa taaagcccac ttgctggccg
 40141 gggttgaca ttattccttc ctgtctggct ctgcaccgta ttgaaactga gttaatgggc
 40201 aaatttgatg aaggtaaact gccaccgat ccacacctga tgctccgact ggccattgaa
 40261 actgttgctc atgactatga tgtcatagtt attgacagcg cgcttaacct gggatcggc
 40321 acgattaatg tcgtatgtgc tgctgatgtg ctgattgttc ccacgcctgc tgagttgttt
 40381 gactacacct ccgcactgca gtttttcgat atgcttctgt atctgctcaa gaacgttgat
 40441 cttaaagggt tcgagcctga tgtacgnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnngac
 40501 agtctatctg ttagttatat tctagccctt tatagcttgc tggctctcaag atgtagaatt
 40561 gctgaaagat gtaattcaga ctgtttggaa agaagacaag tcttccctcc tctctgggtt
 40621 cactgtgaac cacggaggtt tctacgatac atggctaac cactgaaaat ttactgtcct
 40681 tactgagata ttttagaagt gtaaaataca gactgtattt caaagacagc atgaaaaagc
 40741 cagcttttgt agcaggcacc aagcttggtt tactttatac aggcctcccta attcctctct
 40801 gccacttcaa ctttcaactg atatccctgg cagaaggatg aaaaatcaaa agggcaagag
 40861 atagaacatt tgtttcaggt attgggacaa ctccaagtat taagataaca gattcatttc
 40921 atgctgtttc atttaaatcaa tgtttattca tggcaaatat ttttttttat tttttttatt
 40981 ttttatttta atttaagtgg gtacatagta gttttatgta tttatgggtt acgtgagata

FIGURE 8M

41041 ttttgataca ggcacatca aatcacatca gggtaaatgg ggtgtccatc atctcaagta
 41101 tttatccttg tgtcacaac aatccaatta tactcttagt tgtttaaaaa tgcggggagt
 41161 ggagggcaag tggagggaga gcattaggac aaatacctaa tgcacgctgg gcttaaaacc
 41221 tatgtgatgg gttgacaggt gcagcaaac accatggcac atgtatacct atgtaacaa
 41281 cctgcacggt ctgcacatgt atcccgtaat gtaaaagtaa ataaaaatgc ataaaaatcaa
 41341 ataaaggaat cactaatgaa acctacattt gcaaaataaa ttataaatat tgaaaagaaa
 41401 taaaaagtac aaaaaattat ttttgtctat agtcaactta ttgtgctatc aaatactagt
 41461 cttattcatt ctttttggtt tttgtacca ctaaccatcc cactccccgc cctacacccc
 41521 ccaacaaccc gccccatact cttccaagcc tctggtaacc gtccttctac tatctccatg
 41581 agtcgaattg ttttaatttt taacttccac aaataagtg gaatatgtga agtttgtctt
 41641 tctgtacctg gcttaatttt cacttaacat aatgacctcc agttccatcc atgttattgc
 41701 aaatgactgg acctcatttt cttaatggct gaatagtact ccattgtgta tatgtaccac
 41761 attaaaaaaa atcaatttgt tagttgtagg attgctttca aatcttggct attgcaata
 41821 gtgctgcaat agctaagatt tggatatctt tgggagtgtga gatattcttg ggatatcttt
 41881 taatcttttc ttttcttttt gagacagagt ctgcctctgt tgcccaggct ggagtgtagt
 41941 ggcgcaatct tggctcactg caacctctgc ctcccgggtt caaacaattc tctgtcttca
 42001 gcctcctgag tagcttggat tacaggcact caccaccatg cccagataat ttttgtattt
 42061 ttagtagaga cgggggttca ccatgttggc caggctgggtc tcaaactcct gacctcagat
 42121 gatccacca tctcggcctc ccaaagtgtc gggattacag gcgtgagcca cctcggccag
 42181 cctgattttt tttcttttga gtatatacct acctctattt tcagtttttt gaggcacctc
 42241 caaactgttc tccatagtga ttgactaat ttacattccc actaacagtg tacaagggtt
 42301 cctttttctc cctattcttg ctagcatttg ttattgcttg acttttggat aaaagccatt
 42361 ttaactgggg tgagatgata tgtcattgta gttttgattt gcatttctct gatgatcaat
 42421 gacaatgcct ttttgtatgc ttgtttccca cttgtatgtc ttcccttgag aaatgtctat
 42481 gcagatcttt tgcccattta aaaaactgga ttattatatt ttttccata gagttgtttg
 42541 agctcctttt atattctgat tattaacccc ttgtcagatg ggtagtttgc aattatttct
 42601 taccactctg tggtttgtct cttcactttg ttgattcttt cttttgctat gcagaaagt
 42661 ttttaatttga tatgatccta tgtgttcaca ttgtctttgg ttgcctgtgc tttagaggt
 42721 ttactcaagg aatcctttgc tactctggga cttactgttt tcttttacta gtttcatagt
 42781 tgcaggtcct aaatttcagt ctttaatcca ttttgatttg atttttgtat aaggctagag
 42841 ataacaggtc tagttcactc ttttgcatat ggatatccag ttttccagc atcatttatt
 42901 gaagagactg tctgttcccc aatttatgct cttggtaact ttgtcaaaaa tgaattcact
 42961 gcagatgtat gcatttacct ctgggttctc tattctgttc cactgatgta tgtgtctgtt
 43021 tttatgccag taccttgctg ttttggttac tgtagtttta tagtataagt ttaagtcaga
 43081 taaagtgatt tctcccattt tgttcttttt gctcagggtg gctttggctc ttctgggtct
 43141 ttctgtggtc caaatgaatt tttagaattt ttttctattt ctgtgaagaa tgtcattggt
 43201 attttgatag gcattgcatt aaatctgtag atcgctttga gtaatatgga cattttaaca
 43261 ttattgatat ttccaatcca tgaacatgta atgtctttcc ttttttgtgg cttcttcaat
 43321 ttcttgcatc aatgttttat agttttcatt tttagatatca ttacttctgt tagttaattc
 43381 ctaggtattt aattttattt gtagctattg taaatgggat cttttaaaat ttctttttca
 43441 gattgttcac tgttagcata tagaaatgct actgatgttt gtatgttgaa tttgtatcct
 43501 gcaactttac tgagtttggt tatcagttct ttagattttc ttgatgggtat ctttagtatt
 43561 tcccaaatat aagatcatat ctgaaaacta gaataatttg acttcttctc atccaatttg
 43621 gatgcccttt atttctttct cttgtatgat tgcctcaagct aggactttca gtattatgtt
 43681 gaataacagt ggtgtaagtg ggcacccctg ttgttttoca gatcttagag aaaaggcttt
 43741 caatttttcc ccattcagta tgataactaac tctggatctg ttgtatatgc tttttattat
 43801 gttgaggtat gttccttctg taaccagtgt tgtgaggttt ttgttatgaa gggctgttga
 43861 attttatcaa gtgctttttc agcatcaatt gaaatgatca tatagttttg tctttcattc
 43921 tgttgatatg atgtattaca ttaattgatt tgcataatgt gaactatctt tgcaccccta
 43981 ggctaaatct cacttcgtca taatgaatga tgagtgtttg agttagtga tttgatgag
 44041 ttatcgaata ttgagtttga tttggtagta tttgagaatt tttgcatcaa tattcatcag
 44101 aaatattggt gtatagtttt atttttattg atgtgtcttt gtctagtctt agtataaaga
 44161 taatactggc ctcatagaat gagtctggaa gtattccctc ctttctttgt gtttttgaat
 44221 agtttgagta ggattgggtat agtttttttt tatttaattt gtttatttgt cttgagacac
 44281 ggtgtcactc tgtcaccaca ggctggagta cagtgggtgt atcttggctt accatagcct
 44341 ctgcctcgcc tcccaggctc aagcgattct ctaataatat ttgctttata tatctgggtg
 44401 ctccagtgtt tgggtgcatat atatttatca aattgttata tctcttctgt gaattgaccc
 44461 ctttatcatt atatagtac cttcttgttc tcttcttata gtttttgtct tgaaatctat

FIGURE 8N

44521 ttgtctgatt tatccaatatt atttatctga ctctgctct ttttttggtt tccatttgca
 44581 tggaatattt ttttccatcc cttatttttca gtttactgtg tattcttgga caagttactt
 44641 tctgagcctc aatttccctca tctgatagtt ggtgtctggt aggatctatc ttacaggact
 44701 gttttaagga ttaaatagaga caatgcacag tgccctggggc atgatgagat atggtaatta
 44761 ggaaataatt actcaggcca ggcacggtgg ctcatgccta taattccaac attttgaggag
 44821 gctatggtgg gaggatcgct taacaccagc ctgggcaata tagtcacacc cagtctctcc
 44881 aaagaaagaa agaaagaaag aaaaaatta gccactatt gtggtcacat gactgtagtc
 44941 ccagctactc aggaggctga gatgggagga tcacttgagc ctggaagggt gagggtgcag
 45001 tgagccatga ttgtgctact gcgctccagc ttgggcaaca acatgagaac ttatttcaaa
 45061 atagctaaca aatggtagtt attattgtta catttattta tttagaatta ttattcaatt
 45121 attattatgt aataatcaac aaaaattatc cttttttgta gcatcttttt atctcttctc
 45181 tgatttcttt tttgaacaaa tttaaaaaca tattataata ttaaaaaacg gagaccagggt
 45241 ctccctgtgt taccagggt gtccctcaaac tcctgggctc gagcaatcct tccgccacag
 45301 ctttccaaag tgctgcggtt acaggcgtga gccactgtgc ctggccttgc attatttctg
 45361 ttaggggttat ttgtttattt gttatctgtg taatttattt actttgatgt ttaaagcaaa
 45421 gaattacaac tcagtgaagg agatatcctc acatgtaact tgcaactcta aatatgacct
 45481 tatctaagag ggtattagtt tcaattatgc tgcccctatg ggtcattgaa gtgagactct
 45541 tctgtgtgtc ccataagagt gcataaggc aactgaagtc atttgatgtc ctcagccccc
 45601 ttggcaagca cagagggtgt caaaagactg atgaacttgg cactaagatt tttcttccag
 45661 aagacagga gaaatcacca aatggttttt ttttaaagc aaactaata ttagccacc
 45721 ttttgggttc actttttttt ttctttttct tttttactag tcattgactt gaagctcatg
 45781 gttttactct ttaacaccag ccagtcaact gcaggttcct gggacaaaaa gcaaaaggaa
 45841 taatgatccc ttgtggattc ctgagtcacc tgctttgtgg gctgtgcagc gtctgtggtc
 45901 agcaccacac cggctacctc actattgtct aggggtttgtg ctttgggagc tagcctggaa
 45961 gctaagaact ctcaacttca cctggtatta actactttgt ttcttttttt tttttttttt
 46021 tgagacggag tctcgtcttt gtcacccagg ctggagtgc gtggcacgat ctcagctcac
 46081 tgcaacctct gcctcctggg ttcaagcgat tctcctgctc cagcctcccg agtagctggg
 46141 attaaaggct cctgccacca ccccgagcta atttttttta ttttttagtag agatggagtt
 46201 tcatcatggt gggcaggctg gcctcgaact tctgacctcc ggtgatcctc ccacctggc
 46261 ctctgaagt gctgggatta caggcgtgag ccacattgcc cagcctggta ttaactactt
 46321 tctaaaggcg ctctcgtttg cacaagaatg ctgtttgagc gaatgcctgt agacacatga
 46381 accctgggce tgctgtctcc ttaatttgag ggaagctatg gatgtcaagc agaatagagc
 46441 tattttgtta cttgaccagg ttcccataac tttttgcaca tacctttatt cctgcacctg
 46501 tcccacataa ttatcccttt atagctcttt caccagcagg aatataaatg tcatggcagg
 46561 gccaccatgt tgcaaaactc ctagggtcca tcctgcagtt actagcttgt gtgaatggta
 46621 cttcttggag gtaccattgc aatgcacagc ctgagcagcc ctctgcagta agtccaactg
 46681 tggatggggc aaaatgagtg gttagcagaa ttggcctcat acatctttta ttctggcatt
 46741 gagtatgtgg taggcactca agaaatatatt ttaaataaat gacattgggtc ttccattta
 46801 ttttgagtta atttgacca gcttaatcag tggatctttt caactagtta attgtcctac
 46861 ccttccaccc aggaagggtgt ttcagtttta atagattttt gttattgggtg tttttttgca
 46921 cattcagcaa aacctctgga aagaggagtt catatcagcc cctcatgcag agggagctgt
 46981 gagtattcag gctgcttggg gctgctgcgg tctttccagc agagggtggct ggtcctagag
 47041 tgggtggtttg gtccattctt gacctatgat gatgctggga aataactcag tgatgtgggtg
 47101 tcattttttt atctcacaga tgtggctctg gagaagagat ttaagtttat atcttcagaa
 47161 catagcatca atgagtttgg gtcatagtct cagccaactc agccagaaac agatacacag
 47221 tatgcaacca agtgggaata aattcaacct attttctaa tttggaatat agagcctgag
 47281 ggggtgaagtt gtgggtggat tatctgtcct ggggtcttcc tatttctga atttatactt
 47341 tagtgaaggg aaattttgct aactgttaat gtgccagaat gggaaagccc cctacctagg
 47401 ccctcacctc tgaatttttc cagttcaagt ggacaagtag tttttgagca ctcaactatgt
 47461 gtcaggctca ggggtgacct tgcgatttcc acttccctct gatcttttca cctaagcctg
 47521 tgggacttgt gttctgggag aaaattagaa gttacatcat ccttatgggt ctgaaaaaat
 47581 tgagctcccc agacttgggt tcgcctgatc tgcttctcaa atgttaaaga ggaacataaa
 47641 gccatgtaga aaatcctttt cttttgacaa agcctggctt tcaaattcta ctgttgcctg
 47701 agtcacaaa attatacatt tgaatgtcag agattgaatg ttgacatcct tattgcaaaa
 47761 atcctatccc cacttctggc ttagctgccc cagagagctc tgtgtctcgg gctgactaga
 47821 gaaaagacca cacagttaga gatgcaaaaa aggaaatgcc attaacatat ttcagggtga
 47881 atatttcttt gcatttggca ctttgcaatc tagtccaggc ttaagatttg taggatttct
 47941 tttgctgttt cccttttttt acttgtcagg gaaacaaggc ataaatatatt cagcttggac

**DECLARATION AND
POWER OF ATTORNEY
FOR UTILITY OR DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☐ Declaration Submitted with Initial Filing OR ☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number 20499P

First Named Inventor Uebele, et al.

COMPLETE IF KNOWN

Application Number

Filing Date

Group Art Unit

Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL HUMAN CALCIUM SENSITIVE POTASSIUM CHANNEL

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) as United States Application Number or PCT InternationalApplication Number and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Attorney Docket Number	Priority Claimed?	
				YES	NO
PCT/US00/19585	PCT	07/18/2000	20499-PCT	<input checked="" type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	Attorney Docket Number
60/144,764	07/20/1999	20499PV

DECLARATION AND POWER OF ATTORNEY for Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information known to me to be material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Application Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/US00/19585	07/18/2000	
60/144,764	07/20/1999	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint, respectively and individually, as my attorneys or agents with full power of substitution and revocation, the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☒ Registered practitioner(s) name/registration number listed below


Place Customer Number
Bar Code Label here

Name	Registration Number	Name	Registration Number
Joseph A. Coppola	38,413	Jack L. Tribble	32,633

Direct all correspondence to: ☒ Customer Number or Bar Code Label **000210**

Name	Joseph A. Coppola					
Address	Merck & Co., Inc. - Patent Department					
Address	P.O. Box 2000, RY60-30					
City	Rahway	State	NJ	ZIP	07065-0907	
Country	USA	Telephone	(732)594-6734		Fax	(732)594-4720




I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])		Family Name or Surname			
Victor		Uebele			
Inventor's Signature				Date	17 Jan 2002
Residence: City	Wyncote PA	State	PA	Country	US
Citizenship	US				
Post Office Address	Merck & Co., Inc., P.O. Box 2000				
City	Rahway	State	NJ	ZIP	07065-0907

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

DECLARATION AND POWER OF ATTORNEY

ADDITIONAL INVENTOR(S)
Supplemental Sheet

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor													
Given Name (first and middle [if any])				Family Name or Surname											
Richard				Swanson											
Inventor's Signature					Date		1/18/02								
Residence: City		Lansdale PA		State		PA		Country		US		Citizenship		US	
Post Office Address		Merck & Co., Inc., P.O. Box 2000													
City		Rahway			State		NJ		ZIP		07065-0907				
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor													
Given Name (first and middle [if any])				Family Name or Surname											
Yuan				Liu											
Inventor's Signature					Date		1/17/2002								
Residence: City		Lansdale PA		State		PA		Country		US		Citizenship		US	
Post Office Address		Merck & Co., Inc., P.O. Box 2000													
City		Rahway			State		NJ		ZIP		07065-0907				
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor													
Given Name (first and middle [if any])				Family Name or Surname											
Armando				LaGrutta											
Inventor's Signature					Date		1/17/2002								
Residence: City		North Wales PA		State		PA		Country		US		Citizenship		PA	
Post Office Address		Merck & Co., Inc., P.O. Box 2000													
City		Rahway			State		NJ		ZIP		07065-0907				
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor													
Given Name (first and middle [if any])				Family Name or Surname											
Inventor's Signature					Date										
Residence: City				State				Country				Citizenship			
Post Office Address		Merck & Co., Inc., P.O. Box 2000													
City		Rahway			State		NJ		ZIP		07065-0907				